

T.C.
DOKUZ EYLUL UNIVERSITY
İZMİR INTERNATIONAL
BIOMEDICINE AND GENOME
INSTITUTE

**DEVELOPING NOVEL TARGETED
THERAPIES TOWARDS HIGH GRADE
GLIOMA (HGG) BY USING OMICS DATA
INTEGRATION APPROACHES**

FADİME ÖZTOPRAK

MOLECULAR BIOLOGY AND GENETICS
PhD THESIS

İZMİR-2023

TEZ KODU: DEU.IBG.PhD-2016850030

T.C.
DOKUZ EYLUL UNIVERSITY
İZMİR INTERNATIONAL
BIOMEDICINE AND GENOME
INSTITUTE

**DEVELOPING NOVEL TARGETED
THERAPIES TOWARDS HIGH GRADE
GLIOMA (HGG) BY USING OMICS DATA
INTEGRATION APPROACHES**

MOLECULAR BIOLOGY AND GENETICS
PhD THESIS

FADİME ÖZTOPRAK
Supervisor: Asst. Prof. Yavuz OKTAY
Co-Supervisor: Assoc. Prof. Zerrin IŞIK

İZMİR-2023

TEZ KODU: DEU.IBG.PhD-2016850030

Dokuz Eylül University Izmir International Biomedicine and Genome Institute
Department of Genomics and Molecular Biotechnology, Molecular Biology and
Genetics PhD program student Fadime Oztoprak has successfully completed the
PhD thesis entitled “**Developing novel targeted therapies towards high grade
glioma (HGG) by using omics data integration approaches**” on date of
06/11/2023.

HEAD OF THE COMMITTEE

Asst. Prof. Yavuz OKTAY

MEMBER

Assoc. Prof. Gökhan KARAKÜLAH

MEMBER

Asst. Prof. Cihangir YANDIM

MEMBER

Assoc. Prof. Gizem ÇALIBAŞI KOÇAL

MEMBER

Assoc. Prof. Evren KOBAN BAŞTANLAR

7ABL(2) C217(176

LI67 2) 7ABL(6	I9
LI67 2))IG85(6	9
ABB5(9IA7I216	9II
ACK12:L(DG(0(17	IX
AB675AC7	XI
gZ(7	XII
1. I1752D8C7I21	1
2. LI7(5A785(5(9I(:	6
2.1. 2YHUYiHZ RI GOiRPDV	6
2.2. 2YHUYiHZ RI /GG DQG GBO	6
2.3. IQFiGHQFH 5DWH DQG 6uUYiYDO IRU /GG DQG GBO	7
2.4. COiQiFDO 3UHVHQWDWiRQ RI /GG DQG GBO	8
2.5. IQWUiQViF 5iVN)DFWRUV IRU GOiRPDV DQG GBO	9
2.6. 6uEWySHV RI /GG RU GBO BDVHG RQ GHQHWiF 0uWDWiRQV	10
2.6.1. ID+ = iOG 7ySH DQG ID+ 0uWDQW GOiRPDV RU GBO	10
2.6.2. 1S/19T FRGHOHWiRQ	12
2.6.3. 7(57 3URPRWHU 0uWDWiRQ	12
2.6.4. (G)5 APSOiLiFDWiRQ	13
2.6.5. 37(1 0uWDWiRQ	13
2.7. 7UDQVFUiSWRPiF 3URi0iQg IRU /GG	14
2.8. D1A 0HWKyODWiRQ 3URi0iQg IRU /GG	15
2.9. 0uOWi-2PiFV DDWD IQWHgUDWiRQ IRU BiRORgiFDO IQVigKWV	16
3. 0A7(5IAL6 A1D 0(7H2D6	18
3.1. 7UDQVFUiSWRPiFV DDWD CROOHFWiRQ DQG 3UHSURFHVViQg	18
3.2. CRQVWUuFiRQ RI WKH = HigKWHG GHQH CR-HxSUHVViRQ 1HwZRUN	19
3.3. IGHQWiLiFDWiRQ RI COiQiFD00y 6igQiLiFDQW ORGuOHV	20
3.4.)uQFWiRQDO (QUiFKPHQW AQDOyViV	20
3.5. DiIIHUHQWiDO GHQH (xSUHVViRQ AQDOyViV	20
3.6. DUug-gHQH IQWHUDFWiRQV	21
3.7. DDWD CROOHFWiRQ DQG 3UHSURFHVViQg IRU D1A 0HWKyODWiRQ	21
3.8. DiIIHUHQWiDO GHQH (xSUHVViRQ AQDOyViV ZiWK G7Hx GDWD	23
3.9. DiIIHUHQWiDO00y 0HWKyODWHG 5HgIRQ AQDOyViV	23

3.10. IQWHgUDWiRQ RI D(GV DQG DOGV	24
3.11. 1HWZRUN AQDOyViV	24
3.12. 3HUWuUEDWiRQ 3URiOiQg	25
4. 5(68L76	26
4.1. 3UH-SURFHVViQg RI 7CGA-/GG 51A6HT DDWVHV DQG CRQVWUuFWiRQ RI = HigKWHG GHQH CR-HxSUHVViRQ 1HWZRUNV	26
4.2. IGHQWiLiFDWiRQ RI COiQiFD00y 6igQiLiFDQW ORGuOHV	28
4.3. (QUiFKPHQW AQDOyViV IRU ORGuOHV RI IQWHUHVW	32
4.4. DiIIHUHQWiD00y (xSUHVVG GHQH (D(GV)	38
4.5. DUug-GHQH IQWHUFWiRQV	39
4.6. DDWD CROOHFWiRQ DQG 3UHSURFHVViQg IRU D(G AQDOyViV DQG D1A 0HWKyODWiRQ DDWD	41
4.7. DiIIHUHQWiD0 GHQH (xSUHVViRQ AQDOyViV ZiWK G7Hx DDWD WR BH IQWHgUDWHG ZiWK D1A 0HWKyODWiRQ DDWD	42
4.8. DiIIHUHQWiD00y 0HWKyODWHG 5HgIRQ AQDOyViV (CSG ViWHV)	43
4.9. ID+ PuW S7(57P - 4uDOiWy CRQWURO	43
4.10. ID+ PuW S7(57ZW - 4uDOiWy CRQWURO	45
4.11. ID+Z S7(57P - 4uDOiWy CRQWURO	46
4.12. ID+Z S7(57Z - 4uDOiWy CRQWURO	48
4.13. IQWHgUDWiRQ RI 0HWKyODWiRQ DQG (xSUHVViRQ GDWD	50
4.14. 1HWZRUN AQDOyViV DQG (Si)DFWRU	54
4.15. 3HUWuUEDWiRQ 3URiOiQg	57
5. DI6C866I21	60
5.1. 6uEWySH 6SHFiLiF CR-HxSUHVViRQ ORGuOHV DQG 7KHiU (QUiFKPHQW AQDOyViV	61
5.2. D(G6 IURP ORGuOH RI IQWHUHVW	63
5.3. IQWHUFWiRQ RI IGHQWiLiHG GHQH 6igQDwUHV ZiWK KQRZQ DUugV	65
5.4. 0HWKyODWiRQ DDWD IQWHgUDWiRQ ZiWK 7UDQVFUiSWRPiFV DDWD	66
5.5. 1HWZRUN CRQVWUuFWiRQ BDVHG RQ ODGV + ORGuOHV RI IQWHUHVW DQG (VVHQWiD0 (SiIDFWRU AQDOyViV	68
6. C21CL86I21	72
7. 5()(5(1C(6	74
C855IC8L80 9I7A(	96

LI67 2) 7ABL(6

7DEOH 4.1 :	K(GG SDWKZDy HQUiFKPHQW RI WKH F0iQiFD00y VigQiIiFDQW PRGuOHV	32
7DEOH 4.2 :	CRPPRQ SDWKZDyV EHWZHHQ WKH ID+ PuWDQW (ID+ PuW)	
	gUHHQyH00RZ PRGuOH DQG ID+ ZiOG-WySH (ID+ ZW) EOUH PRGu0H	35
7DEOH 4.3 :	ID+ ZiOG-WySH EOUH PRGuOH SDWKZDy-HQUiFKHG D(GV	39
7DEOH 4.4 :	DUug-gHQH iQWHUDFiRQ WDEOH IRU ID+ ZiOG-WySH	
	EOuH PRGuOH SDWKZDy-HQUiFKHG D(GV	40
7DEOH 4.5 :	7KH QuPEHU RI GiIIHUHQWiD00y HxSUHVVG gHQHV iQ	
	GiIIHUHQW /GG VuEWySHV	43
7DEOH 4.6 :	DiIIHUHQWiD00y 0HWKyODWHG CSG ViWHV (DOC) UHVuOWV	50
7DEOH 4.7 :	0HWKyODWiRQ DUiYHQ GHQHV (ODGV) VuPPDUy WDEOH	51
7DEOH 4.8 :	(QUiFKPHQW DQDOyViV RI 9HQQ DiDgUDP gHQHV	52
7DEOH 4.9 :	1HWZRUN WDWiWwifV RQ HSiGHQHWiF GDWD ZiWK ODG QRGHV,	
	HGgHV, QHigKERUV DQG SURWHiQ FRPSOHxHV.	54
7DEOH 4.10 :	C+52126 GHSHQGHQFy VFRUHV RI 66 GiIIuVH g0iRPD PRGHOV	58

LI67 2) IG85(6

)iguUH 3.1 :	ORGuOH FRQVWUFWiRQ DQG FOiQiFD00y VigQiliFDQW PRGuOH GHWHFWiRQ Ey = GC1A	19
)iguUH 4.1D :	6DPSOH GHQGURgUDP RI ID+ PuWDQW VDPsoHV WR GHWHFW RuWoiHUV	26
)iguUH 4.1E :	6DPSOH GHQGURgUDP RI ID+ZW VDPsoHV WR GHWHFW RuWoiHUV	27
)iguUH 4.2D :	+iHUDUFKiFD0 FOuVWHUiQg RI gHQHV ZiWK PRGuOH FRORUV IRU ID+ PuW VDPsoHV.	28
)iguUH 4.2E :	+iHUDUFKiFD0 FOuVWHUiQg RI gHQHV ZiWK PRGuOH FRORUV IRU ID+ ZW VDPsoHV	28
)iguUH 4.3D :	ORGuOH-7UDiW UHODWiRQVKiS SORW IRU /GG ID+ PuW VDPsoHV	30
)iguUH 4.3E :	ORGuOH-7UDiW UHODWiRQVKiS SORW IRU /GG ID+ ZW VDPsoHV	31
)iguUH 4.4D :	6H0HFWHG FRPPRQ K(GG SDWKZDy VFkHPHV RI WKH ID+ ZW S7(57- EOUH PRGuOH DQG ID+ PuW S7(57+ gUHHQyHOORZ PRGuOH a GOuWDPDWHUgiF VyQDSVH	36
)iguUH 4.4E :	6H0HFWHG FRPPRQ K(GG SDWKZDy VFkHPHV RI WKH ID+ ZW S7(57- EOUH PRGuOH DQG ID+ PuW S7(57+ gUHHQyHOORZ PRGuOH a GABAHUgiF VyQDSVH	37
)iguUH 4.4F :	6H0HFWHG FRPPRQ K(GG SDWKZDy VFkHPHV RI WKH ID+ ZW S7(57- EOUH PRGuOH DQG ID+ PuW S7(57+ gUHHQyHOORZ PRGuOH a 5HWURgUDGH HQGRFDQQDEiQRiG VigQD0iQg	37
)iguUH 4.5 :	6DPSOH FOuVWHUiQg RI QRUPD0 VDPsoHV	42
)iguUH 4.6D :	6DPSOH GHQGURgUDP IRU 356743 SUREHV iQ ID+ PW S7(57 PW gURuS	44
)iguUH 4.6E :	0uOWiGiPHQViRQD0 6FD0iQg SORW IRU 1000 PRVW YDUiDEOH SRViWiRQV a ID+ P S7(57 PW	44
)iguUH 4.6F :	+HDWPDS IRU 7RS 1000 YDUiDEOH CSGV a ID+ PW S7(57 PW	45
)iguUH 4.7D :	6DPSOH GHQGURgUDP IRU 356743 SUREHV iQ ID+ PW S7(57 ZW	45
)iguUH 4.7E :	0uOWiGiPHQViRQD0 6FD0iQg SORW IRU 1000 PRVW YDUiDEOH SRViWiRQV a ID+ P S7(57 ZW	46
)iguUH 4.7F :	+HDWPDS IRU 7RS 1000 YDUiDEOH CSGV a ID+ PW S7(57 ZW	47
)iguUH 4.8D :	6DPSOH GHQGURgUDP IRU 356743 SUREHV iQ ID+ ZW S7(57 PW	47
)iguUH 4.8E :	0uOWiGiPHQViRQD0 6FD0iQg SORW IRU 1000 PRVW YDUiDEOH SRViWiRQV a ID+ ZW S7(57 P	47

)iguUH 4.8F :	+HDWPDS IRU 7RS 1000 YDUiDEOH CSGV a ID+ ZW S7(57 PW	47
)iguUH 4.9D :	OD6 SORW RI ID+ ZW S7(57ZW VDPSoHV	48
)iguUH 4.9E :	6DPSOH GHQGURgUDP IRU 356743 SUREHV iQ ID+ ZW S7(57 ZW	48
)iguUH 4.9F :	OuOWiGiPHQViRQD0 6FD0iQg SORW IRU 1000 PRVW YDUiDEOH SRViWiRQV a ID+ ZW S7(57 ZW	49
)iguUH 4.9G :	+HDWPDS IRU 7RS 1000 YDUiDEOH CSGV a ID+ ZW S7(57 ZW	49
)iguUH 4.10 :	9HQQ GiDgUDP RI PHWkyODWiRQ GUiYHQ gHQHV	51
)iguUH 4.11D :	ID+ PW S7(57 P - 3URWHiQ FRPSOHx IRFuVHG VuEQHWZRUN	55
)iguUH 4.11E :	ID+ PW S7(57 ZW - 3URWHiQ FRPSOHx IRFuVHG VuEQHWZRUN	56
)iguUH 4.11F :	ID+ ZW S7(57 P - 3URWHiQ FRPSOHx IRFuVHG VuEQHWZRUN	56
)iguUH 4.11G :	ID+ ZW S7(57 ZW - 3URWHiQ FRPSOHx IRFuVHG VuEQHWZRUN	57

ABB5(9IA7I216

AC	AGHQyODWH CyFODVH
A03A	A0SKD-DPQR-3-KyGURxy-5-PHKKyOiVRxDzR0H4-SURSiRQiF DFiG
AA675	AQDSODVWiF AVWURFyWRPD
A675	AVWURFyWRPD
β	BHWD
B0I4	BHWD OixWuUH 4uDQWiOH GiODWiRQ
CC/(	CDQFHU CH00 /iQH (QFyF0RSHGiD
CGGA	CKiQHVH G0iRPD GHQRPH A00DV
C5I635	COuVWHUHG 5HguODU0y IQWHUVSDFHG 6KRUW 3D0iQGURPiF 5HSHDWV
DA9ID	DDWDEDVH IRU AQQRWDWiRQ, 9iVuDOizDWiRQ, DQG IQWHgUDWHG DiVFRYHUy
D(A	DiIHUHQWiDO gHQH HxSUHVViRQ DQD0yViV
D(GV	DiIHUHQWiD00y (xSUHVViRQ GHQHV
D0C	DiIHUHQWiD00y 0HWKyODWHG CSGV
D0GV	DiIHUHQWiD00y 0HWKyODWHG GHQHV
DI3GV	DiIuVH IQWUiQViF 3RQWiQH G0iRPDV
DGB	DUug GHQH BuGgHU
DGI	DUug-GHQH IQWHUDFWiRQ
(	(igHQgHQH
)C	)ROG CKDQgH
GAB5A3	GDPPD-DPiQR EuWyUiF DFiG UHFHSWRU D0SKD VuEuQi 3
G(2	GHQH (xSUHVViRQ 2PQiEuV
GDC	GHQRPiF DDWD CRPPRQV
G7(x	GHQRWySH-7iVVuH (xSUHVViRQ
GB0	GOiREODVWRPD 0uOWiIRUPH
G5A1	G0uWDPDWH iRQRWURSiF UHFHSWRU A03A WySH 1
+8G2	+uPDQ GHQRPH 2UgDQiVDWiRQ
ICGC	IQWHUQDWiRQD0 CDQFHU GHQRPiFV CRQVRUWiuP
ID+	IVRFiWUDWH DHKyGURgHQDVH
K(GG	KyRWR (QFyF0RSHGiD RI GHQHV DQG GHQRPHV
/GG	/RZHU-GUDGH G0iRPD
ODGV	0HKKyODWiRQ DUiYHQ GHQHV
OD6	0uOWiGiPHQViRQD0 6FD0iQg
O(7AB5IC	OROHFuODU 7DxRQRPy RI BUHDVW CDQFHU IQWHUQDWiRQD0 CRQVRUWiuP

0D6	0uOWiGiPHQViRQD0 VFD0iQg
PW Rr PuW	0uWDQW
1CBI	1DwIRQD0 CHQWHU IRU BIRWHFKQRORgy IQIRUPDWiRQ
16CV	1HuUDO 6WHP CH00V
1G6	1HxW GHQHUDWiRQ 6HTuHQFiQg
2DG	20igRGHQGURgOiRPD
2PiFVDI	2PiFV DiVFRYHUy IQGHx
3I32	SKRVSKDWiGyOiQRViWRO-4,5-EiVSKRVSKDWH
3I33	SKRVSKDWiGyOiQRViWRO-3,4,5-WuVSKRVSKDWH
3KA	3URWHiQ KiQDVH A
4C	4uD0iWY CRQWURO
51A	5iERQuF0HiF AFiG
53K0	5HDGV 3HU KiOREDvH SHU OiooiRQ
675I1G	6HDUFK 7RRO IRU WKH 5HWUihYDO RI IQWHUDEFWiQg GHQHV/3URWHiQV
671	6ROiG 7iVVuH 1RUPDO
6(	6uPPDUizHG (xSHUiPHQW
7CGA	7KH CDQFHU GHQRPH AWODV
)D5	7KH)DOVH DiVFRYHUy 5DWH
S7(57	7(57 SURPRWHU
88ID	8QiYHUVDO0y 8QiTuH IGHQWiLiHU
± GC1A	± HigKWHG GHQH CR-HxSUHVViRQ 1HWZRUN AQD0yViV
ZW	± iOG 7ySH

ACK12:L(DG(0(17

I GiGQ'W NQRZ WKD' VR PDQy uQSUHGiFWDEOH HYHQWV ZRuOG KDSSHQ GuUiQg WKiV WiPH ZKHQ I VWDUWHG Py 3KD SURgUDP. I'P WKuioOHG WR KDYH UHDFKHG WKH IiQiVK OiQH! I ZDQW WR WKDQN WKH DPdZiQg SHRSOH ZKR WRRG Ey PH DQG KHOSHG PH QDYigDWH WKiV OiIH-FKDQgiQg jRuUQHy. 7KHu VuSSRUW DQG guiGDQFH ZHUH iQVWuPHQWDO iQ KHOSiQg PH HDUQ Py GRFWRUUDWH, HYHQ iQ WKH IDFH RI uQHxSHFWHG FKDOOHQgHV.

I HxWHQG Py IRUHPRVW gUDWiWuGH WR Py 3KD VuSHUYiVRUV, AVVW. 3URI. YDYuz Oktay and Assoc. Prof. Zerrin Işık, for their consistent support, guidance, and HQFRuUDgHPHQW, ZKiFK SURYHG iQYD0uDEOH WKURugKRuW WKH HQWiUH UHVHDFK SURFHV. 7KHu uQZDYHuQg SUHVHQFH DQG GHSWK RI NQRZOHGgH KDYH SODyHG D FUuFiDO UROH iQ IRUPiQg Py DFDGHPiF gURZWK IURP WKH HDUOy SKDVHV RI GHYHORSiQg Py UHVHDFK SURSRVDO WR WKH IiQDO VuEPiVViRQ RI Py WKHViV.

BHViGHV Py VuSHUYiVRUV, I ZRuOG OiNH WR WKDQN Py WKHViV FRPPiWWh PHPEHUV Assoc. Prof. Gökhan Karakülâh and Asst. Prof. Cihangir Yandım for their FRQWuEuWiRQV DQG FRPPHQWV. 7KHy KDYH FKDOOHQgHG PH ZiWK FRQVWuFWiYH FuiWiFiVPV PDWuUiQg PH DQG Py UHVHDFK. Oy gHQuiQH WKDQNV DOVR gRHV WR DU. (YDQgH0iD 3HWVDODNi IRU giYiQg PH WKH RSSRUWuQiWy RI IHOORZVKiS iQ (OB/- (BI IRU D UHVHDFK HxSHUiHQFH iQ D GyQDPiF HQYiURQPHQW.

Oy ViQFHUH WKDQNV DOVR gR WR 2NWDy 1HuURgHQRPiFV /DE PHPEHUV iQ IBG especially, Ece Sönmezler Adalı, Işık Esin Kiroğlu, Melike Tetik, Burcu Ekinci, Aykut Kuruoğlu, Güneş Şayan Can, Ebru Bakır, Tutku Yaraş and Dr. Semra Hız for the times RI ZRUN DQG IUiHQGVKiS. I DOVR ZDQW WR WKDQN 3DuOD = HiGHPüOOHU DQG RWKHU PHPEHUV RI WKH 3HWVDODNi UHVHDFK gURuS IRU WKHiU FRPSDQiRQVKiS iQ Py jRuUQHy iQ (BI.

I would like to thank Dr. Aadil Javed, Dr. Vanessa Segovia Aksu, Dr. Güneş Özhan, Dr. Hasan Buğra Çoban for their continued support and friendship during my 3KD jRuUQHy. I ZRuOG DOVR OiNH WR WKDQN WR Py IUiHQGV OH0iNH KöVH, GDPZH Yurdunkulu, Çağrı Buldu, Necati Kaan Kutlu and Dr. Ayşegül Çifçi for their QRuUiVKiQg DQG UHiUHVKiQg FRPSDQiRQVKiS.

I ZRuOG OiNH WR DFNQRZOHGgH WKH 6FiHQWiliF DQG 7HFKQRORgiFD0 5HVHDFK IQVWuWiRQ RI 7uUNHy (78BI7AK - BID(B 2211-C), CRuQFi0 RI +igKHU (GuFDWiRQ (CR+(- YÖK 100/2000), DQG KYK GRFWRUOD VFKRODUVKiS SURgUDPV IRU VuSSRUWiQg PH DQG Py UHVHDFK IiQDQFiDOOy. I ZRuOG DOVR OiNH WR DFNQRZOHGgH 78BI7AK 8/AKBi0, +igK 3HUIRUPDQFH DQG GUiG CRPSuWiQg CHQWHU (758BA UHVruUFHV) IRU VuSSRUWiQg PH

ZiWK FRPSuWDWiRQD0 SRZHU (FRPSuWDWiRQD0 DQD0yVHV SHUIRUPHG iQ WKiV WKHViv ZHUH SDUWiD00y SHUIRUPHG D 758BA).

/DVW EuW QRW OHDVW I ZDQW WR HxSUHVV Py GHHSVW WKDQNuOQHVV WR Py IDPiOy members Doğan Öztoprak, Elife Öztoprak, Derya Öztoprak and Şeyma Öztoprak for EH0iHYiQg iQ PH DQG WKHu QHYHU HQGiQg liQDQFiD0 DQG HPRWiRQD0 VuSSRUW GuUiQg Py ORQg DQG DUGuRuV jRuUQHv.

JDGiPH ÖZ7235AK



AB675AC7

**DHvHORSing 1RvH0 7DUgHWHG 7KHUDSiHV 7RZDUGV HigK GUDGH GOiRmd (HGG) Ey
8Ving 2miFV DDWD InWhgUDWiRn ASSURDFKHV**

GOiRPDV DUH WKH EUDiQ WuPRUV WKDw GHYHORS iQ gOiD0 FH00V DQG SUHVHQW VHYHUH
FKDOOHQgHV EDVHG RQ iQWHUWuPRUD0 KHWURgHQHiWy DVVRFiDwHG ZiWK GiIHUHQW VuEWySHV,
IuUWKHU OHdGiQg WR SRRU SURgQRViV DQG RuWFRPHV IRU SDWiHQWV. 7KiV VWuGy ZDV FRQGuFWHG
WR uWiOizH WKH WUDQVFUiSWRPiFV DQG D1A PHWKyODWiRQ GDWDVHWV DYDiODEOH WR UHVHDFKHUV
WR DUUiYH Dw FRQFOuViRQV WKDw FDQ EH uWiOizHG IRU HiWKHU VFUHHQiQg QRYH0 WDUgHWV RU uVH
DOUHDGy HWWDEOiVKHG GUugV WKDw FDQ WDUgHW WKH VSHFiLiF gHQH VigQDWuUH DVVRFiDwHG ZiWK
ORZ gUDGH gOiRPDV (/GGV), ZKiFK GHYHORS iQWR KigK gUDGH gOiRPDV (+GGV) RU
GOiREODVWRPD PuOWiIRUPH (GBO). z H iGHQWiLiHG FR-HxSUHVViRQ PRGuOHV DQG WKHiU
DVVRFiDwHG SDWKZDyV IRU VSHFiLiF VuEWySHV RI /GG ID+ PuW S7(57-, ID+ PuW
S7(57+, ID+ ZW S7(57-, DQG ID+ ZW S7(57+. z H FRQVWUuFWHG FR-HxSUHVViRQ
PRGuOHV EDVHG RQ WKHVH VuEWySHV DQG IRuQG FRPPRQ DQG GiIHUHQW HQuiFKHG SDWKZDyV
DV VyQDSVH SDWKZDyV DQG iPPuQH-UHODWGH SDWKZDyV, UHVSHFWiYHOy. z H IuUWKHU HxSORUHG
WKH GiIHUHQWiD00y HxSUHVViHG gHQHV (D(GV) DQG IRuQG D gHQH VigQDWuUH RI uSUHguODwHG
G1G12 DQG GRZQUHguODWGH 3LCB1, G5IA2, GAB5A3, anG G1AL DIWHU PDSSiQg
D(GV RQ RuU FR-HxSUHVViRQ PRGuOHV RI iQWHUHW. 7KiV gHQH VigQDWuUH ZDV iQFOuGHG iQ
RuU GUug-gHQH iQWHUDFWiRQ DQD0yViV, OHdGiQg uV WR 4 GUugV (9HPuUDiHQiE, 9DQDGiuP
3HQWRxiGH, IPDWiQiE, DQG CiVSODWiQ,) WKDw FDQ WDUgHW 4 RuW RI 5 gHQHV. 7KHUHIRUH, ZH
UHFPPHQG HxSORUiQg WKH VyQHUGiVWiF HiiHFW RI WKH FRPEiQDWiRQ RI WKHVH GUugV DgDiQVW
ORZ DQG KigK gUDGH gOiRPDV. :H DOVR iQWHgUDWGH WUDQVFUiSWRPiFV DQG D1A PHWKyODWiRQ
GDWD WR GHYHORS QHWZRUV iQFOuGiQg HSiGHQWiF iDFWRUV WKDw FDQ EH WDUgHWHG iQ D VuEWySH
VSHFiLiF PDQQUH. 2uU DQD0yViV UHYHDOHG WKDw 35MT5 FDQ EH uVHG DV D WDUgHW iUUVSHFWiYH
RI WKH /GG VuEWySH DQG WEE1 iV D VSHFiLiF WDUgHW IRU ID+ ZW UHgDUGOHV RI S7(57
VWDuV. 7KH VSHFiLiF FKHPiFD0 iQKiEiWRUV RI WKHVH WDUgHWV EHiQg DYDiODEOH FRuOG iDFiOWDwH
WUDQVODWiRQ RI RuU IiQGiqGv iQWR SUHF0iQiFD0 VHWWiQgV.

KHyZRUGV: GOiREODVWRPD, /RZHU GUDGH GOiRPD, 7UDQVFUiSWRPiFV, CR-HxSUHVViRQ
AQD0yViV, D1A OHWKyODWiRQ, BiRiQIRUPDWiFV 3iSHOiQH, DUug-GHQH iQWHUDFWiRQ

Omics Veri Entegrasyon Yaklaşımlarını Kullanarak Yüksek Dereceli Gliomaya (HGG) Yönelik Yeni Hedefli Tedavilerin Geliştirilmesi

Gliomalar, glial hücrelerde gelişen beyin tümörleridir ve farklı alt tiplerle ilişkili intertümörel heterojenite tedaviyi zorlaştıran bir faktör olup, hastalar için kötü prognoza ve sonuçlara yol açar. Bu çalışma, araştırmacıların kullanımına açık olan transkriptomik ve DNA metilasyon veri setlerinden yararlanılarak yüksek dereceli gliomalar (HGG) / glioblastoma multiforme'ye (GBM) dönüşme potansiyeline sahip düşük dereceli gliomalar (LGG) ile ilişkili spesifik gen imzalarını hedef alabilen öQFHGHQ EHOiUlenmiş ilaçların kullanılmasını veya yeni terapi hedeflerinin belirlenmesi amacıyla gerçekleştirilmiştir. Bu amaçla, LGG IDH mut pTERT-, ID+ PuW S7(57+, ID+ ZW S7(57- YH ID+ ZW S7(57+'QiQ VSHVilIN DOW WISOHUiQGH RUWDN HNVSUHVyRQ PRGüOOHUiQi YH EuQODUOD ilişkili yolakları belirledik. Bu alt tiplere dayanarak ortak gen ifade modülleri oluşturduk ve sırasıyla sinaps yolakları ve bağışıklıkla ilgili yolaklar gibi ortak ve farklı zenginleştirilmiş yolaklar bulduk. Diferansiyel olarak eksprese HGİOHQ gHQOHUi (D(G'ler) daha ileri düzeyde araştırdık ve DEG'leri ilgili ortak ekspresyon modüllerinde haritaladıktan sonra ifadesi artmış *G1G12* ve ifadesi azalmış *3LCB1*, *G5IA2*, *GAB5A3* ve *G1AL*'den oluşan bir gen imzası belirledik. Bu gen imzasının ilaç-gen etkileşimi analizimize dahil edilmesi bizi 5 genden 4'ünü hedef DODEiOHQ 4 iODFD (9HPuUDIHQiE, 9DQDGyuP 3HQWRNVW, IPDWiQiE YH CİVSODWiQ) yönlendirdi. Bu nedenle, bu ilaçların kombinasyonunun düşük ve yüksek dereceli gliomalara karşı sinerjistik etkilerinin araştırılmasını öneriyoruz. Ayrıca alt tipe özgü bir şekilde hedeflenebilecek epigenetik faktörleri içeren ağlar geliştirmek için WUDQVNUiSWRPiN YH D1A PHWiODVyRQ YHUiOHUiQi HQWHgUH HWWiN. AQDOiziPiz, *35MT5*'iQ LGG alt tipinden bağımsız bir hedef olarak kullanılabileceğini ve *WEE1*'iQ, S7(57 durumuna bakılmaksızın IDH wt için spesifik bir hedef olduğunu ortaya çıkardı. Bu hedeflerin spesifik kimyasal inhibitörlerinin mevcut olması bulgularımızı klinik öncesi çalışmalarda kullanım açısından faydalı kılmaktadır.

AndKWDU KH0imHOHU: Glioblastoma, Düşük Dereceli Glioma, Transkriptomik, Ko-ekspresyon Analizi, DNA Metilasyonu, Biyoinformatik, İlaç-Gen Etkileşim

1. INTRODUCTION

Glioblastoma, also known as glioblastoma multiforme (GBM) is an extremely aggressive type of brain tumor initiating in the glial cells of the brain. These cells inherently are involved in maintaining the structural stability of the neurons, which are the fundamental operational units of the nervous system (Hanif et al., 2017). The complex nature of Glioblastoma raises several difficulties in the selection of treatment modalities according to the attributes of the surroundings of the brain as well (Akter et al, 2021). The issues leading to such difficulties include the phenomena of immunosuppression, challenges within the drug development, the recurrence of the disease, location of tumor and its functional impact, the tumor microenvironment, limited treatment options, resistance to available therapeutic options, heterogeneity of the tumor, blood brain barrier, and invasive nature of the tumor. In order to deal with aforementioned hurdles, the expertise of a wide range are necessitated including oncologists, neurologists, researchers, and medical experts (Wu et al, 2021). For enhancing the treatment outcomes for the patients, several elements including inventive treatments such as immunotherapies and precision drugs along with progression in understanding the genetic foundations and molecular signatures of Glioblastoma are required (Ganipineni et al, 2018)..

Integrative omics analysis encompasses the understanding and merging of the data obtained from different advanced biological domains including metabolomics, proteomics, transcriptomics, and genomics among others. This methodology provides a unique and deep perspective on the profiles of biological systems towards specific scenarios which has the capacity to empower the research to further elucidate the intricate biological systems and significant understanding of entities involved in different diseases (Nice et al, 2018). The integrative omics analysis gives rise to the construction of prognostic models, annotation of genome functionalities, facilitation in exploration of novel drugs, tailored medical approaches, investigations in disease mechanisms, and identification of molecular biomarkers (Misra et al, 2019). The strategy has specially been utilized in helping clinicians and researchers in untangling the biological phenomena to further our understanding of the diseases and to incorporate that information in patient well being as the goal (Karczewski & Snyder, 2018).

The comprehensive study of Ribonucleic acid (RNA) molecules in tissues or cells is called transcriptomics, which has been considered indispensable for identifying the various subsets of different cancers based on expression of genes i.e. transcripts (Maniatis et al, 2021). The subsets obtained from gene expression data forming clusters can lead to insights informing the diversity of individual cancers, which can further help in individualizing the therapeutic strategies efficiently (Valdes-Mora et al, 2018). The detailed applications of transcriptomics are exploration of gene expression profiling and its association with targeted therapies, functional enrichment analysis, differential gene expression analysis, unsupervised clustering and integration with other omics data for patient characterization (Supplitt et al, 2021). The sophisticated computational techniques along with the gene expression patterns obtained from transcriptomics analysis facilitate the researchers in diagnosis, treatment strategies, empowering comprehension, and investigate the molecular diversity of different cancers based on pinpointing the subsets within heterogeneous cancers such as Glioblastoma (Fan et al, 2020).

There are other types of omics data which have been used for exploring the biological systems informing the gene expression profiles further in different scenarios such as methylation status of DNA molecules. The methyl groups are attached to DNA molecules which inherently store the genetic information and constitute the chromosomes. This modification of DNA can govern changes in structure of chromatin and influences the accessibility of molecular machinery such as RNA polymerases to DNA molecules, preventing the cellular apparatus from initiating the process of transcription or gene expression (Bock, 2012; Ramsey et al., 2010). The epigenetic regulation of the genome can be delineated from the datasets related to DNA methylation along with the mechanistic details of genetic pathways, subtypes, biomarkers, and gene expression. Therefore, this modification of DNA which can be identified on genomic scale utilizing various platforms holds significant importance in unveiling gene activity and subsequently the molecular signatures arising from the activity or inactivity of various genes in states such as normal or diseased conditions (Horvath et al, 2013). The tailored strategies can be formulated on the plausible therapeutic targets obtained from the epigenomic data (Li et al, 2015).

The molecular changes occurring across different cancer types along with the characterization of the genetic data from cancer patients are the major objectives of

The Cancer Genome Atlas (TCGA), which is the pioneering project undertaken to study cancer genomes (Tomczak et al, 2015). The extensive datasets from TCGA projects contain a plethora of data involving the whole cancer genomes, transcriptomes, epigenomes, and proteomes along with the information obtained from the clinical features of the patients. The clinical application and molecular investigations on cancers at the molecular levels have been impacted profoundly upon utilizing these datasets as the cancer biology field has been revolutionized due to deep knowledge obtained from TCGA datasets (Wang et al, 2016). More recent applications of TCGA datasets involve the determination of survival related markers and application of deep learning methods to predict the drug response (Nicolle et al, 2019; Shen et al, 2023).

Since glioblastoma possesses a more significant threat as a disorder due to challenges mentioned previously along with the fact that aggressive forms of the disease have restricted treatment avenues, more tailored approaches toward molecularly identified subtypes of the disease are required to overcome these challenges. This study is designed to include integrated omics methodology to merge the transcriptomics and DNA methylation profiles of different clusters obtained from differentiated molecular subtypes of glioblastoma arising from TCGA datasets. The major aim of the study is to develop and implement an approach to identify the significant molecular pathways and the genes associated with the progression of low grade gliomas along with the potential plausible therapeutic agents. The gene expression patterns arising from transcriptomics data and its compilation with the DNA methylation data showcasing the epigenetic alterations in cancers, researchers can attain a multifaceted comprehension of the disease (Du et al, 2023), which is important in determining the treatment strategies tailored to molecular signatures of the cancer subtype.

The implementation of the sophisticated computational methods can help dissect the gene expression and DNA methylation trends in different genetic subtypes which can further be aligned with the severity of the disease (Binder et al, 2019). With the usage of unsupervised clustering techniques, molecular subcategories for cancers can be discerned, which can mirror the disparities found in the biological responses, signaling pathways and cellular mechanisms (Zhu et al, 2023). The subsequent gene list obtained within each clustered cohort in subtypes can undergo the functional enrichment analysis which can help in determination of

the disrupted biological pathways fueling the progression of the disease (Timmons et al, 2015). These bioinformatics pipelines can facilitate the identification of direct pathways involved in specific conditions of the disorder. The integration of omics approaches therefore can lead to certain hits which can be used as potential targets in therapeutic interventions or biomarkers (Lund et al, 2017; Song et al, 2019). Therefore, the use of omics technologies and their integration has the potential for customized or refined treatment strategies.

As glioma is a complex disorder with complex genetic subtypes, the transcriptomics and DNA methylation data should provide an in-depth view of the molecular signatures of the disease based on genetic profiles of the patients. Then the integration of these two types of omics data can facilitate the potent targets which can be utilized for tailored therapeutic strategies. Therefore, we employed the integration of these molecular datasets and implicated molecular patterns from low grade gliomas to not only recognize the genes that exhibit differential expression but also the significant epigenetic changes as well. We also executed a bioinformatics based search to identify several drugs that can target the genes expressed differentially in one of the genetic subtypes of gliomas.

The significance of this study emanates from the utilization of the TCGA data which is considered the gold standard among researchers in identifying the molecular patterns of various cancers. The specific outcomes of this study has the capacity to inform the targetable pathways associated with genetic subtypes of gliomas through comprehensive and integrated omics approach utilized in this study. The molecular characteristics and a narrow list of genes with the distinct subtypes can help unravel the diverse and complex molecular pathways involved in the progression of LGGs to HGGs, and the information can be used by both researchers and medical practitioners. Moreover, a detailed and integrated approach can not only amplify the effectiveness of the treatment but also can decrease the undesired impacts due to utilization of the molecular targets that contribute to proliferation of the disease (Paananen & Fortino, 2020). In summary, this study can facilitate the identification of driver genes, molecular and biological pathways along with the potential targets for glioma subtypes. We integrated the transcriptomics and DNA methylation of LGG TCGA dataset and external transcriptomics and methylation data of normal samples to arrive at conclusions dictating the molecular drivers of the disease. We also observed the drug-gene interactions focusing on the genes identified as

up-regulated or down-regulated in one of the subtypes of lower grade glioma, further highlighting the importance of bioinformatic pipelines and their utilization in targeting pathways associated with different forms of glioma.



2. LITERATURE REVIEW

2.1. Overview of Gliomas

The brain tumors likely originating in the glial cells of the brain are termed as gliomas. These cells are responsible for providing the nourishment and support to the functional units of the nervous system i.e. neurons. Different types of gliomas depending on the types of cells the tumors originate from include ependymomas, oligodendrogliomas, and astrocytomas (Whitfield & Huse, 2022). The grading of the gliomas from Grade I to IV is based on the potential for growth of the tumor and its aggressiveness (Zhuge et al, 2020). The slow growing and least aggressive tumors of gliomas are considered Grade I, with Grade IV representing the most severe form of the disease (Zhuge et al, 2020).

The most common symptoms of the gliomas are numbness in the limbs, speech difficulties, changes in the vision capabilities, seizures, and headaches (Dono et al, 2020). The symptoms vary depending on the location of the tumors. Furthermore, the conventional treatment options available for gliomas include chemotherapy, radiation therapy, and surgery and are considered the first line of defense against the disease and depends on the overall health of the patient, location and grade of the tumor along with other factors (Schaff & Mellinghoff, 2023). The advanced forms of therapies for gliomas also exist and include stem cell therapy, molecular targeted therapy, immunotherapy, oncolytic virus therapy, and electric field therapy (Xiong & Wang, 2019).

2.2. Overview of LGG and GBM

Since LGGs can turn into GBM, we integrated the relevant literature to both LGGs and GBM in our study. As mentioned previously glioma is a term which acts as an umbrella for describing multiple types of brain tumors and usually Grade IV gliomas with the most aggressive presentation are termed Glioblastoma. Such types of tumors are also known as Glioblastoma Multiforme (GBM), due to their extreme heterogeneity. Lower Grade Gliomas (LGGs) correlate with younger age, while GBM typically occurs in adults and accounts for more than 60 % of the brain tumors

presented in tumors of the brain in all adults (Grech et al, 2020). The higher incidence rates along with the resistance to treatment modalities and significantly higher recurrence rates make GBM one of the deadliest cancers. The astrocyte Grade II and Grade III tumors, Grade IV Glioblastomas, and Grade II and Grade III oligodendrogliomas comprise the adult diffuse Gliomas according to the World Health Organization (WHO) (Louis et al, 2016).

Glioblastoma is rarely metastasized and is known to invade the nearby areas of the brain, but remains the most deadly and invasive glioma (Paolillo et al, 2018). The diagnostic reproducibility is limited for glioblastoma and the histologic diagnosis is also prone to changes depending on the clinicians (Kan et al, 2020). The *de novo* or primary GBM is the most common and aggressive form of the disease with secondary GBM less prevalent and initiating at lower-grade as astrocytoma but has been known to become Grade IV tumor as well (Urbańska et al, 2014; Nguyen et al, 2021). The pathogenic features of glioblastoma are diverse. The current failures in treatment are also associated with immunosuppression. Therefore, the long term survival of the patients is hard to achieve (Shergalis et al, 2018).

2.3. Incidence Rate and Survival for LGG and GBM

The neuroepithelial tumors of CNS are gliomas with varying behaviors ranging from LGG as tumors that are more or less resectable to the aggressive phenotypes including diffuse intrinsic pontine gliomas (DIPGs) and GBMs having the worse prognosis of all (Farmanfarma et al, 2019). LGGs likely occur in early childhood and high grade gliomas tend to occur at later stages. Normally LGG are graded as Grade I and Grade II with different types including mixed, diffuse, pleomorphic, giant cell, pilomyxoid, pilocytic forms along with desmoplastic infantile ganglioglioma, and oligodendrogliomas (McKhann & Duffau, 2019). The pediatric LGG annual incidence rate is calculated as 1.3-2.1 per 100,000 in the United States (Miguel Llordes et al, 2023). The adult LGG is considered more common as compared to pediatric LGG with cases rising up to 9.1-12.5 per 100,000 in the United States (Lin et al et al, 2021). The cases of adult LGG occur from 2nd to 4th decade of life as most cases are diagnosed during this period (Diwanji et al, 2017).

Among malignant brain and central nervous system tumor histopathologies, glioblastoma comprise 14.2 percent of all tumors and 50.1 percent of all the malignant forms of the tumors in the United States (Ostrom et al, 2022). It is also more prevalent in males as compared to females with males affected at 1.6 fold more than females (Chen et al, 2021). The White ethnic patients are at 2-fold higher risk for glioblastoma compared to the Black patients (Ruhban et al, 2019). The latest age-adjusted incidence rate for Glioblastoma was calculated as 3.22 per 100,000 population in the United States (Ostrom et al, 2019). The 5-year survival rate for Glioblastoma is 4-5% (Batash et al, 2017). The largest cumulative study calculating the survival rate for Glioblastoma over a period of 10 years concluded that the ten year survival rate of Glioblastoma is 0.71% (Tykocki & Eltayeb, 2018). This data indicates that glioblastoma is a lethal disorder and treatment strategies need improvement to increase the survival rate of the patients (Janjua et al, 2021).

2.4. Clinical Presentation of LGG and GBM

The histology and the location of the lesion determine the presentation of LGG clinically in children and adults (Byrne et al, 2017). High grade lesions show progressive symptoms rapidly and low grade lesions present with insidious onset spanning over several months. The long history of seizures is also associated with low grade lesions which are known to be refractory to the antiepileptic treatments (Piotrowski & Blakeley, 2015). The malignant gliomas present with more than 30 % cases having seizures with low grade lesions having more seizures (Samudra et al, 2019). Other signs associated with LGG are aphasia or hemisensory deficits and hemiparesis as focal neurologic deficits along with mental status changes, balance changes, and headaches as higher intracranial pressure (Forst et al, 2014).

The course of the disease of glioblastoma is determined upon the factors such as tissue destruction and the extent of edema along with epilepsy and tumor location. These are the reasons why the clinical presentation for glioblastoma is not typical. Standard treatment options can still help in preserving the cognitive functioning and quality of life for the patients despite the fatal prognosis for glioblastoma. However, the decrease in cognition and decline in quality of life occur rapidly once the treatments start failing and lead to severe outcomes (Palmer et al, 2021; McKinnon et al, 2021; Bruhn et al, 2022).

Headache is the the most common symptom with presentation in one-third of the patients which results from the intracranial pressure occurring at night or patient awakening with dullness (Palmieri et al, 2021). At the time of diagnosis, heightened intracranial pressure can further cause slowing of neurocognition, vomiting, nausea, fatigue, and dizziness. Using steroids such as dexamethasone can lead to amelioration of the symptoms caused by increased intracranial pressure (Grant, 2019).

Glioblastoma can also originate from the brain stem and lead to pediatric glioblastoma with patients typically presenting with occlusive hydrocephalus, dysphagia, and cranial nerve palsies or combination of these symptoms (Alther et al, 2020). Glioblastoma is associated with tropism in the brain, however, cases with liver, bone, lymph nodes, pleura, and lung metastasis are also found (Achi et al, 2023). Therefore, the follow up procedures required to obtain information from other parts of the body are also not required in patients presented with diagnosis of glioblastoma. Moreover, the glioblastoma patients can be donors for organ transplantation as cancer transmission risk is minimal in such scenarios (Warrens et al, 2012; Zhu et al, 2020).

2.5. Intrinsic Risk Factors for Gliomas and GBM

Gliomas can develop without inheritance within a family but there are familial gliomas as well that follow the Mendelian pattern (Louis et al, 2016). Malignant gliomas have been explored using genome wide studies to explore the genetic risks for the development of brain tumors (Ostrom et al, 2019). Such studies indicated that there are 25 susceptibility-associated genomic loci across the incidence variance for glioma in adults encompassing approximately 30 % of the factors, with 70 % remaining unknown (Kinnersley et al, 2015; Ostrom et al, 2019). Somatic mutations play a major role in the tumorigenesis of glioma (Howell et al, 2018), as explained in the following sections.

Apart from the age, other intrinsic risk factors associated with a small proportion of gliomas include hereditary syndromes of cancer including Turcot syndrome, neurofibromatosis I and II types along with Li-Fraumeni syndrome (Mutiarayani, 2023). Brain tumors including pilocytic astrocytoma and brainstem astrocytoma are mainly associated with *NF1* gene as autosomal dominant syndromes

or Neurofibromatosis type 1 (NF1) (D'Angelo et al, 2019). NF2 syndrome is associated with either somatic or germline mutations in *NF2* gene which is a tumor suppressor gene. These mutations give rise to cranial meningiomas and cranial nerve schwannomas which are the tumors of the peripheral and central nervous system (CNS) (Tabor et al, 2023). The mutations in *TP53* tumor suppressor gene lead to Li-Fraumeni syndrome (Rocca et al, 2022). In Li-Fraumeni syndrome, the germline mutations in *TP53* have been associated with neuroepithelial tumors of the CNS, which have been found to be more common in females as compared to males (Xiong et al, 2020).

The Turcot syndrome is associated with mutations in *APC* gene which acts in repairing DNA (Khattab & Monga, 2022). The mutations in *NF1* and *NF2* are linked with neurofibromatosis I and II types (Aldape et al, 2015). The cases of more than one patient of glioblastoma in one family are rare, which makes the identification of risk loci difficult in the relatives of the patients (Molinaro et al, 2019).

The risk alleles for gliomagenesis have been observed from population based genome wide association studies including *RTEL1*, *TERT*, *AF*, *EGFR*, and *TP53* (Wrensch et al, 2019). Both *RTEL1* and *TERT* function in the telomere maintenance and risk alleles are specific for histological classification and diagnosis at older age (Walsh et al, 2013). The genome wide linkage investigations also yielded no significant high penetrance variants that can be linked with the risk of glioblastoma (Walsh et al, 2013). However, for gliomas, recently researchers identified *DMBT1*, *ZCH7B3*, and *HP1BP3* as non-coding variants after surveillance of the genomic landscape using CRISPR knockdown approach (Choi et al, 2023).

2.6. Subtypes of LGG or GBM Based on Genetic Mutations

The mutations in oncogenes and tumor suppressors are known to drive the process of carcinogenesis and in the case of gliomas and glioblastoma, there are several genes that have been linked with the disease-status based on their mutation status and can be used as markers for classification of the disease (Whitfield & Huse, 2022).

2.6.1. IDH Wild Type and IDH Mutant Gliomas or GBM

The discovery of mutations in the isocitrate dehydrogenase 1 (*IDH1*) gene marked a significant milestone in the understanding of the molecular pathology underlying glioblastoma and gliomas in general. Initially, a particular point mutation in the *IDH1* gene, R132H, in samples of glioblastoma patients was found (Parsons et al, 2008). Later, the mutations in *IDH1* and *IDH2* genes were associated with higher survival rates in glioblastoma patients as compared to patients with wild-type *IDH1* or *IDH2* genes (Yu et al, 2010). It was further understood that the features including prognosis and clinical characteristics also differ for patients with *IDH* mutations as compared to patients with wild-type *IDH* genes (Mondesir et al, 2016).

IDH1 enzyme is found in the cytoplasm, while *IDH2* and *IDH3* enzymes reside in the matrix of mitochondria. These are the critical enzymes responsible for oxidative stress resistance and citric acid cycle (Bergaggio & Piva, 2019). The most commonly found mutation of *IDH1* in gliomas is R132H (Parsons et al, 2008). The current WHO classification of glioblastoma includes *IDH* wildtype (wt) and *IDH* mutant (mut), with *IDH* wt tumors displaying necrosis, microvascular proliferation, mitotic activity, diffuse growth pattern, cellular polymorphism, nuclear atypia, differentiation, and more prominently poor survival (Dono et al, 2020; Motomura et al, 2023).

The development of most low grade glioma (LGG) tumors are associated with the *IDH1* or *IDH2* mutations, as these are considered the earliest events in this transformation (Dono et al, 2021). Like in glioblastoma, *IDH* mutation leads to overall longer survival in LGG patients, while at the same time being associated with the malignant transformation of the tumors (Leu et al, 2016). *IDH* wt LGGs are considered heterogeneous with varying outcomes reported in clinical analyses. Furthermore, the inclusion of *EGFR* amplification, *H3F3A* mutation, and *TERT* promoter mutation in this subtype of LGG leads to worse prognosis (Vuong et al, 2019).

The three variants of *IDH* wt glioblastoma are epithelial-like GBM, gliosarcoma, and giant cell GBM (Louis et al, 2016). The epithelial-like GBM manifests as mesencephalic masses with *BRAF* V600E mutation and is more common in young people and children (Broniscer et al, 2014). Furthermore, this subtype lacks *PTEN* loss and *EGFR* amplification, as well (Alexandrescu et al, 2016). The *CDKN2A* deletion is found in Gliosarcoma (*IDH* wt) with less common *EGFR* amplification and *TP53* mutations (Lowder et al, 2019). Moreover, giant cell

GBMs are also reported to lack the *CDKN2A* deletion and *EGFR* amplification, but entail *TP53* and *PTEN* mutations (Ogawa et al, 2020). IDH mut glioblastoma exhibit susceptibility to treatment with temozolomide as compared to IDH wt form (SongTao et al, 2012).

2.6.2. 1p/19q co-deletion

The concurrent deletion of both the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q), known as 1p/19q co-deletion, represents an early genetic event, along with *IDH1/2* mutations, contributing to the initiation of glioma and influencing overall survival outcomes. (Jenkins et al., 2006). Almost all LGGs that have 1p/19 codeletion also have *IDH1* or *IDH2* mutations (Labussiere et al., 2010). Many studies have shown that the LGGs with both 1p/19 codeletion and IDH mutations, has best prognosis (Kujas et al., 2005; Jenkins et al., 2006; Tews et al., 2006; Iwamoto et al., 2008), but the underlying mechanism is still unclear.

Tews et al. (2006) demonstrated that the genes located on deleted arms (1p/19) were differentially expressed between codelet and non-codelet samples, giving rise to the thought that the improved prognosis of patients with 1p/19q co-deleted gliomas may be attributed to at least some of these genes.

2.6.3. TERT Promoter Mutations

TERT encodes a telomerase enzyme responsible for inhibiting the shortening of the ends of chromosomes, thereby regulating the cellular aging process. It is also found as dysregulated in different cancers (Colebatch et al, 2019). The presence of either of two mutations (C228T or C250T) in the promoter of *TERT* gene (TERTp) have been identified as a marker for worse prognosis for glioblastoma (Powter et al, 2021). The TERTp mutation status is associated with elderly patients presenting Grade II/III glioma with 40 % frequency, further implicating that the correlation of TERTp mutation with pathology of glioma can be utilized not only as a prognostic feature but can be targeted for therapy as well (Fujimoto et al, 2021; Aquilanti et al, 2023).

In LGG IDH wt tumors with pTERT mutation leads to clustering of tumor samples with GBM based on DNA methylation profiling, implying that pTERT

mutation is involved in increasing the invasiveness and severity of the disease (Fujimoto et al, 2021). Therefore, it is suggested that the clinical analysis of pTERT mutation in astrocytic gliomas (LGG) displaying features of glioblastoma are required for the diagnosis of diffuse astrocytic LGG.

2.6.4. EGFR Amplification

The *EGFR* mutation in gliomas usually leads to *EGFR* amplification with EGFRvIII variant being the most common (Garima et al, 2022). The genetic loci of *EGFR* is Chr7 (7p12) and encodes the receptor tyrosine kinase functioning at the surface of the cells (Romano & Bucci, 2020). The *EGFR* degradation and internalization is impaired upon EGFRvIII variant activation which further causes the activation of anti-apoptotic signaling mitotic pathways associated with the tumorigenic capacity of GBM (Hoogstrate et al, 2022). Both EGFRvIII and *EGFR* amplification have been implicated in worsening the prognosis for young patients but *EGFR* overexpression is also specifically linked with poor survival in older patients (Chi et al, 2020). In LGG IDH wt (diffuse astrocytoma), *EGFR* mutations or amplification are also reported as clinically instructional, but the use of *EGFR* specific or pathway specific inhibitors have been utilized for glioblastoma with *EGFR* amplification (Yang et al, 2022).

2.6.5. PTEN Mutation

PTEN is a tumor suppressor gene and loss of its function has been associated with carcinogenesis. The *PTEN* protein is involved in catalyzing the removal of a phosphate group from the inositol ring present in PIP3 phospholipid. This reaction leads to the production of PIP2 and is critical for inhibiting the AKT signaling pathway (Yang et al, 2020). In quiescent and differentiated cells, the PI3K/AKT pathway is dormant, however its activation can lead to positive regulation of cell cycle which is required for carcinogenesis (Jiang et al, 2020). The *PTEN* loss disturbs the lipid phosphatase function via the PI3K/AKT pathway and leads to aggressive phenotypes which can be targeted for therapy as well (Choi et al, 2021). Moreover, *PTEN* deleted or mutant gliomas including LGG are known to have very aggressive phenotype, worse prognosis and therapeutic resistance (Zhang et al,

2021). Another study indicated that the PTEN mutant LGG showed highest malignancy comparable to GBM, which can be used as an independent prognostic factor for the disease especially in the case of IDH with PTEN mutant cases (Zhang et al, 2021).

2.7. Transcriptomics Profiling for LGG

Cancers are heterogenous disorders with varying degrees of diversity at genomic, transcriptomic, and proteomic levels. Therefore, in order to not only accurately characterize the pathogenesis of the disease, but also to understand the heterogeneity, transcriptome-wide analysis and profiling can be useful (Fan et al, 2020). The changes in gene expression levels monitored by utilizing the next-generation sequencing technologies including RNA sequencing can result in quantifying the high throughput parallels in multiple scenarios. Therefore, phenotypic alterations occurring at molecular level can be monitored in the perspective of systems biology (Cieřlik & Chinnaiyan, 2018; Fan et al, 2020). According to transcriptomic profiling, *CRY2*, *HDAC1*, *DCLRE1B*, and *KPNA2* genes have been identified as a transcriptomic signature for LGG utilizing the Chinese Glioma Genome Atlas (CGGA) datasets. The same study identified the DNA repair and cell cycle related biological process as dysregulated highly in LGG (Zeng et al, 2019).

The IDH and TP53 mutant cases of LGG were profiled based on integration of genomics and transcriptomics data to identify the biological pathways and it was discovered that the metastases, invasion, immune function, and neuron function related functions were enriched in LGG patients based on selected genes which can be targeted to increase the possible survival outcomes of these patients (Liu et al, 2022). Another study utilized the transcriptomics analysis to separate the LGG patients into two groups of ferroptosis-related clusters (FRC), and concluded that ferroptosis was a major driving force behind forming the tumor microenvironment in LGG (Tu et al, 2022). Therefore, transcriptomics profiling can be utilized in identifying the unknown features associated with the tumor heterogeneity based on different parameters and in the field of LGG biology, has a distinct utilization which should be explored to identify the potential drug targets.

Multiple samples can be included to identify the gene expression patterns using the method of WGCNA, which can cluster the genes in the form of modules displaying the similar patterns of gene expression (Langfelder & Horvath, 2008). The relationship between the modules and specific traits associated with the samples can then be explored. Yang et al in 2018 identified the novel prognostic targets such as *NUSAP1* and *GPR65* that can be utilized as genetic therapeutic strategies against GBM. The study arrived at their conclusion by utilizing the WGCNA based module construction strategy using Differentially Expressed Genes (DEGs) from transcriptomics data from liquid biopsy samples of GBM (Yang et al, 2018).

2.8. DNA Methylation Profiling for LGG

The epigenetic changes have been identified as significant in identifying the cancers, therefore another element of genetic regulation can be used in investigating the common biomarkers (Guo et al, 2019). The genome region rich in CpG dinucleotides are usually linked with the promoters of the genes and DNA methylation of these nucleotides (CpG islands) found in the promoters dramatically silences the expression of the genes (Caiafa & Zampieri, 2005).

The changes in the levels of DNA methylation of promoter regions containing CpG islands can either be hypermethylated leading to gene silencing or hypomethylation causing overexpression of the genes. One of the epigenetic alterations observed in cancers is DNA methylation which functions in the regulation of genomic functions and plays an important role in tumorigenesis (Davalos & Esteller, 2023). It has the potential to be utilized in clinical practice for diagnosis and prognosis of various cancers (Liu et al, 2019). The methylation status of genes are associated with their expression levels as observed for various forms of gliomas (Dabrowski & Wojtas, 2019). For example, for lower grade glioma (LGG) and glioblastoma (higher grade), *MGMT* promoter methylation is considered a prognostic factor and is also associated with the survival rates of the patients suffering these diseases (Brandner et al, 2021; Haque et al, 2022).

Several studies have been conducted to identify the subtypes of gliomas or glioblastoma based on DNA methylation profiles of the patients. In 2013, Brennan et al identified 6 subtypes of glioblastoma based on DNA methylation profiles (Brennan et al, 2013). For diffuse adult LGG, Ferreyra et al (2021) studied 166 cases

for genome-wide DNA methylation and associated methylation classes with IDH mutation status and with other genetic factors such as 1p/19q deletion. IDH wt gliomas could also be sub-categorized in the DNA methylation analysis for different molecular signatures (Ferreyra et al, 2021). Recently, according to *IDH1* mutation status, three genes were identified based on methylation-driven expression: *STEAP3*, *CMYA5*, and *ARL9* for LGG (Guo et al, 2022). Therefore, DNA methylation profiling adds another layer of framework to the guidance in prognosing the diseases such as GBM and LGG.

2.9. Multi-Omics Data Integration for Biological Insights

The integration of multiple data forms originating at high throughput and large scale such as genomics, transcriptomics, DNA methylation profiles, and proteomics, can be integrated in the form of biological pathways or networks which can provide an overview at systems biology level (Subramanian et al, 2020). These approaches have the capacity to combine the individual type of omics data simultaneously leading to comprehension of interplay between different molecules with information flow from one layer of information to another with the goal of bridging the genotype to phenotype gap inherently present in biology (Guo et al, 2021). The field of multi omics analysis is growing fast which has resulted in the development of various platforms, methods and tools for interpretation, visualization, and data analysis of multi omics data (Huang et al, 2017; Rappoport & Shamir, 2018; Wu et al, 2019).

The omics data can either be generated through biological experiments conducted in the laboratory or is readily available from different sources and databases such as The Cancer Genome Atlas (TCGA), International Cancer Genomics Consortium (ICGC), Cancer Cell Line Encyclopedia (CCLE), Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), or Omics Discovery Index (OmicsDI), and archives such as National Center for Biotechnology Information (NCBI) and Gene Expression Omnibus (GEO) (Subramanian et al, 2020). The major biological questions asked in multi omics analysis involve the classification or subtyping of diseases based on multi-omics profiling along with the prediction of driver genes responsible for triggering diseases which can be used as biomarkers as well, and to derive the biological insights behind the disease

mechanisms (Li et al, 2021). The methods or tools utilized for multi-omics approaches are subdivided into categories such as multivariate methods, correlation-based analysis, similarity based methods, fusion, bayesian or network based approaches (Subramanian et al, 2020).

The network based integration approaches can provide the gene prioritization for cancers and their integrated framework. The gene aberrations along with alterations in epigenetics and further downstream players such as microRNAs and subsequent protein expression can be integrated in the network interactions (Li et al, 2021). The network-diffusion model utilizes the per-sample method for directing the network deriving the gene ranking at population level based on the aggregates of the individual rankings with the goal of outputting the global ranking for each sample (Subramanian et al, 2020). Another clustering method based on Neighborhood analysis for multi-omics data is dependent on the similarity based analysis and is constructed upon the already established methods. It constructs the interpatient similarity matrix distances for the individual omic datasets and then integrates the data from multiple omics into a single matrix, which is then separated based on spectral clustering (Demirel et al, 2022). This method can be utilized for partial datasets as well, making it useful in scenarios where complete datasets are missing (Rappoport, N., & Shamir, 2019).

The underlying mechanisms associated with cancer can be deeply investigated with respect to drug targets or biomarkers that can be identified using pathway-based integration of omics data (Kim et al, 2019). The enrichment of pathways and over-representation can be derived from the biological entities such as metabolites, proteins, and genes to link with the already existing biological information in such methods (Tseng et al, 2015). The pipeline of such methods includes the utilization of DEGs or proteins along with their significance in the data sets based on statistical inference and then the over-representation analysis is performed based on certain thresholds to compose the background lists, depending on the number of proteins or transcripts in the reference proteome or transcriptome (Eichner et al, 2014). Any combination of genotypic, transcriptomic, DNA methylation, proteomics, or metabolomics data can be integrated to provide biological insights depending on the research question and appropriate parameters used in the integration or mapping of one dataset to another (Subramanian et al, 2020).

3. MATERIALS AND METHODS

3.1. Transcriptomics Data Collection and Preprocessing

We downloaded the expression data of the lower-grade glioma (LGG) cohort using the TCGABiolinks package (Colaprico et al, 2016). TCGABiolinks enables researchers to query, download, prepare and perform integrative analysis using TCGA data. We first queried NCI's Genomic Data Commons (GDC) portal for the TCGA-LGG project, gene expression quantification data type, Illumina HiSeq platform and legacy data using the “GDCquery” function. After creating our query, both gene expression and clinic data were downloaded using the “GDCdownload” function and prepared with “GDCprepare” function. The GDCprepare function creates a SummarizedExperiment (SE) (Huber et al, 2015) object for downstream analysis.

We divided our samples into two separate groups according to their IDH mutation status: IDH mutant and IDH wildtype (Figure 3.1). These expression matrices were then normalized and filtered with “TCGAanalyze_Normalization” (geneInfo) and “TCGAanalyze_Filtering” (quantile method, qnt.cut 0.25) functions respectively. We constructed sample clustering trees using the average method and removed the outliers. The number of samples in IDH mutant and IDH wild type subtypes of LGG along with the number of genes after normalization and filtering pipelines are shown in Figure 3.1. One outlier was excluded from IDH mutant and 5 outliers were excluded from IDH wild type samples. The selected modules with respective colors as differentiating a parameter are also given in Figure 3.1. The RNA-sequencing data exhibits non-normal distribution characteristics, warranting modeling approaches such as Poisson or negative binomial distributions for an accurate representation (de Torrenté et al, 2020). Prior to constructing weighted gene coexpression networks we normalized RNA-sequencing data with the voom methodology (Law et al, 2014) from the limma library in R (Ritchie et al, 2015) and investigated the gene quality. The voom function calculates the mean-variance of the log-counts and creates each observation's precision weight. This transformation enables us to perform comparative analysis with WGCNA which were developed for microarray analyses. Employing voom transformation on RNA-seq data is a common

practice in computational biology (Wang et al. 2017, Breen et al. 2019, Ota et al. 2021, Michlmayr et al. 2020, Singhanian et al. 2018). To ensure robustness in our analysis, we employed the median absolute deviation (MAD) as a reliable metric of variability. This choice was motivated by the need to address situations where two genes exhibit minimal variations in expression levels among patients, leading to strong correlations in WGCNA analysis.

3.2. Construction of the Weighted Gene Co-expression Network (WGCNA)

Scale-free undirected co-expression networks were constructed using the WGCNA library in R (Langfelder & Horvath, 2008; Niu et al, 2023). Soft threshold power beta values were determined using the “pickSoftThreshold” function on the scale-free topology criterion. The suggested β is the lowest value where R^2 is bigger than 0.8 (Hou et al, 2019). In accordance with this criterion, we selected beta values “6” and “12” for the IDH mut cohort and the IDH wt cohort, respectively. Setting the module size to 30 and the merge cut height to 0.25, we have constructed the gene modules with the correlation network methodology.




Figure 3.1. Module construction and clinically significant module detection by Weighted Gene Co-expression Network Analysis (WGCNA).

3.3. Identification of Clinically Significant Modules

We related the co-expression modules to clinical traits to identify clinically significant modules. This relationship is based on the eigengene network methodology. The module eigengene (*E*) is the first principal component of a given module and they are defined as the summary of each module (Langfelder & Horvath, 2008). These eigengenes are associated with the external traits (clinical information) to determine most significant associations. TCGA clinical information contains 110 features in the clinical data frame which is a collection of data related to patient diagnosis, demographics, exposures, laboratory tests, and family relationships. In this study we aimed to explore gene expression modules related to significant molecular alterations and we prioritized 8 features (of 110) that have prognostic value in clinical implications to identify clinically significant modules. These 8 features are: Chr7gain.Chr10Loss, Chr19_20.co.gain, TERT.promoter.status, TERTexpression.log2, TERTexpression.status, ATRX.status, Telomere.Maintenance and BRAF.V600E.status. We identified a module as significant if its correlation value with the TERT.promoter.status was above 0.5 or below -0.5.

3.4. Functional Enrichment Analysis

To better understand the biological mechanisms behind the modules of interest, module genes were extracted and converted to Entrez identifiers. Functional enrichment analysis was performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) platform to perform enrichment analysis (Sherman et al, 2022).

3.5. Differential Gene Expression Analysis

Differential gene expression analysis (DEA) is a widely used application to elucidate differentially expressed genes (DEGs) across two or more conditions. We analyzed differential expressed genes in LGG IDH wt samples and LGG IDH wt samples compared to solid tissue normal (STN). In addition we have compared two lower grade glioma subtypes with each other to detect differentially expressed genes between them. The TCGA-LGG cohort does not contain normal samples. We used

the Solid Tissue Normal (STN) samples from the TCGA-GBM cohort. Same preprocessing steps were applied as stated in section 3.1.

Differential gene expression analysis was performed using the “TCGAanalyze_DEA” function (TCGABiolinks package) with the “exactTest” method. The false discovery rate (FDR) threshold was set at 0.01 and the absolute logarithmic fold change (logFC) was set to 1. We further screened the genes in the selected modules (IDH wt pTERT- blue and IDH mut pTERT- greenyellow) on matching DEGs lists (normal tissue vs LGG IDH wt, normal tissue vs LGG IDH mut and IDH mut vs. IDH wt). In addition, the genes enriched in common pathways between greenyellow and blue modules were inscribed. We focused on blue module genes as these were observed in distinct components of the common pathways,

3.6. Drug-gene Interactions

An association between a medicine and a genetic variation that may have an impact on a patient's response to the treatment. This phenomenon is known as a drug-gene interaction (DGI). We tested drugs that were altering the expression of previously selected genes using the Drug Gene Budger (DGB) tool (Wang et al, 2019). Using the CRowd Extracted Expression of Differential Signatures dataset (Wang et al, 2016), drugs that have inhibitory or activatory effects on up-regulated or down-regulated genes respectively were chosen in our investigation.

3.7. Data Collection and Preprocessing for DNA Methylation

The TCGA-LGG (Brain Lower Grade Glioma) DNA methylation data from Illumina Human Methylation 450 platform (legacy data) were queried, downloaded and prepared with “GDCquery”, “GDCdownload” and “GDCprepare” functions of the TCGABiolinks package (Colaprico et al, 2016) respectively. The downloaded data was the beta values (β) of raw methylation data. Beta values represent the estimated levels of methylation, determined by the ratio of intensities between methylated and unmethylated alleles. These values range from 0 to 1, where 0 signifies no methylation (unmethylated) and 1 indicates complete (full) methylation. The TCGA-LGG methylation samples were divided into four groups according to their IDH and TERT promoter mutation status. We created four different beta

matrices for subgroups: IDH mut TERTp mt, IDH mut TERTp wt, IDH wt TERTp mt and IDH wt TERTp wt.

The DNA methylation data of the Glioblastoma Multiforme (TCGA-GBM) cohort were downloaded and 2 Solid Tissue Normal (STN) samples in this dataset were extracted. The probes with beta values missing for both of these normal samples were filtered. To increase our normal sample size we searched the literature for more normal samples of brain methylation data. Capper et al in 2018 reported a study including various central nervous system (CNS) tumors and a variety of control samples (Capper et al, 2018). The methylation data was obtained using Illumina Human Methylation 450 platform and was aligned to hg19, which is compatible with TCGA-LGG and TCGA-GBM methylation data. From the control samples of various CNS normal tissues we decided to use hemispheric cortex samples (CONTR, HEMI). We downloaded the beta matrix from the Gene Expression Omnibus (GEO) (GSE90496) and extracted 6 hemispheric cortex samples (samples 382 - 387).

We further filtered the probe names compatible with the probes coming from TCGA-GBM STN samples and merged them into a beta matrix. A sample clustering tree was constructed with the average method to observe sample similarities as they are coming from different studies. We used the ChAMP package (Morris et al, 2014) to impute missing values with the champ.impute function and normalized with the champ.norm functions using BMIQ method (Teschendorff et al, 2013). On Illumina bead arrays, there are two types of probe designs (type I and type II) with different hybridisation chemistries. This difference affects distributions of probes coming from different types. Type II probes show a reduced dynamic range and this can lead to a bias in the selection of type-I over type-II probes. To avoid this technical effect, normalization of probes against the type-II probe bias is recommended (Dedeurwaerder et al, 2011). After normalization, we visualized normalized data with QC.GUI.

Normal brain expression data is necessary to perform differential expression analysis (DEA). Unfortunately there were no normal samples in the TCGA-LGG cohort and there were only 5 normal samples in the TCGA-GBM cohort. To make our DEA more effective we decided to use the Genotype-Tissue Expression (GTEx) project data. The GTEx portal serves as an extensive public repository for exploring tissue-specific gene expression and regulation. It encompasses data from 54

non-diseased tissue sites, involving the analysis of nearly 1000 individuals. (Carithers & Moore, 2015). We decided to use brain cortex expression data. The TCGABiolinks package makes users able to use TCGA data and GTex data for downstream analysis. We queried brain tissue data from both TCGA and GTex projects using the “TCGAquery_recount2” function and obtained Summarized Experiment (SE) objects separately.

We only selected the "Brain - Cortex" samples from GTex SE. As GTex data is available as counts and were aligned to hg38, we have queried, downloaded and prepared TCGA - LGG data in "STAR - Counts" workflow for consistency. The counts were scaled and the number of reads were checked. We then created subgroups of LGG data according to their IDH and TERT promoter mutation status. We gathered four subgroups: IDH mut TERTp mt, IDH mut TERTp wt, IDH wt TERTp mt, and IDH wt TERTp wt. Before starting the analysis we replaced Universally Unique Identifiers (UUIDs) with TCGA barcodes and subgroups were merged with normal samples separately using the rownames. All of these count matrices were normalized (by geneLength method) and filtered (by quantile method, qnt.cut=0.25) before performing differential expression analysis.

3.8. Differential Gene Expression Analysis with GTex data

Differential gene expression analysis was performed on previously created subgroups separately to obtain differentially expressed genes between normal samples and LGG samples with different molecular subtypes. To perform DEA we used the “TCGAanalyze_DEA” function with the limma pipeline and the glmLRT method (TCGABiolinks package). “Voom” argument was set to TRUE, false discovery rate cut (fdr.cut) was set to 0.01 and logarithmic fold change cut (logFC.cut) was set to 2. We removed the duplicated Ensembl gene identifiers and converted them to the HUGO symbols using the Biomart package (Drost & Paszkowski, 2017) and visualized the results using the “TCGAVisualize_volcano” function.

3.9. Differentially Methylated Regions Analysis

For each subgroup created previously we created Summarized Experiment (SE) objects as the input for the analysis. SE objects consist of features as rows (rowRanges), samples in columns (colData) and values as matrix (assays). We performed differentially methylated regions analysis using the “TCGAanalyze_DMC” function. We set the differential mean methylation cut (diffmean.cut) to 0.30 and adjusted p-value cut (p.cut) to 0.01. To annotate the differentially methylated CpGs we used Illumina HumanMethylation450 BeadChip [UBC enhanced annotation v1.0] data frame (GPL16304). The first 22 rows of this data frame contain column explanations, so we have duplicated the file but cleaned the informative rows in the second document. In this data frame we were specifically interested in “Distance_closest_TSS” and “Closest_TSS_gene_name” columns. The closest TSS gene names were obtained from the UCSC knownGene table. There is an estimation that 4% of probes have the same distance from more than one TSS. In this case, the annotated gene name of the first gene which appears in the UCSC knownGene table was utilized. We filtered out probes that contained known SNPs and hit the XY chromosomes. For the purpose of this study we filtered probes at 50kB downstream or upstream from the closest gene. In this case for some genes there were multiple differentially methylated probes. To obtain genes based on differential methylation values we aggregated DMC results by median function of the dplyr package in R (Wickham et al, 2019). At the end we obtained differentially methylated genes (DMGs) for each LGG subgroup.

3.10. Integration of DEGs and DMGs

In order to obtain both differentially expressed and differentially methylated genes in each subgroup we integrated our results from previous sections. For a better visualization we filtered DEGs and DMGs by adjusted *p-value* (< 0.01). For DEGs, logFC threshold was set to 2 and for DMGs DNAmethylation difference threshold was set to 0.3.

3.11. Network Analysis

Gene markers identified by differential expression and differential methylation analysis, methylation driven genes (MDGs), were mapped onto STRING

v10 [T800] (Szkłarczyk et al, 2015) and on the Cytoscape (Kohl et al, 2011) to incorporate our findings with the known interactions. We then selected the first neighbors of the identified MDGs for better understanding of disease mechanisms. Considering the objectives of our study, we further searched MDGs and their first neighbors on the EpiFactors (Medvedeva et al, 2015; Marakulina et al, 2023) database for the genes which are part of protein complexes playing a role as epigenetic factors. We reduced the network structures to epigenetic factor focused smaller networks as the biological networks are large, complex and contain a number of different molecular system signatures such as signal transduction, and gene regulation. We color coded the network as red (hypermethylated and downregulated MDGs), green (hypomethylated and upregulated MDGs) and blue (genes in the epigenetic factor protein complexes).

3.12. Perturbation Profiling

DepMap is a large-scale functional genomic profiling consortium to map the landscape of cancer vulnerabilities. The genetic perturbation platform specifically aims to screen mammalian cells and identify genetic alterations changing the phenotype, by perturbing genes with different approaches including CRISPR/Cas9 constructs. Cancer dependencies were modeled using analytical methods such as CERES (Meyers et al, 2017) and CHRONOS dependency score (Dempster et al, 2021).

After detecting the large module structures in each subtypes, we screened the gene effect on the DepMap portal using CRISPR (DepMap Public 22Q4+Score, Chronos) data and diffuse glioma models.

4. RESULTS

4.1. Pre-processing of TCGA-LGG RNASeq Dataset and Construction of Weighted Gene Co-expression Networks

The TCGA-LGG cohort expression matrix contained 21,022 genes and 513 samples. 419 of these samples were IDH mut and 94 of them were IDH wt. We preprocessed RNASeq data of TCGA-LGG subtypes separately. After filtering and normalization steps 14,893 genes were left in each group. We detected five outliers in the TCGA IDH mut group (Figure 4.1a) and one outlier in the IDH wt group (Figure 4.1b) and removed them. Sample dendrograms show transcriptionally different samples compared to other samples. The dendrogram signifies the division of complex data into meaningful and differentiated clusters of transcriptionally relevant cohorts.





Figure 4.1a. Sample dendrogram of IDH mutant samples to detect outliers.



27




Figure 4.2a. Hierarchical clustering of genes with module colors for IDH mut samples.




Figure 4.2b. Hierarchical clustering of genes with module colors for IDH wt samples.

4.2. Identification of Clinically Significant Modules

We further the observed module-trait relationships correlation to discover clinically significant modules. The threshold value was set to 0.5 for positive correlations and -0.5 for negative correlations. The IDH mutant group did not show correlation for Chr19_20.co.gain or BRAF.V600E.status features thus we discarded

these columns for simplicity. As *TERT* promoter mutations are shared by glioblastomas and oligodendrogliomas, but with two different prognostic outcomes, we concentrated on modules that correlated with *TERT* promoter mutation status.

For the LGG IDH wt subgroup, blue module (No. of genes: 1622, cor: 0.61, p-val: 2e-10), green module (No. of genes: 655, cor: 0.60, p-val: 5e-10), and tan module (No. of genes: 102, cor: 0.59, p-val: 9e-10) showed a positive correlation with *TERT* promoter mutation status. Yellow module (No. of genes: 830, cor: -0.53, p-val: 7e-08) and salmon module (No. of genes: 100, cor: -0.51, p-val: 4e-07) had negative correlation values that were below the threshold (Figure 4.3a).

For the LGG IDH mut subgroup, green module (No. of genes: 1032, cor: 0.86, p-val: 8e-124), salmon module (No. of genes: 391, cor: 0.68, p-val: 2e-58), blue module (No. of genes: 1354, cor: 0.54, p-val: 3e-33), darkgreen module (No. of genes: 64, cor: 0.52, pval: 8e-31), and lightgreen module (No. of genes: 106, cor: 0.52, p-val: 2e-30) showed positive correlation with *TERT* promoter mutation status. White module (No. of genes: 36, cor: -0.64, p-val: 4e-50) and greenyellow module (No. of genes: 538, cor: -0.57, p-val: 1e-37) showed negative correlation values that were below the threshold (Figure 4.3b).

The clinically relevant modules are showcased in the figures 4.3a-b as the rows indicate the modules detected through WGCNA and the columns indicate the clinical features selected in our study. The Pearson correlation values above 0.5 and below -0.5 were selected for stipulating the clinically significant modules. The darker shades of the color green and red highlight the clinically significant modules with lower and higher Pearson correlation values respectively.

Module-trait relationships LGG IDHmt




Figure 4.3a. Module-Trait relationship plot for LGG IDH mut samples.




Figure 4.3b. Module-Trait relationship plot for LGG IDH wt samples.

4.3. Enrichment Analysis for Modules of Interest

The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment was conducted on the selected modules and the results are summarized in Table 4.1. For IDH wt group, we observed immune-related pathways enrichment in modules that are negatively correlated with the pTERT status (pTERT-) while synaptic and glutamatergic pathways enrichment in modules that are positively correlated (pTERT+) with the pTERT status. For IDH mut group, we observed cellular differentiation and proliferation, and synaptic pathways enrichment in modules that are negatively correlated with the pTERT status (pTERT-) while metabolomic and immune-related pathways enrichment in modules that are positively correlated (pTERT+) with the pTERT status. Despite being enriched in similar pathways, IDH wt pTERT+ blue module and IDH mut pTERT-greenyellow module have inverse correlations with pTERT status as observed in Table 4.1. The table shows identifiers of the statistically significant modules and their enriched pathways. We identified the biological pathways behind the “clinically significant” modules observed in Figures 4.3a-b.

Table 4.1. KEGG pathway enrichment of the clinically significant modules.

IDH mutation status	pTERT status (correlation)	Module	Term	p-value	Bonferroni
Wildtype	Negative	Yellow	hsa04060:Cytokine-cytokine receptor interaction	2.37E-10	7.29E-08
			hsa04064:NF-kappa B signaling pathway	8.00E-08	2.46E-05
			hsa04620:Toll-like receptor signaling pathway	1.68E-06	0.0005
			hsa04650:Natural killer cell mediated cytotoxicity	2.28E-06	0.0007
			hsa04062:Chemokine signaling pathway	2.62E-06	0.0008
		Salmon	hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer	0.0106	0.8196
			hsa04660:T cell receptor signaling pathway	0.0161	0.9265
			hsa04630:JAK-STAT signaling pathway	0.0501	0.9997
			hsa04662:B cell receptor signaling pathway	0.0663	0.9999
			hsa04625:C-type lectin receptor signaling pathway	0.0997	0.9999
	Positive	Tan	hsa04621:NOD-like receptor signaling pathway	1.61E-10	1.34E-08
			hsa04622:RIG-I-like receptor signaling pathway	6.66E-06	0.0006

			hsa04625:C-type lectin receptor signaling pathway	0.0052	0.3486
			hsa04620:Toll-like receptor signaling pathway	0.0052	0.3486
			hsa04062:Chemokine signaling pathway	0.0399	0.9658
		Green	hsa04724:Glutamatergic synapse	1.07E-06	0.0003
			hsa04921:Oxytocin signaling pathway	3.44E-06	0.0009
			hsa04022:cGMP-PKG signaling pathway	4.03E-05	0.0116
			hsa04010:MAPK signaling pathway	4.49E-05	0.0129
			hsa04725:Cholinergic synapse	0.0004	0.1027
			hsa04728:Dopaminergic synapse	0.0005	0.1226
		Blue	hsa04721:Synaptic vesicle cycle	1.19E-18	3.77E-16
			hsa04727:GABAergic synapse	5.60E-13	1.77E-10
			hsa04724:Glutamatergic synapse	3.30E-11	1.04E-08
			hsa04723:Retrograde endocannabinoid signaling	5.64E-11	1.78E-08
			hsa04728:Dopaminergic synapse	5.40E-10	1.71E-07
			hsa04080:Neuroactive ligand-receptor interaction	8.20E-10	2.59E-07
			hsa04024:cAMP signaling pathway	9.60E-08	3.03E-05
Mutant	Negative	White	hsa05202:Transcriptional misregulation in cancer	0.0537	0.9903
			hsa04024:cAMP signaling pathway	0.0682	0.9974
			hsa04014:Ras signaling pathway	0.0765	0.9988
		Greenyellow	hsa04724:Glutamatergic synapse	2.11E-08	4.87E-06
			hsa04080:Neuroactive ligand-receptor interaction	3.42E-06	0.0008
			hsa04721:Synaptic vesicle cycle	6.58E-06	0.0015
			hsa04727:GABAergic synapse	0.0001	0.0294
			hsa04723:Retrograde endocannabinoid signaling	0.0004	0.0825
			hsa04725:Cholinergic synapse	0.0032	0.5218
	Positive	Green	hsa00100:Steroid biosynthesis	0.0031	0.6146
			hsa01100:Metabolic pathways	0.0220	0.9990
			hsa00280:Valine, leucine and isoleucine degradation	0.0374	0.9999
			hsa00250:Alanine, aspartate and glutamate metabolism	0.0416	0.9999
			hsa05231:Choline metabolism in cancer	0.0692	0.9999
		Salmon	hsa04146:Peroxisome	0.0001	0.0312
			hsa05022:Pathways of neurodegeneration - multiple diseases	0.0569	0.9999
			hsa04330:Notch signaling pathway	0.0954	1
			hsa04392:Hippo signaling pathway - multiple species	0.0998	1
		Blue	hsa04060:Cytokine-cytokine receptor interaction	1.81E-09	5.83E-07
			hsa04064:NF-kappa B signaling pathway	6.13E-09	1.98E-06

			hsa04662:B cell receptor signaling pathway	6.13E-08	1.97E-05
			hsa04621:NOD-like receptor signaling pathway	3.70E-07	0.0001
			hsa04620:Toll-like receptor signaling pathway	4.39E-07	0.0001
		Darkgreen	hsa03010:Ribosome	5.58E-11	3.23E-09
		Lightgreen	hsa04015:Rap1 signaling pathway	0.0075	0.7415
			hsa01100:Metabolic pathways	0.0270	0.9927
			hsa04921:Oxytocin signaling pathway	0.0615	0.9999
			hsa04218:Cellular senescence	0.0634	0.9999
			hsa04390:Hippo signaling pathway	0.0644	0.9999

To better understand resemblances and dissimilarities, we further looked into common KEGG pathways. In terms of synaptic pathways, we found 13 connections between the IDH mut green-yellow module and the IDH wt blue module (Table 4.2). Glutamate ionotropic receptor NMDA type subunits were marked in both modules in the "Glutamatergic Synapse" pathway, however glutamate ionotropic receptor AMPA type subunit 1 (GRIA1) was only annotated in the IDH wt blue module. While GRM2 was annotated only in the IDH wt blue module, glutamate metabotropic receptors were annotated in both the blue and greenyellow modules. In addition to GRM2, the IDH wt blue module was enriched for G protein alpha subunits (i1, i3, and o1) and adenylate cyclases (ADCY1, ADCY5). The Greenyellow and Blue modules come from different subtypes (IDH mut and IDH wt respectively) and they are oppositely correlated with pTERT status. The following table 4.2 shows the details of shared pathways between these two modules.

Table 4.2. Common pathways between the IDH mutant (IDH mut) greenyellow module and IDH wild-type (IDH wt) blue module.

IDH mut_greenyellow_pTERT-				IDH wt_blue_pTERT+			
Term	Count	%	p-value	Term	Count	%	p-value
hsa04724:Glutamatergic synapse	16	3.0246	0.0000	hsa04721:Synaptic vesicle cycle	36	2.2402	0
hsa04080:Neuroactive ligand-receptor interaction	24	4.5369	0.0000	hsa04727:GABAergic synapse	32	1.9913	0
hsa04721:Synaptic vesicle cycle	11	2.0794	0.0000	hsa04724:Glutamatergic synapse	34	2.1157	0
hsa04727:GABAergic synapse	10	1.8904	0.0001	hsa04723:Retrograde endocannabinoid signaling	39	2.4269	0
hsa04723:Retrograde endocannabinoid signaling	12	2.2684	0.0004	hsa04728:Dopaminergic synapse	35	2.1780	0.0000
hsa04725:Cholinergic synapse	9	1.7013	0.0032	hsa04080:Neuroactive ligand-receptor interaction	65	4.0448	0.0000
hsa04726:Serotonergic synapse	9	1.7013	0.0036	hsa04713:Circadian entrainment	29	1.8046	0.0000
hsa04360:Axon guidance	11	2.0793	0.0064	hsa04024:cAMP signaling pathway	43	2.6757	0.0000
hsa04024:cAMP signaling pathway	12	2.2684	0.0089	hsa04725:Cholinergic synapse	27	1.6801	0.0000
hsa04070:Phosphatidylinositol signaling system	6	1.1342	0.0606	hsa04070:Phosphatidylinositol signaling system	22	1.3690	0.0000
hsa04713:Circadian entrainment	6	1.1342	0.0606	hsa04726:Serotonergic synapse	24	1.4935	0.0000
hsa04728:Dopaminergic synapse	7	1.3233	0.0686	hsa04360:Axon guidance	30	1.8668	0.0002
hsa00330:Arginine and proline metabolism	4	0.7561	0.0952	hsa00330:Arginine and proline metabolism	9	0.5600	0.0441

The KEGG pathways were further investigated and downloaded from the database as shown in the Figures 4.4a-c. The individual pathways are highlighted in this study for the relevant modules. The different and same components of the pathway with common genes from IDH mut Greenyellow and IDH wt blue modules are shown in the figures. One component of the pathway includes more than one gene. G-protein-coupled receptors activate adenylate cyclase (AC), which in turn

activates Protein Kinase PKA. The "Retrograde endocannabinoid signaling" route, where this interaction also takes place, is found in the mitochondria (Figure 4.4c). When adenylate cyclase is activated by G-protein coupled receptors, it turns on PKA. This interaction also happens within the mitochondria in the "Retrograde endocannabinoid signaling" pathway (Figure 4.4c).




Figure 4.4a. Selected common KEGG pathway schemes of the IDH wt pTERT- blue module and IDH mut pTERT+ greenyellow module ~ Glutamatergic synapse

In figures 4.4a-c the pathways Glutamatergic synapse, GABAergic synapse and retrograde endocannabinoid signalling were selected. The components which were painted red were enriched in both greenyellow and blue module; blue components were only enriched in blue module and darkgreen components were only enriched in greenyellowmodule, while others were left in their default color.




Figure 4.4b. Selected common KEGG pathway schemes of the IDH wt pTERT- blue module and IDH mut pTERT+ greenyellow module ~ GABAergic synapse




Figure 4.4c. Selected common KEGG pathway schemes of the IDH wt pTERT- blue module and IDH mut pTERT+ greenyellow module ~ Retrograde endocannabinoid signaling

4.4. Differentially Expressed Genes (DEGs)

We identified 3025 DEGs in LGG IDH mut group compared to normal samples and 2804 DEGs in LGG IDH wt group compared to normal samples. Additionally we have identified 1958 genes in LGG IDH wt group compared to LGG IDH mut group. As a result of screening DEGs in the modules of interests, we further identified 206 of co-expressed genes were also differentially expressed in the IDH mut pTERT- greenyellow module (module size 538), and 986 of co-expressed genes were also differentially expressed in the IDH wt pTERT+ blue module, (module size 1622). Moreover, we identified 146 common genes differentially expressed between normal vs. IDH wt and IDH mut vs IDH wt DEGs (upregulated: 53, downregulated: 93). Among DEGs we focused on genes that showed the highest change in expression in IDHwt tumors, while also being altered in IDH mut tumors albeit to a lesser extent in the same direction.

The *GRIN3A* gene had the lowest logFC value (IDH mut vs IDH wt -1.96; normal vs IDH wt -2.95) while the *HPD* gene had the highest logFC value (IDH mut vs IDH wt 2.01; normal vs IDH wt 6.53). Intriguingly, the logFC values for the IDH mut vs IDH wt and normal vs IDH wt groups did not differ significantly for genes that were downregulated, but they did differ significantly for genes that were upregulated. In the IDH wt blue module, we listed 182 genes, and in the IDH mut greenyellow module, 54 genes which were enriched in common pathways. 143 and 27 of them, respectively, were differentially expressed. 22 out of 182 blue module genes were also DEGs in both IDH mut and IDH wt. Additionally, 15 of these 22 genes showed differential expression between normal vs IDH wt samples (Table 4.3). These genes were enriched in the aforementioned pathways and are both differentially expressed between normal vs IDH wt and IDH mut and IDH wt. The genes highlighted (bold) were only enriched in blue module but not in greenyellow module.

Table 4.3. IDH wild-type blue module pathway-enriched DEGs.

	*Normal vs IDH wt	Normal (RPKM)	IDH wt (RPKM)	*IDH mut vs IDH wt	IDH mut (RPKM)	IDH wt (RPKM)
<i>SLC1A6</i>	-2.2365	989.8	234.4494	-1.1974	514.5239	234.4494
<i>GRIA2</i>	-1.4941	15266	5926.5056	-1.0580	11873.9067	5926.5056
<i>PLCB1</i>	-1.4048	5828.6	2446.4719	-1.0379	4828.8660	2446.4719
<i>GNG12</i>	2.2310	1181.8	6309.8539	1.5414	2087.4952	6309.8539
<i>GRIN3A</i>	-2.9484	1916.6	272.1124	-1.9578	1032.8684	272.1124
<i>SSTR1</i>	-2.4319	2161.4	449.9550	-1.2700	1018.7297	449.9551
<i>SSTR2</i>	-2.5210	2055	399.4607	-1.7434	1284.4665	399.4607
<i>CHRNA4</i>	-1.6524	2051.6	749.1685	-1.0276	1409.4377	749.1685
<i>GABRB3</i>	-2.2102	9864.4	2436.4719	-1.0300	4725.7607	2436.4719
<i>GABRA3</i>	-2.1735	1813.8	444.5843	-1.5058	1251.0909	444.5843
<i>PDYN</i>	-2.1334	5622.8	1506.6517	1.1126	645.9139	1506.6517
<i>VIPR2</i>	2.3059	329.6	1830.6180	-1.5287	4821.8445	1830.6180
<i>CHRM4</i>	-2.3974	334.2	70.5056	-1.022	136.3301	70.5056
<i>ATP6V1G2</i>	-2.0278	13698.6	3727.4045	-1.0769	7554.8421	3727.4045
<i>GNAL</i>	-2.2018	2163.6	530.2809	-1.0779	1077.7105	530.2809

4.5. Drug-Gene Interactions

GRIA2, *PLCB1*, *GNG12*, *GABRA3*, *PDYN*, and *GNAL* [6 of the 15 genes at the intersection of both DEGs lists (normal vs. IDH mut, IDH mut vs. IDH wt)] were solely enriched in the blue module. *PDYN* was not included since its expression pattern was not complying with our hypothesis of a gradual change of expression from normal to IDH mut to IDH wt. Only *GNG12* was upregulated among the genes above, others were downregulated (Table 4.4). Therefore, we have focused on inhibitory drugs / small molecules for *GNG12* and activatory drugs / small molecules for *GRIA2*, *PLCB1*, *GNG12*, *GABRA3*, and *GNAL*. Since *GNG12* was the most interesting candidate target, we have compared listed drugs for *GNG12* with drugs targeting other candidates (Table 4.4). As cisplatin, imatinib, vanadium pentoxide, and vemurafenib affect the expression of four out of five listed genes (including *GNG12*), these compounds were identified as potential therapeutics candidates. Table 4.4 shows the drugs that inactivate *GNG12* and activate the other four genes (*GRIA2*, *PLCB1*, *GABRA3*, *GNAL*) that are downregulated in our analyses.

Table 4.4. Drug-Gene interaction table for IDH wild-type blue module pathway-enriched DEGs.

Drug Name	GNG12	GRIA2	PLCB1	GABRA3	GNAL
1,25 dihydroxyvitamin d	x				
4-hydroxynonenal	x		x		x
Adenosine triphosphate	x	x		x	
Alfacalcidol	x				
Aminolevulinic acid	x				x
Androstanolone	x				
Aplidin	x				x
Apratoxin a	x				
Bexarotene	x	x			
Bisphenol a	x		x	x	
Cediranib	x			x	
Cetuximab	x				
Chlorpyrifos	x		x		
Cisplatin	x		x	x	x
Clinafloxacin	x				
Cytarabine	x				
Diclofenac	x	x			x
Doxorubicin	x	x			x
Doxycycline	x				
Estradiol	x		x		
Harman	x				
Imatinib	x		x	x	x
Interferon beta-1a	x				
Interferon gamma-1b	x				x
Mesalazine	x		x		
Metformin	x				x
Nickel	x				
Plx4032	x		x	x	
Puromycin, ec50, 1 d	x			x	
Puromycin, ec50, 5 d	x				
Resveratrol	x				
Sapphyrin pci-2050	x				
Tibolone	x				
Triiodothyronine-[13c6] hydrochloride (t3 thyronine)	x	x			
Trovafoxacin	x				
Vanadium pentoxide	x	x		x	x
Vemurafenib	x	x	x	x	
Vx	x				
Y15	x				

4.6. Data Collection and Preprocessing for DEG analysis and DNA methylation Data

The TCGA LGG and GBM DNA methylation data were carrying 485577 probes at the beginning. We extracted only Solid Tissue Normal samples from the GBM cohort. The LGG cohort is divided into subgroups by IDH mutation status and then each group is divided into further subgroups according to their pTERT mutation status. Out of 419 LGG IDH mut samples, 93 of them were pTERTmt and 143 of them were pTERTwt. There was no pTERT status information for 183 samples. Out of 94 LGG IDH wt samples, 37 of them were pTERTmt and 19 of them were pTERTwt. There was no pTERT status information for 38 samples. After creating the subgroups according to their IDH and pTERT mutation status we further checked their 1p 19q codeletion status. For the IDH mut pTERTmt subgroup there were 86 1p19q-codeleted and 7 1p19q-intact samples. For the IDH mut pTERTwt subgroup there were 2 1p19q-codeleted and 141 1p19q-intact samples. All of the IDH wt samples were 1p19q-intact samples. We excluded 1p19q-intact samples from the IDH mut and pTERT mutant group and 1p19q-codeleted samples from the IDH mut and pTERTwt group for homogeneity.

The probes that displayed NA values for all the samples were filtered from each subgroup separately. After filtering, 396059 probes were left for solid tissue normal and 396065 probes left for the LGG subgroups. There were 428799 probes for 6 brain hemispheric cortex (CONTR_HEMI) samples extracted from the paper. There were 356774 probes which are the same with solid tissue normal samples. The solid tissue normal samples (TCGA-GBM) and the hemispheric cortex samples (CONTR, HEMI) (Capper et al., 2018) were merged to form a normal brain tissue beta matrix consisting of 8 samples and 356774 probes. The sample tree plot showed that although these normal samples originated from different studies, they were not very different from each other, and therefore, it was concluded that this beta matrix can be used as a normal brain beta matrix (Figure 4.5). The figure highlights the

compatibility of normal samples coming from TCGA and the study mentioned above.




Figure 4.5. Sample clustering of normal samples from paper and TCGA-GBM (Solid Tissue Normal samples only). The branches are samples and the y-axis shows the branch height.

4.7. Differential Gene Expression Analysis with GTex Data to be Integrated with DNA Methylation Data

The probes of four different subgroups of LGG were filtered to be compatible with 356774 probes defined above. GTex expression data for brain tissue was carrying 707 samples, both TCGA and GTex expression data for brain tissue were carrying 58037 genes at the SE objects created at the beginning of differential expression analysis. Out of 707 samples in GTex brain expression data, 132 were expression data from brain cortex. We filtered LGG STAR - Counts data compatible with the subgroups defined above. After normalization and filtering the gene counts at the merged matrices, we ended up with 34003 genes and 218 samples for the IDH mut pTERTmt subgroup, 34148 genes and 271 samples for the IDH mut pTERTwt subgroup, 34188 genes and 169 samples for the IDH wt pTERTmt subgroup and 34390 genes and 151 samples for the IDH wt pTERTwt subgroup (132 samples of these samples are GTex brain cortex data).

Differential gene expression analysis results are shown in Table 4.5. In the IDH mt pTERTmt (1p-19q codeleted) subtype, 54.8% of DEGs were upregulated and 45.2% of DEGs were downregulated. In the IDH mut pTERTwt (1p-19q-intact)

subtype, 52.6% of DEGs were upregulated and 47.4% of DEGs were downregulated. In the IDH wt pTERTmt subtype, 60.2% of DEGs were upregulated and 39.8% of DEGs were downregulated. In the IDH wt pTERTwt subtype, 58.1% of DEGs were upregulated and 41.9% of DEGs were downregulated. Interestingly, the IDH wt pTERTmt subtype shows higher upregulation patterns compared to other subtypes. The parameters used for DEG analysis included TCGAanalyze_DEA, $\text{fdr.cut} = 0.01$, $\text{logFC.cut} = 2$, and $\text{method} = \text{"glmLRT"}$.

Table 4.5. The number of differentially expressed genes in different LGG subtypes.

	Total DEGs	Upregulated	Downregulated
IDH mut pTERTmt codel	4086	2240	1846
IDH mut pTERTwt noncodel	3873	2039	1834
IDH wt pTERTmt	5342	3216	2126
IDH wt pTERTwt	2937	1706	1231

4.8. Differentially Methylated Regions Analysis (CpG sites)

After imputing the missing values and normalizing the methylation data we observed the samples with QC.GUI function. Although the normal samples from the TCGA GBM and the aforementioned study (Capper et al in 2018) were separated at the dendrograms for all probes, the heatmap and Multidimensional scaling (MDS) plots for the most variable CpGs showed separation of tumor and normal samples for the most variable 1000 CpGs. Three tumor samples from the LGG IDH wt pTERTwt subgroup were clustered with normal samples at the MDS 1000 most variable positions plot. We have observed the adjusted *p-values* in this subgroup were relatively higher compared to other subgroups. Thus, we excluded three samples and reperformed the analysis.

4.9. IDH mut pTERTmt - Quality Control Plots

The dendrogram comparing the normal samples with tumor samples for quality control is shown in Figure 4.6a. A multidimensional scaling plot highlighting the red dots as normal samples and green dots as tumor samples for 1000 most variable positions is shown in Figure 4.6b. A heatmap constructed for 1000 most

variable CpGs with rows indicating CpGs and columns displaying the samples, is depicted in Figure 4.6c. These plots summarize the background quality control checks conducted on the samples for DNA methylation data collection and preprocessing.




Figure 4.6a. Sample dendrogram for 356743 probes in IDH mut pTERTmt group.



Figure 4.6b. Multidimensional Scaling (MDS) plot for 1000 most variable positions for IDH mut pTERTmt group.




Figure 4.6c. Heatmap for Top 1000 variable CpGs for IDH mut pTERTwt group.

4.10. IDH mut pTERT wt - Quality Control Plots

The dendrogram comparing the normal samples with tumor samples for quality control of IDH mut pTERTwt genetic subtype is indicated in Figure 4.7a. This data contains 356730 probes in total with branch height displayed in y-axis. Another MDS plot for top 1000 variable CpGs for IDH mut pTERTwt is shown in Figure 4.7b, where the red dots show normal samples and green dots indicate the tumor samples. The heat map is also drawn for top 1000 variable CpGs from these samples, where the rows display the CpGs and columns depict the samples (Figure 4.7c).




Figure 4.7a. Sample dendrogram for 356730 probes in IDH mut pTERTwt group.




Figure 4.7b. Multidimensional Scaling (MDS) plot for 1000 most variable positions for IDH mut pTERTwt group..




Figure 4.7c. Heatmap for Top 1000 variable CpGs for IDH mut pTERTwt group.

4.11. IDH wt pTERTmt - Quality Control Plots

The dendrogram comparing the normal samples and tumor samples for the genetic subtype of IDH wt pTERTmt- is shown in Figure 4.8a for highlighting the quality control of the samples. Similarly, the MDS plot displaying the normal samples in red and tumor samples in green for the top 1000 variable positions is shown in Figure 4.8b. The heat map for the variable regions is shown in Figure 4.8c.




Figure 4.8a. Sample dendrogram for 356709 probes in IDH wt pTERTmt group.




Figure 4.8b. Multidimensional Scaling (MDS) plot for 1000 most variable positions for IDH wt pTERTmt.




Figure 4.8c. Heatmap for Top 1000 variable CpGs for IDH wt pTERTmt.

4.12. IDH wt pTERTwt - Quality Control Plots

The MDS for 1000 most variable positions in IDH wt pTERTwt is shown in Figure 4.9a, where the red dots display the normal samples and green dots show the tumor samples. Moreover, the dendrogram is shown in Figure 4.9b to show the quality control check and processing of the samples and MDS plot is shown in Figure 4.9c and heat map in Figure 4.9d.




Figure 4.9a. MDS plot of IDH wt pTERTwt samples for IDH wt pTERTwt subtype.




Figure 4.9b. Sample dendrogram for 356743 probes in IDH wt pTERTwt group.

compared to IDH mut samples. Interestingly, in the IDH wt pTERTmt subtype higher percentage of genes were hypomethylated than hypermethylated, which is just the opposite of other samples showing higher percentage of hypermethylated genes. The parameters used to arrive at the number of DMCs include TCGAanalyze_DMC, adj.p value < 0.01, and diffmean.cut = 0.3.

Table 4.6. Summary of Differentially Methylated CpG sites (DMC).

	hyper probs	hypo probs	hyper genes	hypo genes
IDH mut pTERTmt	22162	495	7573	229
IDH mut pTERTwt	18129	601	6852	285
IDH wt pTERTmt	3721	2570	1703	1756
IDH wt pTERTwt	508	273	398	228

4.13. Integration of Methylation and Expression Data

The venn diagram was constructed which shows the hypermethylated+downregulated; hypomethylated+upregulated genes' distribution in 4 different subtypes (based on IDH and TERT promoter mutation status) of low grade gliomas. The Figure 4.10 shows that there were 422 genes which were common MDGs between IDH mut pTERTmt and IDH wt pTERTwt subtypes (more than 65% of the MDGs in each group), 337 of them were common only between them (more than 65% of the MDGs in each group). This result was expected as IDH mutations are mainly responsible for epigenetic changes in gliomas and these two subtypes are composed of IDH mutant samples. Meanwhile, only 150 MDGs were common among other groups, out of 422 MDGs (35.5%) compared to 272 out of 422 MDGs from this group. 72 of them were hypermethylated and downregulated while 200 of these were hypomethylated and upregulated.

The summary of integration of differential expression and differential methylation data (hyper methylated and downregulated; hypomethylated and upregulated) in 4 different LGG subtypes is shown in Table 4.7.

Table 4.7. The summary of Methylation Driven Genes (MDGs) in different genetic subtypes of LGG.

MDGs Summary table		
	hyper.down	hypo.up
IDH mut pTERTmt	617	31
IDH mut pTERTwt	585	26
IDH wt pTERTmt	200	222
IDH wt pTERTwt	7	7




Figure 4.10. Venn diagram of methylation driven genes (G1: IDH mut pTERTmt, G2: IDH mut pTERTwt, G3: IDH wt pTERTmt, G4: IDH wt pTERTwt).

Table 4.8 details the enrichment analysis of the genes in different sections of the venn diagram. Hypermethylated and downregulated genes were enriched in Neuroactive ligand receptors while hypomethylated and upregulated genes were enriched in immune related pathways (Table 4.8).

77 genes at the intersection of G1&G2&G3-only were enriched in ion channel activities, transport activities (GO Molecular Ontology) and in nervous systems (GABAergic synapse, Retrograde endocannabinoid signaling) and environmental information processing (Neuroactive ligand-receptor interaction). 337 genes at the G1&G2-only intersection were enriched with Calmodulin binding and Voltage-gated channel activities (GO Molecular Ontology). 48 genes at the

G2&G3-only intersection were enriched with ion channel activities and transport activities (GO Molecular Ontology). 140 genes at the G2-only area were enriched with Nervous System Pathways (GABAergic synapse, Glutamatergic synapse, Long-term potentiation, Cholinergic synapse, Synaptic vesicle cycle, Dopaminergic synapse, Serotonergic synapse), Signal Transduction (Phosphatidylinositol signaling system, Calcium signaling pathway, cAMP signaling pathway, Rap1 signaling pathway, MAPK signaling pathway) and Environmental Information Processing (Neuroactive ligand-receptor interaction) (Table 4.8).

272 genes at the G3-only area were enriched with Signaling molecules and interaction (Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction) Molecular Ontology enrichment for this subtype was receptor activities (immune receptor activity, signaling receptor activity) and binding (tumor necrosis factor binding, extracellular matrix binding, cytokine binding). Interestingly, we have detected immune system activities for the G3 only area and we further investigated these genes. 72 out of 272 genes were hyper methylated and downregulated, and they were related to the neuroactive ligand-receptor interaction pathway. 200 out of 272 genes were hypomethylated and upregulated, and they were enriched with immune system related pathways. We have further identified 56 of these genes in the immune system at the Reactome pathway [HSA-168256, Immune System (56/1956)] (Table 4.8).

Table 4.8. Enrichment analysis of Venn Diagram genes ($p\text{-value} < 0.05$).

Group	Term	Count	%	p-Value	Fold Enrichment	Bonferroni	Benjamini	FDR
G1G2G3 (77 genes)	hsa04727:GABAergic synapse	6	7.79	1.82E-05	17.29	0.0016	0.0008	0.0008
	hsa04080:Neuroactive ligand-receptor interaction	8	10.38	0.0004	5.59	0.0300	0.0077	0.0076
	hsa04723:Retrograde endocannabinoid signaling	5	6.49	0.0022	8.66	0.1736	0.0381	0.0377
	hsa04024:cAMP signaling pathway	4	5.19	0.0498	4.64	0.9883	0.6193	0.6121
G1G2-only (337 genes)	hsa04080:Neuroactive ligand-receptor interaction	16	4.74	6.77E-05	3.34	0.0147	0.0148	0.0147
	hsa04020:Calcium signaling pathway	11	3.26	0.0010	3.51	0.2017	0.1126	0.1120
	hsa04014:Ras signaling pathway	10	2.96	0.0034	3.25	0.5204	0.2445	0.2434
	hsa04723:Retrograde endocannabinoid signaling	7	2.07	0.0121	3.63	0.9300	0.5286	0.5262
	hsa04724:Glutamatergic synapse	6	1.78	0.0158	4.04	0.9691	0.5749	0.5723

	hsa04727:GABAergic synapse	5	1.48	0.0278	4.31	0.9979	0.7585	0.7550
	hsa04728:Dopaminergic synapse	6	1.78	0.0278	3.49	0.9979	0.7585	0.7550
	hsa04713:Circadian entrainment	5	1.48	0.0365	3.95	0.9997	0.7965	0.7929
	hsa04721:Synaptic vesicle cycle	3	6.25	0.0198	13.15	0.7281	0.5734	0.5734
G2-only (48 genes)	hsa04020:Calcium signaling pathway	12	8.57	7.21E-07	6.95	0.0001	0.0001	0.0001
	hsa04724:Glutamatergic synapse	7	5	0.0001	8.54	0.0226	0.0059	0.0052
	hsa04024:cAMP signaling pathway	9	6.42	0.0001	5.66	0.0233	0.0059	0.0052
	hsa04727:GABAergic synapse	6	4.28	0.0004	9.38	0.0610	0.0126	0.0111
	hsa04080:Neuroactive ligand-receptor interaction	10	7.14	0.0010	3.79	0.1473	0.0234	0.0206
	hsa04929:GnRH secretion	5	3.57	0.0010	10.86	0.1545	0.0234	0.0206
	hsa04725:Cholinergic synapse	6	4.28	0.0012	7.38	0.1707	0.0234	0.0206
	hsa04721:Synaptic vesicle cycle	5	3.57	0.0022	8.91	0.2955	0.0338	0.0298
	hsa04728:Dopaminergic synapse	6	4.28	0.0023	6.32	0.3111	0.0338	0.0298
	hsa04015:Rap1 signaling pathway	7	5	0.0035	4.64	0.4309	0.0433	0.0382
	hsa04010:MAPK signaling pathway	8	5.71	0.0044	3.78	0.5108	0.0452	0.0399
	hsa04070:Phosphatidylinositol signaling system	5	3.57	0.0048	7.17	0.5377	0.0453	0.0399
	hsa04726:Serotonergic synapse	5	3.57	0.0087	6.05	0.7545	0.0777	0.0685
	hsa04720:Long-term potentiation	4	2.85	0.0117	8.30	0.8487	0.0988	0.0872
	hsa04270:Vascular smooth muscle contraction	5	3.57	0.0146	5.19	0.9066	0.1177	0.1038
	hsa05214:Glioma	4	2.85	0.0158	7.42	0.9230	0.1211	0.1068
	hsa05207:Chemical carcinogenesis - receptor activation	6	4.28	0.0166	3.94	0.9325	0.1215	0.1071
	hsa04723:Retrograde endocannabinoid signaling	5	3.57	0.0203	4.70	0.9633	0.1422	0.1254
	hsa04014:Ras signaling pathway	6	4.28	0.0251	3.54	0.9833	0.1684	0.1485
	hsa04022:cGMP-PKG signaling pathway	5	3.57	0.0300	4.16	0.9926	0.1846	0.1628
	hsa04713:Circadian entrainment	4	2.85	0.0309	5.73	0.9937	0.1846	0.1628
G3-Only (272 genes)	hsa04060:Cytokine-cytokine receptor interaction	16	5.88	4.68E-05	3.48	0.0102	0.0102	0.0100
	hsa04080:Neuroactive ligand-receptor interaction	17	6.25	0.0002	2.97	0.0345	0.0176	0.0172
	hsa04610:Complement and coagulation cascades	8	2.941	0.0004	5.96	0.0741	0.0257	0.0251
	hsa04640:Hematopoietic cell lineage	8	2.94	0.0008	5.18	0.1654	0.0452	0.0442
	hsa04350:TGF-beta signaling pathway	7	2.57	0.0035	4.72	0.5311	0.1138	0.1112
	hsa05150:Staphylococcus aureus infection	7	2.57	0.0036	4.67	0.5497	0.1138	0.1112
	hsa04061:Viral protein interaction with cytokine and cytokine receptor	7	2.57	0.0044	4.49	0.6233	0.1218	0.1190

	hsa05145:Toxoplasmosis	7	2.57	0.0077	4.01	0.8155	0.1683	0.1645
	hsa04621:NOD-like receptor signaling pathway	8	2.94	0.0239	2.79	0.9950	0.4024	0.3932
	hsa04072:Phospholipase D signaling pathway	7	2.57	0.0271	3.03	0.9976	0.4238	0.4141
	hsa05200:Pathways in cancer	15	5.51	0.0347	1.81	0.9996	0.5063	0.4947

4.14. Network Analysis and EpiFactors

The methylation driven genes alone are not informative enough on a biological level as these are individual genes. We further included the first neighbors of MDGs and constructed a more biologically interpretable network. The MDGs + first neighbor were still very crowded. Therefore, we focused on Epigenetic factor protein complexes and attempted to understand which epigenetic protein complexes might be playing a role in methylation differences.

Table 4.9. Network statistics on epigenetic data with MDG nodes, edges, neighbors and protein complexes.

	MDGs nodes	MDGs edges	MDGs + first neighbors nodes	MDGs + first neighbors edges	Protein complex focused nodes	Protein complex focused edges
IDH mut pTERTmt	427	390	3907	93668	435	415
IDH mut pTERTwt	411	477	3620	88792	419	505
IDH wt pTERTmt	309	313	4131	155613	326	363
IDH wt pTERTwt	9	1	125	596	11	5

Table 4.9 summarizes the statistics from different networks constructed. Epigenetic factor protein complex focused subnetworks show a clear difference between IDH mut pTERTwt (G3) group and IDHmut groups (G1, G2). For simplicity smaller networks and single nodes were excluded during visualization. Interestingly GABA complexes created a separate network in G1, G2 and G3. Potassium voltage-gated channel subfamily members were separate in G1 but they were wired to the large network in G2 and G3. As shown in Table 4.9, G2 large network structures have higher numbers of calcium signaling pathways (Figure 12a-d).

The G1 protein complex focused subnetwork was highlighted in Figure 4.12a for IDH mut pTERTmt subtype, where red genes were hypermethylated and downregulated, green genes were hypomethylated and upregulated, and blue genes showed protein complex genes. Furthermore, G2 protein complex focused subnetwork for IDH mut pTERTwt data contained red genes, which are hypermethylated and downregulated, green genes are hypomethylated and upregulated, whereas blue genes are protein complex genes (Figure 4.12b). The G3 protein complex focused subnetwork for IDH wt pTERTmt subtype is highlighted in Figure 4.12c, where red genes are hypermethylated and downregulated, green genes are hypomethylated and upregulated, and blue genes protein complex genes. Subsequently, the G4 protein complex focused subnetwork for IDH wt pTERTwt subtype is displayed in Figure 4.12d, where red genes are hypermethylated and downregulated, green genes are hypomethylated and upregulated, and blue genes showcase the protein complex genes.




Figure 4.11a. IDH mut pTERTmt - Protein complex focused subnetwork




Figure 4.11b. IDH mut pTERTwt - Protein complex focused subnetwork




Figure 4.11c. IDH wt pTERTmt - Protein complex focused subnetwork




Figure 4.11d. IDH wt pTERTwt - Protein complex focused subnetwork

4.15. Perturbation Profiling

DepMap screening of the protein complex focused subnetwork genes returned perturbation effect of 6 genes (*ACTB*, *BRCA1*, *HCFC1*, *MET*, *PPP4C*, *PRMT5*) from IDH mut pTERTmt subtype, 4 genes (*ACTB*, *BRCA1*, *PPP4C*, *PRMT5*) from IDH mut pTERTwt subtype, 11 genes (*ACTB*, *ACTL6A*, *BRCA1*, *CDK6*, *HCFC1*, *MIS18A*, *PRMT5*, *RUVBL1*, *SOX2*, *WEE1*, *ZNF217*) from IDH wt pTERTmt subtype and 2 genes (*PRMT5*, *WEE1*) from IDH wt pTERTwt subtype at least in one diffuse glioma model analyzed by the DepMap (Table 4.10). The Chronos dependency score is derived from a cell depletion assay, where a lower score suggests a greater likelihood of the gene being essential in a specific cell. A score of 0 implies non-essentiality, while -1 is akin to the median among all pan-essential genes. The Chronos dependency scores were available for 66 diffuse glioma models which included 2 for Anaplastic Astrocytoma (AASTR), 13 for Astrocytoma (ASTR), 49 for Glioblastoma (GB), and 2 for Oligodendroglioma (ODG). The data is compiled to show the genes which were selected from network modules processed in our study for various subtypes and they display the perturbation effect on different aforementioned models.

Table 4.10. CHRONOS dependency scores of 66 diffuse glioma models

Models	<i>ACTB</i>	<i>ACTL6A</i>	<i>BRCA1</i>	<i>CDK6</i>	<i>HCFC1</i>	<i>MET</i>	<i>MIS18A</i>	<i>PPP4C</i>	<i>PRMT5</i>	<i>RUVBL1</i>	<i>SOX2</i>	<i>WEE1</i>	<i>ZNF217</i>
AASTR_ACH-001126	NA	-1.75	NA	-1.17	-2.04	NA	-1.10	-1.67	-1.05	-2.40	NA	-2.60	NA
AASTR_ACH-002257	-1.05	-1.99	NA	-1.08	-1.96	-1.28	-1.03	NA	-1.48	-2.50	NA	-1.94	NA
ASTR_ACH-000040	NA	-1.69	NA	NA	-1.80	NA	NA	NA	-1.05	-2.27	NA	-2.53	NA
ASTR_ACH-000128	NA	-2.29	NA	NA	-2.14	NA	-1.29	-1.50	-1.06	-1.82	-1.50	-1.35	-1.33
ASTR_ACH-000232	NA	-1.74	NA	NA	-1.65	NA	-1.18	NA	NA	-2.08	-1.06	-1.96	NA
ASTR_ACH-000329	-1.00	-1.84	NA	NA	-2.29	NA	NA	NA	NA	-2.45	NA	-3.03	NA
ASTR_ACH-000389	NA	-1.46	NA	NA	-1.93	NA	NA	-1.13	NA	-2.43	NA	-2.79	NA
ASTR_ACH-000437	NA	-1.46	NA	NA	-1.75	NA	-1.36	NA	-1.99	-2.34	NA	-2.31	NA
ASTR_ACH-000591	NA	-1.29	NA	NA	-1.59	NA	-1.53	NA	-1.10	-2.30	NA	-2.50	NA
ASTR_ACH-000592	NA	-1.91	NA	NA	-2.18	NA	-1.34	NA	-1.74	-2.10	NA	-2.89	NA
ASTR_ACH-000655	NA	-1.85	NA	NA	-2.07	NA	NA	NA	-1.58	-2.40	NA	-2.87	NA
ASTR_ACH-001016	-1.30	-1.78	NA	NA	-2.14	NA	-1.21	-1.08	-1.64	-1.98	NA	-2.15	NA
ASTR_ACH-001172	NA	-1.31	NA	NA	-1.71	NA	-1.62	-1.18	-1.29	-2.38	NA	-3.00	NA
ASTR_ACH-002269	NA	-1.45	NA	NA	-1.91	NA	-1.57	-1.53	-1.47	-2.04	NA	-2.42	NA
ASTR_ACH-002304	-1.30	-1.57	NA	NA	-1.35	NA	-1.27	-1.31	-1.12	-2.21	NA	-2.83	NA
ODG_ACH-000067	NA	-1.59	NA	NA	-1.81	NA	NA	NA	-1.35	-1.92	NA	-2.41	NA
ODG_ACH-000807	-1.30	-1.73	NA	NA	-1.56	NA	-1.65	-1.19	-1.72	-2.14	NA	-1.99	NA
GB_ACH-000036	NA	-1.86	NA	-1.11	-1.68	NA	-1.23	NA	-1.53	-1.35	NA	-2.78	NA
GB_ACH-000075	NA	-1.74	NA	NA	-2.05	NA	NA	-1.03	-1.46	-2.11	NA	-2.48	NA
GB_ACH-000098	NA	-1.52	NA	NA	-1.97	NA	-1.14	NA	-1.26	-2.00	NA	-2.55	NA
GB_ACH-000137	NA	-1.83	NA	NA	-2.04	NA	-1.33	-1.05	-1.35	-1.96	NA	-2.57	NA
GB_ACH-000152	NA	-1.65	-1.11	NA	-2.18	NA	NA	-1.07	-1.08	-2.32	NA	-2.41	NA
GB_ACH-000200	NA	-1.69	NA	NA	-2.23	NA	-1.24	-1.14	-1.17	-1.87	NA	-2.59	NA
GB_ACH-000215	NA	-2.29	NA	NA	-2.16	NA	-1.49	-1.60	-1.38	-2.25	NA	-2.79	NA
GB_ACH-000231	NA	-2.11	NA	NA	-1.61	NA	-1.61	-1.37	-1.70	-1.92	NA	-2.91	NA
GB_ACH-000244	NA	-1.77	NA	NA	-2.03	NA	-1.01	-1.52	-1.28	-2.02	NA	-1.76	NA
GB_ACH-000269	NA	-1.79	NA	-1.15	-1.92	NA	NA	NA	-1.90	-1.79	NA	-2.17	NA
GB_ACH-000323	NA	-1.54	NA	NA	-2.02	NA	NA	NA	-1.58	-2.19	NA	-2.45	NA
GB_ACH-000368	NA	-1.58	NA	-1.38	-1.97	NA	-1.04	-1.04	-1.23	-2.28	NA	-2.33	NA
GB_ACH-000370	NA	-1.52	NA	NA	-1.86	NA	NA	-1.07	NA	-2.01	NA	-2.58	NA
GB_ACH-000376	NA	-1.55	NA	NA	-1.74	NA	-1.27	-1.32	-1.75	-2.55	NA	-2.22	NA
GB_ACH-000445	NA	-1.45	NA	NA	-1.17	NA	-1.18	NA	-1.54	-2.27	NA	-2.84	NA
GB_ACH-000455	NA	-2.07	NA	NA	-1.71	NA	-1.00	-1.51	-1.84	-1.70	NA	-2.93	NA
GB_ACH-000464	-1.09	-2.13	NA	NA	-2.28	NA	-1.17	NA	-1.71	-2.33	NA	-2.72	NA
GB_ACH-000469	NA	-1.82	NA	NA	-1.63	NA	-1.31	NA	-1.54	-2.15	NA	-2.55	NA
GB_ACH-000479	NA	-1.61	NA	-1.01	-1.69	NA	-1.25	-1.53	-1.34	-2.03	-1.24	-2.36	NA
GB_ACH-000504	-1.13	-1.42	NA	NA	-1.73	NA	NA	NA	NA	-2.16	NA	-2.65	NA
GB_ACH-000558	NA	-1.67	NA	NA	-2.07	NA	NA	-1.27	-2.25	-2.06	NA	-2.61	NA

GB_ACH-000570	NA	-1.55	NA	NA	-1.97	NA	-1.50	-1.14	-1.60	-2.47	NA	-2.65	NA
GB_ACH-000571	NA	-1.84	NA	NA	-2.03	NA	NA	NA	-1.30	-2.18	NA	-2.82	NA
GB_ACH-000595	NA	-2.20	NA	NA	-1.78	NA	-1.41	-1.35	-1.67	-2.31	NA	-2.62	NA
GB_ACH-000609	NA	-1.54	NA	NA	-1.64	NA	-1.11	-1.15	NA	-1.94	NA	-2.65	NA
GB_ACH-000622	NA	-1.27	NA	-1.19	-2.00	NA	NA	NA	NA	-1.92	-1.76	-2.74	NA
GB_ACH-000623	-1.04	-1.10	NA	NA	-1.68	NA	NA	-1.08	-1.84	-2.13	NA	-2.60	NA
GB_ACH-000634	-1.16	-1.58	NA	NA	-1.88	NA	-1.42	-1.59	-1.55	-2.12	NA	-2.80	NA
GB_ACH-000673	NA	-2.24	NA	NA	-2.07	NA	-1.39	-1.10	-1.84	-2.19	NA	-2.54	NA
GB_ACH-000676	NA	-1.59	NA	NA	-1.76	NA	-1.30	-1.39	-1.55	-2.38	NA	-2.93	NA
GB_ACH-000738	NA	-1.73	NA	NA	-2.06	NA	-1.32	-1.17	-1.54	-2.27	NA	-1.64	NA
GB_ACH-000760	NA	-1.56	NA	NA	-1.87	NA	NA	-1.45	-1.69	-1.94	NA	-2.96	NA
GB_ACH-000819	NA	-1.64	NA	NA	-1.79	NA	-1.02	NA	NA	-1.56	NA	-2.21	NA
GB_ACH-000863	-1.16	-1.17	NA	NA	-1.59	NA	-1.45	-1.20	-1.23	-1.77	NA	-2.80	NA
GB_ACH-000887	NA	-1.54	NA	NA	-2.20	NA	-1.65	-1.62	-1.52	-1.64	NA	-2.93	NA
GB_ACH-001329	NA	-2.16	NA	NA	-2.49	NA	NA	NA	NA	-2.19	NA	-2.49	NA
GB_ACH-001605	NA	-1.31	NA	NA	-2.08	NA	NA	NA	NA	-2.19	NA	-1.11	NA
GB_ACH-001606	NA	-1.74	NA	NA	-1.46	NA	NA	NA	NA	-1.91	NA	-2.49	NA
GB_ACH-001608	-1.23	-1.54	NA	NA	-2.25	NA	-1.77	-1.56	-1.83	-2.36	NA	-1.97	NA
GB_ACH-001609	NA	-2.15	NA	NA	-2.09	NA	-1.22	-1.20	-1.76	-2.24	NA	-2.95	NA
GB_ACH-001610	NA	-1.72	NA	NA	-2.00	NA	-1.69	-1.23	-1.86	-1.91	NA	-1.49	NA
GB_ACH-001611	NA	-1.52	NA	NA	-1.56	NA	-1.17	-1.19	-1.53	-2.25	NA	-2.19	NA
GB_ACH-001622	NA	-1.91	NA	NA	-2.06	NA	-1.07	-1.14	-1.04	-2.34	NA	-3.00	NA
GB_ACH-001623	NA	-1.91	-1.30	NA	-2.02	NA	-1.36	-1.14	-1.18	-2.21	NA	-2.96	NA
GB_ACH-001624	NA	-2.07	NA	-1.01	-1.59	NA	-1.39	NA	NA	-1.40	NA	-2.67	NA
GB_ACH-002228	NA	-1.40	NA	NA	-1.57	NA	-1.47	-1.72	-1.35	-2.41	NA	-2.44	NA
GB_ACH-002229	NA	-1.75	NA	NA	-1.81	NA	-1.17	-1.26	-1.45	-1.80	NA	-2.60	NA
GB_ACH-002230	-1.08	-2.28	NA	NA	-2.08	NA	NA	NA	NA	-1.93	NA	-2.60	NA
GB_ACH-002680	NA	-1.98	NA	-1.40	-2.37	NA	-1.38	-1.13	-1.41	-2.43	NA	-2.74	NA

5. DISCUSSION

The gliomas present massive challenges in terms of innovating new treatment strategies despite the efforts put forth by researchers in recent years (Sanders & Debinski, 2020). The co-expression patterns of genes in cancers have become a new trend in identifying the targetable entities (Yi et al, 2020). Therefore, initially we investigated the co-expression profiles and their differences between different subtypes of LGG based on *IDH* mutation status and to explore the common pathways between these subtypes.

Even though these subtypes belong to LGG, the survival rate and the progression of the disease are significantly dissimilar for LGG with *IDH* mutation status (Sharma & Graber, 2020). The LGG with *IDH1* mut, pTERT wt and 1p19q-co-deleted genotype has the best chance of survival (Aoki et al, 2018). The overall survival shortenst with only incorporation of pTERT mutations on the aforementioned genotype (Eckel-Passow et al, 2015). Therefore, these genotypic traits are important to consider while exploring either genotypic or transcriptomic profiles of gliomas.

In this study, we explored the discrepancies between transcriptomic profiles of LGG subtypes and incorporated the perspective of co-expression data to identify the shared biological pathways that significantly differ between the normal samples and LGG subtypes, and further looking at the differentiating features from one subtype to another (clinical parameters). Furthermore, the tumors belonging to CNS were previously characterized on the basis of histological parameters; however, with the advances and popularization of NGS and high throughput methodologies, the molecular profiling or characterization of complex disorders has become possible (Varghese et al, 2017).

The genetic subtypes especially in the cases of gliomas such as *IDH* mutation parameter being a biomarker of the disease, can further assist in understanding the molecular heterogeneity of the cancers by utilizing sequencing data (Carter et al, 2017). It can further be utilized in understanding the oncogenic drivers which can be targeted at the earliest stages to combat the worse prognosis associated with eventual progression to GBM (Lim-Fat et al, 2022). Therefore, we utilized datasets detailing the transcriptomics and DNA methylation events at genomic scale to arrive at

specific conclusions in our study regarding the biological pathways, targetable genes with specific drugs, and how the integration of transcriptomics and DNA methylation can guide in understanding the diverse profiles of LGG subtypes.

5.1. Subtype Specific Co-expression Modules and Their Enrichment Analysis

The clinical features of interest were correlated with different modules from the weighted gene co-expression analysis performed. Our analysis showed that Chr7 gain, which is associated with *EGFR* amplification and Chr10 loss, which is linked with PTEN deletion (Stichel et al, 2018), are not associated with either IDH wt or IDH mut subtypes of LGG. Although these clinical features have been extensively studied and may be clinically relevant, Sienkiewicz et al. found that these features are not enough to be used in diagnosis as well (Sienkiewicz et al, 2022).

The module-trait relationship plots are shown in Figures 4.3a-b. Moreover, for IDH mut subtype, pTERT mutation status as a clinical feature was positively correlated with five co-expression modules in our study and negatively correlated with only two modules (white and GreenYellow module). This feature has been linked with the prognosis of LGG for IDH wt subtype as well (Aoki et al, 2018); therefore, the co-expression modules negatively correlating with IDH mut indicates that this set of genes are inactive in IDH mut, which is less aggressive form of LGG. IDH wt subtype had four negatively correlated and two positively correlated co-expression modules for pTERT mutation status. Here, the modules of interest are positively correlated ones (blue, green). In IDH mut samples, TERTexp.status feature was positively correlated with three modules (Blue, Green and Salmon) and negatively correlated with two modules (White and GreenYellow). Moreover, in IDH wt samples, TERTexp.status was not positively correlated with any module based on our threshold values, but found as negatively correlated with only one module (Turquoise).

Dono et al. identified patients of gliomas with IDH wt subtype and *BRAF* V600E mutation have the potential to be given BRAF-targeted therapies (Dono et al, 2020). Therefore, *BRAF* V600E mutation status was explored in IDH wt subtype for co-expression based analysis and according to our correlation criteria (less than -0.5 or more than 0.5); the co-expression modules were not correlated with IDH wt LGG samples. Braf protein functions in cellular growth and V600E mutation in *BRAF*

gene is associated with tumor metastasis for different brain tumors including GBM, ganglioma, and astrocytomas (Sithanandam et al, 1990; Davies et al, 2002; Kaley et al, 2018). Based on our analysis of *BRAF* mutation status, there are no or few co-expressed targets that can be identified and targeted together if BRAF inhibitors are utilized as intervention therapy for IDH wt LGG patient.

The GBM and oligodendrogliomas represent opposite prognosis, but both types possess pTERT mutations (Aoki et al, 2018); therefore, IDH wt and IDH mut LGGs were explored in our study further with regard to pTERT mutation status for selecting modules of interest (based on cut-off of correlation values). Subsequently, enrichment analysis was performed on such modules for identifying the enriched pathways associated with individual modules based on weighted co-expression, which are shown in Table 4.1.

Immune-related pathways were enriched in IDH wt Salmon and Yellow modules having negative correlation with pTERT status, meanwhile IDH mut Blue module showing positive correlation with pTERT was enriched for immune system related pathways. The tumor associated responses from the immune system for differing oncogenic profiles (Berghoff et al, 2017) along with the heterogeneous tumor microenvironment (Anderson et al, 2021) explains the correlation variance for immune related pathways being regulated differently, which could possibly explain our findings regarding the pTERT mutation status.

The synaptic pathways were shared among Green and Blue modules which are positively correlated with pTERT mutation status in IDH wt subtype. Moreover, the GreenYellow module in IDH mut subtype was also enriched for synaptic pathways but was negatively correlated with the status of pTERT mutation. A study exploring DNA methylation status and molecular profiling discovered that IDH wt LGG exhibit the activation of synaptic pathway (Ceccarelli et al, 2016), however, our analysis is the first of its kind which investigated co-expression modules to identify that synaptic pathways are linked with pTERT mutation status in IDH wt LGG.

The IDH wt Blue pTERT positively correlated and IDH mut GreenYellow pTERT negatively correlated modules contained 13 shared pathways as shown in the Table 4.2. The Glutamatergic synapse pathway of both modules contained Glutamate ionotropic receptor NMDA type subunits. NMDA receptor mediated signaling has been associated with invasive nature and proliferation of glioma and glioblastoma cells (Ramaswamy et al, 2014; Müller-Längle et al, 2019). However, Glutamate

ionotropic receptor AMPA type 1 (*GRA1*) was a component of IDH wt blue models and was absent in GreenYellow module, which is known to facilitate the growth and cytoskeletal regulation in glioma cells (Wirsching & Weller et al, 2020). This data indicates that in IDH wt pTERT mutant-correlated LGG, the activity of NMDA type receptors play a role in oncogenic transformation. However, in IDH mut pTERT mutant negatively correlated LGG, *GRA1* mediated signaling is activated. This data can assist in differentiating the molecular subtypes of LGG further at the transcriptomics level.

5.2. DEGS from Module of Interest

After exploring the clinically relevant modules and their pathways along with the parameters of IDH mutation and pTERT mutation, we further investigated the differentially expressed genes (DEGs) between normal samples and LGG IDH wt or between normal and IDH mut samples; then mapped these genes on the relevant final module of interest (IDH wt Blue). Since the IDH wt Blue module was correlated with pTERT mut status in both IDH wt and IDH mut samples, this type of analysis assists in understanding the transcriptionally active or inactive genes correlating with the clinical features.

After mapping the DEGs, we observed that *GNG12* was upregulated and *PLCB1*, *GRIA2*, *GABRA3*, and *GNAL* were downregulated in the IDH wt Blue module, furthermore these were absent in the IDH mut GreenYellow module. Interestingly, the downregulated genes were also downregulated in our Normal vs IDH wt and Normal vs IDH mut LGG analyses. Therefore, we postulate that these are the hub genes based on co-expression analysis and relevant with IDH and pTERT mutation status in LGG samples.

GNG12 has been associated with metastases, differentiation and cell division along with other tumor promoting pathways and belongs to the G-family of proteins (Morishita et al, 1995; Luo et al, 2018). Liu et al. has recently identified *GNG12* as not only a novel biomarker for glioma but *GNG12* can also be utilized in targeted therapy as well (Liu et al, 2022). Our analysis also revealed that *GNG12* expression was correlated with severity of LGG indicated with lowest expression in normal samples and highest in IDH wt LGG. This finding is significant from the perspective

of this independent study as our data can be utilized for clinical relevancy as it is validated from other investigations.

A G-protein alpha subunit stimulatory protein *GNAL* was found downregulated among our DEGs, which has already been identified as one of the 24 genes linked with prognosis of glioma with an inverse correlation of its expression with glioma grades (Zhang et al, 2020). In our analysis, *GNAL* expression was highest in normal samples and downregulated in IDH mut with lowest expression in LGG IDH wt samples. This data further validates our findings. Another downregulated gene *GABRA3* (Gamma-amino butyric acid receptor alpha subunit 3) has also been identified in an independent study as downregulated in glioma, where its loss has been associated with invasion and metastasis of glioma (Patil et al, 2020). Patil et al utilized the Cancer Cell Line Encyclopedia glioma data and TCGA data in their analyses, further implying that our study produced validated results.

Glutamate ionotropic receptor AMPA type subunit 2 (*GRIA2*) has been studied extensively in glioma and glioblastoma cells with invasive behavior of cells linked with higher expression levels of *GRIA2* (Oakes et al, 2017; Zhang et al, 2018; Hu et al, 2020). However, AMPA receptor expression (*GRIA1-4*) was negatively correlated with glioma grade in one study, with RNA editing of *GRIA2* depending on the glutamate environment of the cells (van Vuurden et al, 2009). In our study, we found *GRIA2* to be among the downregulated cohort of genes, which is interesting. Moreover, *GRIA2* being enriched in Blue module only and not in GreenYellow, indicates that there is a difference in how *GRIA2* is regulated among different subtypes of LGG. AMPA receptors are involved in regulation of calcium homeostasis via activation of the Akt pathway (Ishiuchi et al, 2007).

The inhibition of the Akt pathway in combination with ERK has been identified as a synergistic and potent inhibitor of glioma (Wu et al, 2017). The glutamatergic synapse pathways are involved in ERK regulation via PKC and Phospholipase C beta 1 (*PLCB1*). We identified *PLCB1* as downregulated in IDH wt LGG as compared to IDH mut LGG and normal samples. Moreover, *PLCB1* was also discovered as downregulated in glioblastoma as compared to normal samples recently (Marvi et al, 2022). The low expression of *PLCB1* has been significantly associated with poor survival of GBM (Cai et al, 2022). Therefore, the gene signature of downregulated *GNAL*, *GABRA3*, *GRIA2*, *PLCB1* and upregulated *GNG12* presents a unique opportunity as a result of this study for researchers to

explore in the biomarker, diagnosis, prognosis, and therapeutic intervention of LGG based on its molecular subtypes.

5.3. Interaction of Identified Gene Signature with Known Drugs

After identifying the gene signature associated with the progression of LGG, we investigated the drugs that can be used to target this signature for best utilization with the aim of inactivating the upregulated *GNG12* and activating the downregulated *PLCB1*, *GRIA1*, *GABRA3*, and *GNAL*. The comprehensive analysis is shown in Table 4.4. We identified four drugs namely Vemurafenib, Vanadium Pentoxide, Imatinib, and Cisplatin, which targeted four out of five genes in our gene signature.

Temozolomide and Cisplatin have been investigated for combined treatment against recurrent GBM with acceptable toxicity and active performance (Wang et al, 2017). Temozolomide is used against glioma, however the treatment leads to resistance and eventual recurrence (Daniel et al, 2019). Cisplatin has been used with other drugs for incurring synergistic effects (Maciejka et al, 2019; Zhai et al, 2021) but not with other drugs targeting our gene signature such as Imatinib and Vanadium Pentoxide. Moreover, Imatinib is known to elicit autophagy and subsequent cytotoxicity in glioma cells (Shingu et al, 2009) and has been used for investigating its synergistic potential with other drugs (Lu et al, 2020) and also against GBM (Rashidi et al, 2020). However, the combination of Imatinib with other drugs targeting our gene signature has not been investigated and provides an opportunity to researchers to explore this new targeted approach.

Vanadium Pentoxide has not been investigated to date directly in treating glioma, but its effect on cancer cell lines and animal models has been studied (García-Rodríguez et al, 2016; Zwolak, 2014). Furthermore, Vanadium-based nanoparticles have been explored in cytotoxicity and drug encapsulation studies with modest results (Guo et al, 2020), however, the direct use of Vanadium Pentoxide is yet to be investigated. Vemurafenib is known to target the BRAFV600E in pediatric glioma (Bautista et al, 2014) and LGG (Del Bufalo et al, 2018) in a Phase I clinical study (Nicolaidis et al, 2020) with high grade glioma leading to resistance (Lehmann et al, 2022). Vemurafenib was combined with Cobimetinib in a study against GBM with positive outcome in a recent study (Rajan et al, 2023). It was also combined

with Cobimetinib, and Dabrafenib and Trametinib in patient derived pediatric LGG cells (Usta et al, 2020). However, the combination of Vemurafenib in similar models or patients with aforementioned identified drugs targeting our gene signature is yet to be performed.

Although imatinib shows poor penetration through the blood brain barrier (BBB) (Takayama et. al., 2002), Bihorel et al. (2007) demonstrated that combining imatinib with P-gp (and Bcrp1) transporter inhibitors like elacridar may increase imatinib's brain delivery and increase its ability to treat malignant gliomas. In addition, Durmus et al. (2012) showed that brain penetration of Vemurafenib can be enhanced with elacridar coadministration. Vanadium (V) crosses the BBB (Avila-Costa et al. 2015). Dorado-Martínez et al. showed that Vanadium Pentoxide (V_2O_5) induced death in Alzheimer-like cells in rats through cytoskeletal and synaptic alterations. According to pharmacokinetic analyses in nonhuman primates, cisplatin and carboplatin only partially penetrate the CNS (3.7% and 2.6%, respectively) (Jacobs et. al. 2005). Zhang et. al. (2017) has shown that cisplatin-loaded nanoparticles (70 nm in diameter) penetrate deeper into the brain with local administration by either manual injection or convection-enhanced delivery (CED). The drugs prioritized in this study might have poor or limited BBB penetration, which is one of the grand challenges in glioma treatment, but drug delivery systems such as nanoparticles, convection-enhanced delivery, focused ultrasound, and disruption of the BBB using microbubbles might be helpful to combat this issue in the future applications (Arvanitis et. al. 2020, Wen et. al., 2020, Drappatz et. al., 2013, Idbaih et. al., 2019).

5.4. Methylation Data Integration with Transcriptomics Data

After identifying the gene signature based on co-expression analysis and exploring DEGs among different subtypes of LGG and drugs that can target the gene signature comprehensively, we aimed to investigate the alterations occurring at DNA methylation levels among different subtypes of LGG. Since DNA methylation is directly involved in regulating the gene expression and co-expressed genes can be co-regulated with common epigenetic factors functioning in DNA methylation profiles (Yang et al, 2017), this analysis can be integrated into our processed transcriptomics data as well.

Before processing the DNA methylation data, we explored more normal samples to get enriched data to be compared with cancer samples in our study. In the previous analysis exploring the co-expression data, we had 5 samples belonging to the normal group for analyzing the differentially expressed genes and then mapped them onto the genes contained in specific modules. Therefore, we repeated the DEGs with normalized samples from the GTEx database and included them in our analysis compared with TCGA LGG samples (Table 4.5). In short, we analyzed the 4 subtypes 1) IDH mut pTERTmt Chr1p19q codel 2) IDH mut pTERTwt Chr1p19q noncodel, 3) IDH wt pTERTmt Chr1p19q noncodel, 4) IDH wt pTERTwt Chr1p19q noncodel. After conducting the DEG analysis, we explored the differentially methylated regions, which were later explored to arrive at the hypo- or hyper-methylated genes.

Each subtype explored in our study showed a subset of DEGs, but the most aggressive subtype of LGG with IDH wt pTERT mut showed the most downregulated genes. This data is consistent with our previous DEG analysis performed with normal samples from TCGA GBM data. In our differentially methylated genes analysis, we observed that IDH mut subtypes showed a significantly higher proportion of hypermethylated genes, which has been studied in literature as well (Unruh et al, 2019; Braun et al, 2021). The CpG island hypermethylation is associated with epigenetic alterations occurring at genomic level due to IDH mutation has already been reported (Noushmehr et al, 2010).

The number of hypomethylated genes observed in IDH wt pTERT mut subtype as compared to normal samples was significantly higher as compared to other subtypes when compared with normal samples (Table 4.6). Genome instability has been linked with DNA hypomethylation (Ehrlich & Lacey, 2012), which can result in more aggressive phenotype in cancer cells (Yao & Dai, 2014). The role of DNA hypomethylation has been reviewed recently in the context of glioma where the emphasis on chromatin regulation was made, in order to identify the heterogeneity associated with different subtypes of gliomas (Dabrowski & Wojtas, 2019). Furthermore, the Akt signaling pathway has also been associated with DNA hypomethylation in glioma (Briand et al, 2019), which we discussed in our analysis of gene signature being involved in the intersection with Akt signaling. The detailed analysis of differentially methylated genes are shown in Figure 4.10 showcasing the subtype specific genes driven through differential methylation status.

These subtype specific MDGs were enriched for biological pathways (Table 4.8). The subtype specific or shared MDGs for the explored subtypes showed enrichment for CNS specific pathways or major signaling pathways we identified in our previous analysis for co-expression modules. However, interestingly, the hypomethylated and overexpressed genes for IDH wt pTERT mut subtype which is the most aggressive subtype, were enriched for immune-related pathways. The pTERT alteration and its associated effects has been associated with the tumor microenvironment and changed signaling referring to immune evasion for gliomas and GBM (Olympios et al, 2021).

Moreover, the hypermethylated and downregulated genes for IDH wt pTERT mut were enriched for neuroactive ligand-receptor interaction pathways, implying that the aggressive oncogenic transformation in glioma is associated with over activation of ligand-receptor mediated signaling. Recently, MD2 was observed as a biomarker for immune infiltration for gliomas, with MD2 mediated neuroactive ligand-receptor interactions for T cell co-stimulation as a differentiating factor (Zhao et al, 2022). Therefore, our analyses revealed that the most aggressive subtype of LGG based on IDH and pTERT mutation status (IDH wt pTERT mut) has differential response to immune related pathway and neuroactive ligand receptor interaction based pathways, as an underlying feature at both transcriptome and DNA methylation level, leading to tumor heterogeneity and consequent aggressiveness and worse prognosis.

5.5. Network Construction based on MDGs + Modules of Interest and Essential Epifactor Analysis

We further explored our WGCNA-based co-expression analysis in the context of DMGs to investigate the co-expressed and co-methylated cohorts. The MDGs were mapped onto the co-expressed cohorts (modules) as shown in Figure 4.10a-b. The mapped IDH wt pTERT+ Blue module genes were mostly co-hypomethylated and IDH mut pTERT- GreenYellow module genes were co-hypomethylated. This data supports the hypothesis that the DNA methylation profiles can serve as a differentiating factor for further characterizing the LGG subtypes that are already based on genetic alterations. The subnetworks obtained as a result of our analyses

inform us that the DNA methylation has a role in regulation of the genes that are co-expressed and can be targeted for specific subtypes.

Since, the aforementioned subnetworks associated with modules of interest are specific with MDGs incorporated onto co-expressed genes, we further explored their neighbors to construct a more biologically interpretable network containing nodes that can be targeted. Therefore, we included epigenetic factor protein complexes (also known as epifactors) in our analysis to illustrate the comprehensible subtype module or subtype specific network. The number of complexes with nodes and edges for subtype specific networks and their statistics are displayed in Table 4.9. This analysis resulted in targetable entities which are involved in regulation of both DNA methylation and also the co-expressed genes extracted from transcriptomics data which are associated with specific subtypes of LGG based on IDH mutation status and its correlation with pTERT mutation status.

The IDH mut pTERT- subtype (least aggressive subtype among the ones investigated) co-expression module of interest with incorporated MDGs showed targetable Epifactors such as *HDAC1*, *BRCA1*, *CTBP1*, *PRMT5*, *PPP4C*, and *CSNK2A1* (Figure 4.12b). Furthermore, the IDH wt pTERT+ subtype (most aggressive subtype among the ones investigated) co-expression module of interest with incorporated MDGs showed more targetable Epifactors such as *CBX3*, *PRMT5*, *KDM1A*, *HDAC1*, *CTBP1*, *CSNK2A1*, *ACTL60*, *EPC1*, *BRCA1*, *ACTB*, *HCFC1*, *ACTL6A*, and *MIS18A* among others. Recently, in high grade gliomas, the Epifactors were screened and identified using CRISPR screening method, and targeted to illustrate the importance of these factors in targeting the brain tumors (Wenger et al, 2023), however, for LGG and adult GBM, such an approach has not been utilized. As a consequence of our study, we propose that the Epifactors can be identified as potential targets for LGG as these factors regulate the genes expressed together in a subtype specific manner.

Lastly, we performed perturbation analysis on the Epifactors that are common for all the subtypes we explored in our analysis for LGG. Thirteen Epifactors were screened for perturbation effects in 66 models of diffuse glioma. We identified a 5-Epifactor signature (*ACTL6A*, *HCFC1*, *RUVBL1*, *PRMT5*, and *WEE1*), which can be considered essential for cell survival (Table 4.10). Interestingly, *PRMT5* was shared across all subtypes of LGG used in all analyses across our study with *WEE1* common for only IDH wt subtypes regardless of pTERT mutation status. *PRMT5* is a

protein arginine methyltransferase which acts in the methylation of both histones and non-histone proteins for regulating the gene expression (Pollack et al, 2009; Branscombe et al, 2001). It also affects the stability, recruitment, and activity of different transcription factors (Koh et al, 2015). *PRMT5* inhibition has been investigated as a potential therapeutic intervention in glioblastoma with positive outcomes in targeting cancer stemness (Yan et al, 2014; Banasavadi-Siddegowda et al, 2018; Sachamitr et al, 2021). In glioma, the expression of *PRMT5* has been associated with malignancy of the tumor (Han et al, 2014) and its interaction with *HOXC10* leading to upregulation of *VEGFA* as a mechanism of inducing malignant behavior (Tan et al, 2018). Moreover, in glioblastoma, the inhibition of *PRMT5* can lead to increased sensitivity to mTOR inhibition for targeting cancer cells (Holmes et al, 2019). However, there is a dearth of literature concerning the mode of action of *PRMT5* in gliomas, therefore our study revealing *PRMT5* as a common essential Epifactor observed in all clinically relevant co-expression modules of LGG subtypes observed, makes it a prime target that can be utilized in therapeutic strategies.

Wee1 protein, encoded by the *WEE1* gene, functions in the regulation of G2/M checkpoint of the cell cycle, and is overexpressed in many cancers and considered a potential target for therapy with many clinical trials underway (Vakili-Samiani et al, 2022). In glioblastoma, both genetic and pharmacological inhibition of *WEE1* has been associated with sensitivity of cancer cells to ionizing radiation leading to mitotic catastrophe, further implying that *WEE1* is a potent target for brain tumors (Mir et al, 2010). *WEE1* is overexpressed in many cancers including glioblastoma (De Witt Hamer et al, 2011). Caretti et al in 2013 showed that *WEE1* inhibition using MK-1775 leads to enhanced response to radiation in the xenograft model of diffuse intrinsic pontine glioma (Caretti et al, 2013). In high Grade gliomas, a specific inhibitor of *WEE1* MK-1775 in combination with radiation treatment was proposed as a targeted therapy option with promising results (Mueller et al, 2014). MK-1775 has been used in combination with Temozolomide to study the heterogeneous distribution across the blood brain barrier, which indicated the limited distribution to brain tumors (Pokorny et al, 2015; Lescarbeau et al, 2016). Therefore, other ways of delivery may be explored to utilize this compound in clinical settings against glioblastoma. In glioblastoma, *WEE1* is considered a prognostic marker and in glioma, its expression was correlated with *MGMT* status (Music et al, 2016). Adavosertib, a *WEE1* inhibitor in synergy with cranial radiation therapy (CRT) has

been utilized in a Phase I consortium study against diffuse intrinsic pontine glioma (Mueller et al, 2022). An integrated analysis using only DNA Damage and Repair (DDR) related genes in DEG analysis for LGG showed that *WEE1* is associated with IDH mutation status (Pang et al, 2020). Our independent study initiating from clinically relevant co-expression modules based on IDH and pTERT mutation status and integration with DNA methylation profiles with subsequent Epifactor analysis resulted in identifying *WEE1* as a IDH wt specific Epifactor complex, which can be targeted for LGG therapy.



6. CONCLUSION

Gliomas present challenges as they subsequently progress from lower grade to higher grade forms of the disease with worse prognosis for patients. With high-throughput data and analysis techniques available to researchers, the molecular signatures of the disease can be deciphered with the goal of finding pathways or targets that can be readily targeted for incorporation in treatment strategies. Therefore, we designed a bioinformatics pipeline to investigate the clinical data available from the relevant databases in order to explore the common pathways shared between different molecular subtypes of LGG. We further identified the enriched pathways associated with the co-expression modules and identified the drugs that can target a cohort of targets based on our investigation. We further implemented DNA methylation analysis to discover the altered methylation profiles associated with different subtypes of LGG and integrated our analysis with transcriptomics data. This deep analysis exercise was further enhanced by incorporating the epigenetics-based interactome analysis to find the potential Epifactors enriched in a subtype specific manner and can be used as direct targets in intervention strategies. Our initial findings based on co-expression modules of LGG subtypes were already established in the relevant literature and suggested that co-expression based modules associated with clinical subtypes of IDH mutation status and pTERT mutation status can differentiate the subtypes based on co-expressed genes, which are enriched in synapse-related or immune-related pathways. We further arrived at a gene signature of upregulated *GNG12* and downregulated *PLCB1*, *GRIA2*, *GABRA3*, and *GNAL* after mapping DEGs on our co-expression modules constructed using WGCNA. Based on our analysis, we identified four drugs Vemurafenib, Vanadium Pentoxide, Imatinib, and Cisplatin, that can target four out of five genes in our gene signature simultaneously. These findings have direct implications in developing clinical and pre-clinical intervention strategies for aggressive LGG IDH wt pTERT mut patients having the worse prognosis.

We further explored the LGG samples and compared the DNA methylation profiles of normal samples incorporated from different datasets with appropriate normalization techniques. We integrated the hyper and hypo-methylated genes with differentially expressed genes from different subtypes of LGG and observed a higher

number of hypomethylated genes in IDH wt pTERT mut subtype as compared to normal samples. To arrive at biologically interpretable insights from DNA methylation integration with co-expression modules, we found the co-expressed and co-methylated cohorts and explored their neighbors to construct the networks associated with different genetic subtypes of LGG. The epigenetic factors of the individual networks were then investigated to find the targetable entities for each subtype. This deep analysis converged on two targets which can be utilized in further studies in combination with aforementioned drugs to aggressively treat the LGG tumors. *PRMT5* was found to be enriched in all subtypes as a methylator factor, and therefore can lead to a broad target for brain tumors and has already been explored in clinical studies. Interestingly, *WEE1* was discovered as a LGG IDH wt specific target in our analysis, and its inhibitors has been explored against high grade gliomas, but LGGs with IDH wt having worse prognosis can be targeted using *WEE1* inhibitors as well. Therefore, this multi-omics approach of integrating transcriptomics and DNA methylation high throughput data provided us with a narrow gene signature that can be targeted with already established drugs and also unique targets which can be targeted in combination with established drugs against different types of LGG or GBM.

7. REFERENCES

- Achi J, Achi XW, Veintimilla P, Cueva J. Unusual extraneural metastasis of glioblastoma. *Surg Neurol Int.* 2023;14:218.
- Akter F, Simon B, de Boer NL, Redjal N et al. Pre-clinical tumor models of primary brain tumors: Challenges and opportunities. *Biochim Biophys Acta Rev Cancer.* 2021;1875(1):188458.
- Aldape K, Zadeh G, Mansouri S, Reifenberger G, et al. Glioblastoma: pathology, molecular mechanisms and markers. *Acta Neuropathol.* 2015;129(6):829-848.
- Alexandrescu S, Korshunov A, Lai SH, Dabiri S et al. Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomas--Same Entity or First Cousins?. *Brain Pathol.* 2016;26(2):215-223.
- Alther B, Mylius V, Weller M, Gantenbein A. From First Symptoms to Diagnosis: Initial Clinical Presentation of Primary Brain Tumors. *Clinical and Translational Neuroscience.* 2020; 4(2):17.
- Andersen BM, Faust Akl C, Wheeler MA, Chiocca EA et al. Glial and myeloid heterogeneity in the brain tumour microenvironment. *Nat Rev Cancer.* 2021;21(12):786-802.
- Aoki K, Nakamura H, Suzuki H, Matsuo K et al. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. *Neuro Oncol.* 2018;20(1):66-77.
- Aquilanti E, Kageler L, Watson J, Baird D et al. Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume. *Neuro Oncol.* 2023;25(7):1275-1285.
- Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. *Nat Rev Cancer.* 2020;20(1):26-41.
- Avila-Costa MR, Colín-Barenque L, Zepeda-Rodríguez A, Antuna SB et al. Ependymal epithelium disruption after vanadium pentoxide inhalation. A mice experimental model. *Neurosci Lett.* 2005;381(1-2):21-25.
- Banasavadi-Siddegowda YK, Welker AM, An M, Yang X et al. PRMT5 as a druggable target for glioblastoma therapy. *Neuro Oncol.* 2018;20(6):753-763.

- Batash R, Asna N, Schaffer P, Francis N et al. Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review. *Curr Med Chem.* 2017;24(27):3002-3009.
- Bautista F, Paci A, Minard-Colin V, Dufour C et al. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. *Pediatr Blood Cancer.* 2014;61(6):1101-1103.
- Bergaggio E, Piva R. Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy. *Cancers (Basel).* 2019;11(4):563.
- Berghoff AS, Kiesel B, Widhalm G, Wilhelm D et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. *Neuro Oncol.* 2017;19(11):1460-1468.
- Bihorel S, Camenisch G, Lemaire M, Scherrmann JM. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. *Pharm Res.* 2007;24(9):1720-1728.
- Binder H, Willscher E, Loeffler-Wirth H, Hopp L et al. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development. *Acta Neuropathol Commun.* 2019;7(1):59.
- Bock C. Analysing and interpreting DNA methylation data. *Nat Rev Genet.* 2012;13(10):705-719.
- Brandner S, McAleenan A, Kelly C, Spiga F et al. MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. *Neuro Oncol.* 2021;23(9):1457-1469.
- Branscombe TL, Frankel A, Lee JH, Cook JR et al. PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins. *J Biol Chem.* 2001;276(35):32971-32976.
- Braun Y, Filipinski K, Bernatz S, Baumgarten P et al. Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma. *Neuropathol Appl Neurobiol.* 2021;47(3):379-393.
- Breen MS, Bierer LM, Daskalakis NP, Bader HN et al. Differential transcriptional response following glucocorticoid activation in cultured blood immune cells: a novel approach to PTSD biomarker development [published

- correction appears in *Transl Psychiatry*. 2020 Jan 6;10(1):1]. *Transl Psychiatry*. 2019;9(1):201.
- Brennan CW, Verhaak RG, McKenna A, Campos B et al. The somatic genomic landscape of glioblastoma [published correction appears in *Cell*. 2014 Apr 24;157(3):753]. *Cell*. 2013;155(2):462-477.
- Briand J, Nadaradjane A, Bougras-Cartron G, Olivier C et al. Diuron exposure and Akt overexpression promote glioma formation through DNA hypomethylation. *Clin Epigenetics*. 2019;11(1):159.
- Broniscer A, Tatevossian RG, Sabin ND, Klimo P Jr et al. Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma. *Neuropathol Appl Neurobiol*. 2014;40(3):327-336.
- Bruhn H, Blystad I, Milos P, Malmström A et al. Initial cognitive impairment predicts shorter survival of patients with glioblastoma. *Acta Neurol Scand*. 2022;145(1):94-101.
- Byrne S, Connor S, Lascelles K, Siddiqui A et al. Clinical presentation and prognostic indicators in 100 adults and children with neurofibromatosis 1 associated non-optic pathway brain gliomas. *J Neurooncol*. 2017;133(3):609-614.
- Cai X, Chen Z, Huang C, Shen J et al. Development of a novel glycolysis-related genes signature for isocitrate dehydrogenase 1-associated glioblastoma multiforme. *Front Immunol*. 2022;13:950917.
- Caiafa P, Zampieri M. DNA methylation and chromatin structure: the puzzling CpG islands. *J Cell Biochem*. 2005;94(2):257-265.
- Capper D, Jones DTW, Sill M, Hovestadt V et al. DNA methylation-based classification of central nervous system tumours. *Nature*. 2018;555(7697):469-474.
- Caretti V, Hiddingh L, Lagerweij T, Schellen P et al. WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas. *Mol Cancer Ther*. 2013;12(2):141-150.
- Carithers LJ, Moore HM. The Genotype-Tissue Expression (GTEx) Project. *Biopreserv Biobank*. 2015;13(5):307-308.
- Carter JH, McNulty SN, Cimino PJ, Cottrell CE et al. Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas:

- Application of the World Health Organization's 2016 Revised Criteria for Central Nervous System Tumors. *J Mol Diagn.* 2017;19(2):328-337.
- Ceccarelli M, Barthel FP, Malta TM, Sabedot TS et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. *Cell.* 2016;164(3):550-563.
- Chen B, Chen C, Zhang Y, Xu J. Recent incidence trend of elderly patients with glioblastoma in the United States, 2000-2017. *BMC Cancer.* 2021;21(1):54
- Chi AS, Cahill DP, Reardon DA, Wen PY et al. Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. *JCO Precis Oncol.* 2020;4:PO.19.00295.
- Choi DJ, Armstrong G, Lozzi B, Vijayaraghavan P et al. The genomic landscape of familial glioma. *Sci Adv.* 2023;9(17):eade2675
- Choi SW, Lee Y, Shin K, Koo H et al. Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma. *Cell Death Dis.* 2021;12(4):374.
- Cieřlik M, Chinnaiyan AM. Cancer transcriptome profiling at the juncture of clinical translation. *Nat Rev Genet.* 2018;19(2):93-109.
- Colaprico A, Silva TC, Olsen C, Garofano L et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. *Nucleic Acids Res.* 2016;44(8):e71.
- Colebatch AJ, Dobrovic A, Cooper WA. TERT gene: its function and dysregulation in cancer. *J Clin Pathol.* 2019;72(4):281-284.
- D'Angelo F, Ceccarelli M, Tala, Garofano L et al. The molecular landscape of glioma in patients with Neurofibromatosis 1. *Nat Med.* 2019;25(1):176-187.
- Dabrowski JM, Wojtas B. Global DNA Methylation Patterns in Human Gliomas and Their Interplay with Other Epigenetic Modifications. *Int J Mol Sci.* 2019;20(14):3478.
- Daniel P, Sabri S, Chaddad A, Meehan B et al. Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities. *Front Oncol.* 2019;9:41.
- Davalos V, Esteller M. Cancer epigenetics in clinical practice. *CA Cancer J Clin.* 2023;73(4):376-424.
- Davies H, Bignell GR, Cox C, Stephens P et al. Mutations of the BRAF gene in human cancer. *Nature.* 2002;417(6892):949-954

- de Torrenté L, Zimmerman S, Suzuki M, Christopeit M et al. The shape of gene expression distributions matter: how incorporating distribution shape improves the interpretation of cancer transcriptomic data. *BMC Bioinformatics*. 2020;21(Suppl 21):562
- De Witt Hamer PC, Mir SE, Noske D, Van Noorden CJ et al. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. *Clin Cancer Res*. 2011;17(13):4200-4207.
- Dedeurwaerder S, Defrance M, Calonne E, Denis H et al. Evaluation of the Infinium Methylation 450K technology. *Epigenomics*. 2011;3(6):771-784.
- Del Bufalo F, Ceglie G, Cacchione A, Alessi I et al. BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas. *Front Oncol*. 2018;8:526.
- Demirel HC, Arici MK, Tuncbag N. Computational approaches leveraging integrated connections of multi-omic data toward clinical applications. *Mol Omics*. 2022;18(1):7-18
- Dempster JM, Boyle I, Vazquez F, Root DE et al. Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects. *Genome Biol*. 2021;22(1):343.
- Diwanji TP, Engelman A, Snider JW, Mohindra P. Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. *Adolesc Health Med Ther*. 2017;8:99-113.
- Dono A, Ballester LY, Primdahl D, Esquenazi Y et al. IDH-Mutant Low-grade Glioma: Advances in Molecular Diagnosis, Management, and Future Directions. *Curr Oncol Rep*. 2021;23(2):20.
- Dono A, Takayasu T, Ballester LY, Esquenazi Y. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics. *J Clin Neurosci*. 2020;82(Pt A):1-8
- Dono A, Vu J, Anapolsky M, Hines G et al. Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses. *J Neurooncol*. 2020;149(3):463-472
- Dono A, Wang E, Lopez-Rivera V, Ramesh, A. V et al. Molecular characteristics and clinical features of multifocal glioblastoma. *J Neurooncol*. 2020;148(2):389-397.

- Drappatz J, Brenner A, Wong ET, Eichler A et al. Phase I study of GRN1005 in recurrent malignant glioma. *Clin Cancer Res.* 2013;19(6):1567-1576.
- Drost HG, Paszkowski J. Biomart: genomic data retrieval with R. *Bioinformatics.* 2017;33(8):1216-1217.
- Du M, Gu D, Xin J, Peters U et al. Integrated multi-omics approach to distinct molecular characterization and classification of early-onset colorectal cancer. *Cell Rep Med.* 2023;4(3):100974.
- Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. *N Engl J Med.* 2015;372(26):2499-2508.
- Ehrlich M, Lacey M. DNA hypomethylation and hemimethylation in cancer. *Adv Exp Med Biol.* 2013;754:31-56.
- Eichner J, Rosenbaum L, Wrzodek C, Häring HU, Zell A et al. Integrated enrichment analysis and pathway-centered visualization of metabolomics, proteomics, transcriptomics, and genomics data by using the InCroMAP software. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2014;966:77-82.
- Fan J, Slowikowski K, Zhang F. Single-cell transcriptomics in cancer: computational challenges and opportunities. *Exp Mol Med.* 2020;52(9):1452-1465.
- Farmanfarma KK, Mohammadian M, Shahabinia Z, Hassanipour S et al. Brain cancer in the world: an epidemiological review. *World Cancer Res. J,* 2019;6(5), 1-5.
- Ferreira Vega S, Olsson Bontell T, Corell A, Smits A et al. DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas. *Clin Epigenetics.* 2021;13(1):102
- Forst DA, Nahed BV, Loeffler JS, Batchelor TT. Low-grade gliomas. *Oncologist.* 2014;19(4):403-413.
- Fujimoto K, Arita H, Satomi K, et al. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. *Acta Neuropathol.* 2021;142(2):323-338.
- Ganipineni LP, Danhier F, Pr  at V. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment. *J Control Release.* 2018;281:42-57.
- Garc  a-Rodr  guez Mdel C, Hern  ndez-Cort  s LM, Altamirano-Lozano MA. In Vivo Effects of Vanadium Pentoxide and Antioxidants (Ascorbic Acid and

- Alpha-Tocopherol) on Apoptotic, Cytotoxic, and Genotoxic Damage in Peripheral Blood of Mice. *Oxid Med Cell Longev*. 2016;2016:6797851.
- Garima G, Thanvi S, Singh A, Verma V. Epidermal Growth Factor Receptor Variant III Mutation, an Emerging Molecular Marker in Glioblastoma Multiforme Patients: A Single Institution Study on the Indian Population. *Cureus*. 2022;14(6):e26412.
- Grant R. Medical management of adult glioma. *Management of adult glioma in nursing practice*, Springer 2019;61-80.
- Grech N, Dalli T, Mizzi S, Meilak L et al. Rising Incidence of Glioblastoma Multiforme in a Well-Defined Population. *Cureus*. 2020;12(5):e8195.
- Guo M, Peng Y, Gao A, Du C et al. Epigenetic heterogeneity in cancer. *Biomark Res*. 2019;7:23. Published 2019 Oct 31.
- Guo Q, Yin M, Fan J, Yang Y et al. Peroxidase-mimicking TA-VOx nanobranches for enhanced photothermal/chemodynamic therapy of glioma by inhibiting the expression of HSP60. *Materials & Design*, 2022;224, 111366.
- Guo X, Song Y, Liu S, Gao M et al. Linking genotype to phenotype in multi-omics data of small sample. *BMC Genomics*. 2021;22(1):537.
- Guo Y, Li Y, Li J, Tao W et al. DNA Methylation-Driven Genes for Developing Survival Nomogram for Low-Grade Glioma. *Front Oncol*. 2022;11:629521. Published 2022 Jan 17.
- Han X, Li R, Zhang W, Yang X et al. Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. *J Neurooncol*. 2014;118(1):61-72.
- Hanif F, Muzaffar K, Perveen K, Malhi SM et al. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. *Asian Pac J Cancer Prev*. 2017;18(1):3-9.
- Haque W, Teh C, Butler EB, Teh BS. Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma. *J Neurooncol*. 2022;157(1):137-146.
- Holmes B, Benavides-Serrato A, Saunders JT, Landon KA et al. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma. *J Neurooncol*. 2019;145(1):11-22.
- Hoogstrate Y, Ghisai SA, de Wit M, de Heer I et al. The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis. *Neuro Oncol*. 2022;24(3):429-441.

- Horvath S. DNA methylation age of human tissues and cell types [published correction appears in *Genome Biol.* 2015;16:96]. *Genome Biol.* 2013;14(10):R115.
- Hou MX, Gao YL, Liu JX, Shang J et al. A new method for mining information of co-expression network based on multi-cancers integrated data. *BMC Med Genomics.* 2019;12(Suppl 7):155.
- Howell AE, Zheng J, Haycock PC, McAleenan A et al. Use of Mendelian Randomization for Identifying Risk Factors for Brain Tumors. *Front Genet.* 2018;9:525
- Hu G, Wang R, Wei B, Wang L et al. Prognostic Markers Identification in Glioma by Gene Expression Profile Analysis. *J Comput Biol.* 2020;27(1):81-90.
- Huang S, Chaudhary K, Garmire LX. More Is Better: Recent Progress in Multi-Omics Data Integration Methods. *Front Genet.* 2017;8:84.
- Huber W, Carey VJ, Gentleman R, Anders S et al. Orchestrating high-throughput genomic analysis with Bioconductor. *Nat Methods.* 2015;12(2):115-121.
- Idbaih A, Canney M, Belin L, Desseaux C et al. Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma. *Clin Cancer Res.* 2019;25(13):3793-3801.
- Ishiuchi S, Yoshida Y, Sugawara K, Aihara M et al. Ca²⁺-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. *J Neurosci.* 2007;27(30):7987-8001.
- Iwamoto FM, Nicolardi L, Demopoulos A, Barbashina V et al. Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. *J Neurooncol.* 2008;88(3):293-298.
- Jacobs SS, Fox E, Dennie C, Morgan LB et al. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. *Clin Cancer Res.* 2005;11(4):1669-1674.
- Janjua TI, Rewatkar P, Ahmed-Cox A, Saeed I et al. Frontiers in the treatment of glioblastoma: Past, present and emerging. *Adv Drug Deliv Rev.* 2021;171:108-138.
- Jenkins RB, Blair H, Ballman KV, Giannini C et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better

- prognosis of patients with oligodendroglioma. *Cancer Res.* 2006;66(20):9852-9861.
- Jiang N, Dai Q, Su X, Fu J et al. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior. *Mol Biol Rep.* 2020;47(6):4587-4629.
- Kaley T, Touat M, Subbiah V, Hollebecque A et al. BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study. *J Clin Oncol.* 2018;36(35):3477-3484.
- Kan LK, Drummond K, Hunn M, Williams D et al. Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis. *BMJ Neurol Open.* 2020;2(2):e000069
- Karczewski KJ, Snyder MP. Integrative omics for health and disease. *Nat Rev Genet.* 2018;19(5):299-310.
- Khattab A, Monga DK. Turcot Syndrome. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; June 26, 2023.
- Kim SY, Jeong HH, Kim J, Moon JH et al. Robust pathway-based multi-omics data integration using directed random walks for survival prediction in multiple cancer studies. *Biol Direct.* 2019;14(1):8.
- Kinnersley B, Mitchell JS, Gousias K, Schramm J et al. Quantifying the heritability of glioma using genome-wide complex trait analysis. *Sci Rep.* 2015;5:17267.
- Koh CM, Bezzi M, Guccione E. The where and the how of PRMT5. *Curr Mol Bio Rep.* 2015;1, 19–28
- Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks. *Methods Mol Biol.* 2011;696:291-303.
- Kujas M, Lejeune J, Benouaich-Amiel A, Crinière E et al. Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. *Ann Neurol.* 2005;58(2):322-326.
- Labussière M, Idbaih A, Wang XW, Falet C et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. *Neurology.* 2010;74(23):1886-1890.
- Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. *BMC Bioinformatics.* 2008;9:559.
- Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol.* 2014;15(2):R29.

- Lehmann R, Rayner BS, Ziegler DS. Resistance mechanisms in BRAFV600E paediatric high-grade glioma and current therapeutic approaches. *Front Oncol.* 2022;12:1031378.
- Lescarbeau RS, Lei L, Bakken KK, Sims PA et al. Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma. *Mol Cancer Ther.* 2016;15(6):1332-1343.
- Leu S, von Felten S, Frank S, Boulay JL et al. IDH mutation is associated with higher risk of malignant transformation in low-grade glioma. *J Neurooncol* 2016;127, 363–372
- Li H, Hong G, Xu H, Guo Z. Application of the rank-based method to DNA methylation for cancer diagnosis. *Gene*, 2015;555(2), 203-207.
- Li Y, Ma L, Wu D, Chen G. Advances in bulk and single-cell multi-omics approaches for systems biology and precision medicine. *Brief Bioinform.* 2021;22(5):bbab024.
- Lim-Fat MJ, Youssef GC, Touat M, Iorgulescu JB et al. Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. *Neuro Oncol.* 2022;24(7):1140-1149.
- Lin D, Wang M, Chen Y, Gong J et al. Trends in Intracranial Glioma Incidence and Mortality in the United States, 1975-2018. *Front Oncol.* 2021;11:748061.
- Liu B, Liu Y, Pan X, Li M et al. DNA Methylation Markers for Pan-Cancer Prediction by Deep Learning. *Genes (Basel).* 2019;10(10):778.
- Liu HQ, Li WX, An YW, Wu T et al. Integrated analysis of the genomic and transcriptional profile of gliomas with isocitrate dehydrogenase-1 and tumor protein 53 mutations. *Int J Immunopathol Pharmacol.* 2022;36:3946320221139262.
- Liu R, Liu Z, Zhao Y, Cheng X et al. GNG12 as A Novel Molecular Marker for the Diagnosis and Treatment of Glioma. *Front Oncol.* 2022;12:726556.
- Louis DN, Perry A, Reifenberger G, von Deimling A et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol.* 2016;131(6):803-820.
- Lowder L, Hauenstein J, Woods A, Chen HR et al. Gliosarcoma: distinct molecular pathways and genomic alterations identified by DNA copy number/SNP microarray analysis. *J Neurooncol.* 2019;143(3):381-392.

- Lu J, Hu Y, Qian R, Zhang Y et al. Enhanced proliferation inhibition and apoptosis in glioma cells elicited by combination of irinotecan and imatinib. *Eur J Pharmacol.* 2020;874:173022.
- Lund RJ, Huhtinen K, Salmi J, Rantala J et al. DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer. *Sci Rep.* 2017;7(1):1469.
- Luo C, Zhao S, Dai W, Zheng N et al. Proteomic analyses reveal GNG12 regulates cell growth and casein synthesis by activating the Leu-mediated mTORC1 signaling pathway. *Biochim Biophys Acta Proteins Proteom.* 2018;1866(11):1092-1101.
- Maciejka A, Kopa P, Galita G, Pastwa E et al. Comparison of the effect of three different topoisomerase II inhibitors combined with cisplatin in human glioblastoma cells sensitized with double strand break repair inhibitors. *Mol Biol Rep.* 2019;46(4):3625-3636
- Maniatis S, Petrescu J, Phatnani H. Spatially resolved transcriptomics and its applications in cancer. *Curr Opin Genet Dev.* 2021;66:70-77.
- Marakulina D, Vorontsov IE, Kulakovskiy IV, Lennartsson A et al. EpiFactors 2022: expansion and enhancement of a curated database of human epigenetic factors and complexes. *Nucleic Acids Res.* 2023;51(D1):D564-D570.
- Marvi MV, Mongiorgi S, Ramazzotti G, Neri I et al. Phospholipase C b1 and Phospholipase C g1: key regulators of Glioblastoma aggressiveness and progression. *Italian Journal of Anatomy and Embryology,* 2022;126, 178-178.
- McKhann GM, Duffau H. Low-Grade Glioma: Epidemiology, Pathophysiology, Clinical Features, and Treatment. *Neurosurg Clin N Am.* 2019;30(1):xiii-xiv.
- McKinnon C, Nandhabalan M, Murray SA, Plaha P. Glioblastoma: clinical presentation, diagnosis, and management. *BMJ.* 2021;374:n1560
- Medvedeva YA, Lennartsson A, Ehsani R, Kulakovskiy IV et al. EpiFactors: a comprehensive database of human epigenetic factors and complexes. *Database (Oxford).* 2015;2015:bav067.
- Meyers RM, Bryan JG, McFarland JM, Weir BA et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. *Nat Genet.* 2017;49(12):1779-1784.
- Michlmayr D, Kim EY, Rahman AH, Raghunathan R et al. Comprehensive Immunoprofiling of Pediatric Zika Reveals Key Role for Monocytes in the

- Acute Phase and No Effect of Prior Dengue Virus Infection. *Cell Rep.* 2020;31(4):107569.
- Miguel Llordes G, Medina Pérez VM, Curto Simón B, Castells-Yus I et al. Epidemiology, Diagnostic Strategies, and Therapeutic Advances in Diffuse Midline Glioma. *J Clin Med.* 2023;12(16):5261.
- Mir SE, De Witt Hamer PC, Krawczyk PM, Balaj L et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. *Cancer Cell.* 2010;18(3):244-257.
- Misra BB, Langefeld CD, Olivier M, Cox LA. Integrated Omics: Tools, Advances, and Future Approaches. *J Mol Endocrinol.*
- Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma. *Nat Rev Neurol.* 2019;15(7):405-417.
- Mondesir J, Willekens C, Touat M, de Botton S. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. *J Blood Med.* 2016;7:171-180.
- Montiel-Flores E, Mejía-García OA, Ordoñez-Librado JL, Gutierrez-Valdez AL et al. Alzheimer-like cell death after vanadium pentoxide inhalation. *Heliyon.* 2021;7(8):e07856.
- Morishita R, Nakayama H, Isobe T, Matsuda T et al. Primary structure of a γ subunit of G protein, $\gamma 12$, and its phosphorylation by protein kinase C. *Journal of Biological Chemistry.* 1995;270(49), 29469-29475.
- Morris TJ, Butcher LM, Feber A, Teschendorff AE et al. ChAMP: 450k Chip Analysis Methylation Pipeline. *Bioinformatics.* 2014;30(3):428-430.
- Motomura K, Kibe Y, Ohka F, Aoki K et al. Clinical characteristics and radiological features of glioblastoma, IDH-wildtype, grade 4 with histologically lower-grade gliomas. *Brain Tumor Pathol.* 2023;40(2):48-55
- Mueller S, Cooney T, Yang X, Pal S et al. Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children's Oncology Group phase I consortium study. *Neurooncol Adv.* 2022;4(1):vdac073.
- Mueller S, Hashizume R, Yang X, Kolkowitz I et al. Targeting Wee1 for the treatment of pediatric high-grade gliomas. *Neuro Oncol.* 2014;16(3):352-360.
- Müller-Längle A, Lutz H, Hehlhans S, Rödel F et al. NMDA Receptor-Mediated Signaling Pathways Enhance Radiation Resistance, Survival and Migration in

- Glioblastoma Cells-A Potential Target for Adjuvant Radiotherapy. *Cancers (Basel)*. 2019;11(4):503.
- Music D, Dahlrot RH, Hermansen SK, Hjelmberg J et al. Expression and prognostic value of the WEE1 kinase in gliomas. *J Neurooncol*. 2016;127(2):381-389.
- Mutiarayani, D. Brain Tumor in Pediatrics: Pediatric Glioblastoma. *Green Medical Journal*, 2023;5(1), 1-10.
- Nguyen HM, Guz-Montgomery K, Lowe DB, Saha D. Pathogenetic Features and Current Management of Glioblastoma. *Cancers (Basel)*. 2021;13(4):856.
- Nice EC. Challenges for omics technologies in the implementation of personalized medicine. *Expert Review of Precision Medicine and Drug Development*, 2018;3(4), 229-231.
- Nicolaides T, Nazemi KJ, Crawford J, Kilburn L et al. Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). *Oncotarget*. 2020;11(21):1942-1952.
- Nicolle R, Raffenne J, Paradis V, Couvelard A et al. Prognostic Biomarkers in Pancreatic Cancer: Avoiding Errata When Using the TCGA Dataset. *Cancers (Basel)*. 2019;11(1):126.
- Niu X, Pan Q, Zhang Q, Wang X et al. Weighted correlation network analysis identifies multiple susceptibility loci for low-grade glioma. *Cancer Med*. 2023;12(5):6379-6387.
- Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. *Cancer Cell*. 2010;17(5):510-522.
- Oakes E, Anderson A, Cohen-Gadol A, Hundley HA. Adenosine deaminase that acts on RNA 3 (ADAR3) binding to glutamate receptor subunit B pre-mRNA inhibits RNA editing in glioblastoma. *Journal of Biological Chemistry*, 2017;292(10), 4326-4335.
- Ogawa K, Kurose A, Kamataki A, Asano K et al. Giant cell glioblastoma is a distinctive subtype of glioma characterized by vulnerability to DNA damage. *Brain Tumor Pathol*. 2020;37(1):5-13.
- Olympios N, Gilard V, Marguet F, Clatot F et al. TERT Promoter Alterations in Glioblastoma: A Systematic Review. *Cancers (Basel)*. 2021;13(5):1147.

- Ostrom QT, Adel Fahmideh M, Cote DJ, Muskens IS et al. Risk factors for childhood and adult primary brain tumors. *Neuro Oncol.* 2019;21(11):1357-1375.
- Ostrom QT, Cioffi G, Gittleman H, Patil N et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. *Neuro Oncol.* 2019;21(Suppl 5):v1-v100
- Ostrom QT, Price M, Neff C, Cioffi G et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. *Neuro Oncol.* 2022;24(Suppl 5):v1-v95.
- Ota M, Nagafuchi Y, Hatano H, Ishigaki K et al. Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases. *Cell.* 2021;184(11):3006-3021.e17.
- Paananen J, Fortino V. An omics perspective on drug target discovery platforms. *Brief Bioinform.* 2020;21(6):1937-1953.
- Palmer JD, Chavez G, Furnback W, Chuang PY et al. Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma. *Front Oncol.* 2021;11:772261.
- Palmieri A, Valentinis L, Zanchin G. Update on headache and brain tumors. *Cephalalgia.* 2021;41(4):431-437.
- Pang FM, Yan H, Mo JL, Li D et al. Integrative analyses identify a DNA damage repair gene signature for prognosis prediction in lower grade gliomas. *Future Oncol.* 2020;16(8):367-382
- Paolillo M, Boselli C, Schinelli S. Glioblastoma under Siege: An Overview of Current Therapeutic Strategies. *Brain Sci.* 2018;8(1):15.
- Parsons DW, Jones S, Zhang X, Leary RJ et al. An integrated genomic analysis of human glioblastoma multiforme. *Science.* 2008;321(5897):1807-1812.
- Patil V, Pal J, Mahalingam K, Somasundaram K. Global RNA editome landscape discovers reduced RNA editing in glioma: loss of editing of gamma-amino butyric acid receptor alpha subunit 3 (GABRA3) favors glioma migration and invasion. *PeerJ.* 2020;8:e9755.
- Piotrowski AF, Blakeley J. Clinical Management of Seizures in Patients With Low-Grade Glioma. *Semin Radiat Oncol.* 2015;25(3):219-224.
- Pokorny JL, Calligaris D, Gupta SK, Iyekegbe DO et al. The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by

- Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. Clin Cancer Res. 2015;21(8):1916-1924.
- Pollack BP, Kotenko SV, He W, Izotova LS et al. The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity. Journal of Biological Chemistry, 1999;274(44), 31531-31542.
- Powter B, Jeffreys SA, Sareen H, Cooper A et al. Human TERT promoter mutations as a prognostic biomarker in glioma. J Cancer Res Clin Oncol. 2021;147(4):1007-1017.
- Rajan RG, Fernandez-Vega V, Sperry J, Nakashima J et al. In Vitro and In Vivo Drug-Response Profiling Using Patient-Derived High-Grade Glioma. Cancers (Basel). 2023;15(13):3289
- Ramaswamy P, Aditi Devi N, Hurmath Fathima K, Dalavaikodihalli Nanjaiah N. Activation of NMDA receptor of glutamate influences MMP-2 activity and proliferation of glioma cells. Neurol Sci. 2014;35(6):823-829.
- Ramsey SA, Knijnenburg TA, Kennedy KA, Zak DE et al. Genome-wide histone acetylation data improve prediction of mammalian transcription factor binding sites. Bioinformatics. 2010;26(17):2071-2075.
- Rappoport N, Shamir R. Multi-omic and multi-view clustering algorithms: review and cancer benchmark [published correction appears in Nucleic Acids Res. 2019 Jan 25;47(2):1044]. Nucleic Acids Res. 2018;46(20):10546-10562.
- Rappoport N, Shamir R. NEMO: cancer subtyping by integration of partial multi-omic data. Bioinformatics. 2019;35(18):3348-3356.
- Rashidi R, Hadjighassem M, Negahdari B. Comparison of 3D and 2D cultures for evaluating the effect of combination therapy with Erlotinib and Imatinib on Glioblastoma multiforme. Research Square; 2023.
- Ritchie ME, Phipson B, Wu D, Hu Y et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
- Rocca V, Blandino G, D'Antona L, Iuliano R et al. Li-Fraumeni Syndrome: Mutation of TP53 Is a Biomarker of Hereditary Predisposition to Tumor: New Insights and Advances in the Treatment. Cancers (Basel). 2022;14(15):3664.
- Romano R, Bucci C. Role of EGFR in the Nervous System. Cells. 2020;9(8):1887. Published 2020 Aug 12.

- Ruhban IA, Khoudeir MW, Saad AM, Al-Husseini MJ et al. Racial disparities in incidence and mortality trends of glioblastoma; a population-based study. *Annals of Oncology*. 2019;30, vi133-vi134.
- Sachamitr P, Ho JC, Ciamponi FE, Ba-Alawi W et al. PRMT5 inhibition disrupts splicing and stemness in glioblastoma. *Nat Commun*. 2021;12(1):979.
- Samudra N, Zacharias T, Plitt A, Lega B et al. Seizures in glioma patients: An overview of incidence, etiology, and therapies. *J Neurol Sci*. 2019;404:80-85.
- Sanders S, Debinski W. Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma. *Int J Mol Sci*. 2020;21(8):2759.
- Schaff LR, Mellinghoff IK. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. *JAMA*. 2023;329(7):574-587.
- Sharma A, Graber JJ. Overview of prognostic factors in adult gliomas. *Ann Palliat Med*. 2021;10(1):863-874.
- Shen B, Feng F, Li K, Lin P et al. A systematic assessment of deep learning methods for drug response prediction: from in vitro to clinical applications. *Brief Bioinform*. 2023;24(1):bbac605.
- Shergalis A, Bankhead A 3rd, Luesakul U, Muangsin N et al. Current Challenges and Opportunities in Treating Glioblastoma. *Pharmacol Rev*. 2018;70(3):412-445.
- Sherman BT, Hao M, Qiu J, Jiao X et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). *Nucleic Acids Res*. 2022;50(W1):W216-W221.
- Shingu T, Fujiwara K, Böglér O, Akiyama Y et al. Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells. *Int J Cancer*. 2009;124(5):1060-1071.
- Sienkiewicz K, Chen J, Chatrath A, Lawson JT et al. Detecting molecular subtypes from multi-omics datasets using SUMO. *Cell Rep Methods*. 2022;2(1):100152.
- Singhania A, Verma R, Graham CM, Lee J et al. A modular transcriptional signature identifies phenotypic heterogeneity of human tuberculosis infection. *Nat Commun*. 2018 Jun 19;9(1):2308.
- Sithanandam G, Kolch W, Duh FM, Rapp UR. Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. *Oncogene*. 1990;5(12):1775-1780.

- Song Z, Huang Y, Zhao Y, Ruan H et al. The Identification of Potential Biomarkers and Biological Pathways in Prostate Cancer. *J Cancer*. 2019;10(6):1398-1408.
- SongTao Q, Lei Y, Si G, YanQing D et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. *Cancer Sci*. 2012;103(2):269-273.
- Stichel D, Ebrahimi A, Reuss D, Schrimpf D et al. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. *Acta Neuropathol*. 2018;136(5):793-803.
- Subramanian I, Verma S, Kumar S, Jere A et al. Multi-omics Data Integration, Interpretation, and Its Application. *Bioinform Biol Insights*. 2020;14:1177932219899051.
- Supplitt S, Karpinski P, Sasiadek M, Laczmanska I. Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine. *Int J Mol Sci*. 2021;22(3):1422.
- Szkarczyk D, Franceschini A, Wyder S, Forslund K et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. *Nucleic Acids Res*. 2015;43(Database issue):D447-D452.
- Tabor JK, O'Brien J, Vasandani S, Vetsa S et al. Clinical and genomic differences in supratentorial versus infratentorial NF2 mutant meningiomas. *J Neurosurg*. 2023;139(6):1648-1656.
- Takayama N, Sato N, O'Brien SG, Ikeda Y et al. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. *Br J Haematol*. 2002;119(1):106-108.
- Tan Z, Chen K, Wu W, Zhou Y et al. Overexpression of HOXC10 promotes angiogenesis in human glioma via interaction with PRMT5 and upregulation of VEGFA expression. *Theranostics*. 2018;8(18):5143-5158.
- Teschendorff AE, Marabita F, Lechner M, Bartlett T et al. A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. *Bioinformatics*. 2013;29(2):189-196.

- Tews B, Felsberg J, Hartmann C, Kunitz A et al. Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. *Int. J. Cancer* 2006;119:792–800. 10.1002/ijc.21901.
- Timmons JA, Szkop KJ, Gallagher IJ. Multiple sources of bias confound functional enrichment analysis of global -omics data. *Genome Biol.* 2015;16(1):186.
- Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. *Contemp Oncol (Pozn).* 2015;19(1A):A68-A77.
- Tseng G, Ghosh D, Zhou XJ. Integrating omics data. Cambridge University Press, 2015
- Tu Z, Li J, Long X, Wu L et al. Transcriptional Patterns of Lower-Grade Glioma Patients with Distinct Ferroptosis Levels, Immunotherapy Response, and Temozolomide Sensitivity. *Oxid Med Cell Longev.* 2022;2022:9408886.
- Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. *J Clin Neurosci.* 2018;54:7-13.
- Unruh D, Zewde M, Buss A, Drumm MR et al. Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers. *Sci Rep.* 2019;9(1):8946.
- Urbańska K, Sokołowska J, Szmidt M, Sysa P. Glioblastoma multiforme - an overview. *Contemp Oncol (Pozn).* 2014;18(5):307-312.
- Usta D, Sigaud R, Buhl JL, Selt F et al. A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells. *Mol Cancer Ther.* 2020;19(8):1736-1750.
- Vakili-Samiani S, Khanghah OJ, Gholipour E, Najafi F et al. Cell cycle involvement in cancer therapy; WEE1 kinase, a potential target as therapeutic strategy. *Mutat Res.* 2022;824:111776.
- Valdes-Mora F, Handler K, Law AMK, Salomon R et al. Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology. *Front Immunol.* 2018;9:2582.
- van Vuurden DG, Yazdani M, Bosma I, Broekhuizen AJ et al. Attenuated AMPA receptor expression allows glioblastoma cell survival in glutamate-rich environment. *PLoS One*, 2009;4(6), e5953.

- Varghese AM, Arora A, Capanu M, Camacho N et al. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. *Ann Oncol.* 2017;28(12):3015-3021.
- Vuong HG, Tran TTK, Ngo HTT, Pham TQ et al. Prognostic significance of genetic biomarkers in isocitrate dehydrogenase-wild-type lower-grade glioma: the need to further stratify this tumor entity—a meta-analysis. *European Journal of Neurology*, 2019;26(3), 379-387.
- Walsh KM, Anderson E, Hansen HM, Decker PA et al. Analysis of 60 reported glioma risk SNPs replicates published GWAS findings but fails to replicate associations from published candidate-gene studies. *Genet Epidemiol.* 2013;37(2):222-228.
- Walsh KM, Rice T, Decker PA, Kosel ML et al. Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. *Neuro-oncology*, 2013;15(8), 1041-1047.
- Wang H, Bender A, Wang P, Karakose E et al. Insights into beta cell regeneration for diabetes via integration of molecular landscapes in human insulinomas. *Nat Commun.* 2017;8(1):767.
- Wang Z, He E, Sani K, Jagodnik KM et al. Drug Gene Budger (DGB): an application for ranking drugs to modulate a specific gene based on transcriptomic signatures. *Bioinformatics.* 2019;35(7):1247-1248.
- Wang Z, Jensen MA, Zenklusen JC. A Practical Guide to The Cancer Genome Atlas (TCGA). *Methods Mol Biol.* 2016;1418:111-141.
- Wang Z, Monteiro CD, Jagodnik KM, Fernandez NF et al. Extraction and analysis of signatures from the Gene Expression Omnibus by the crowd. *Nat Commun.* 2016;7:12846.
- Warrens AN, Birch R, Collett D, Daraktchiev M et al. Advising potential recipients on the use of organs from donors with primary central nervous system tumors. *Transplantation.* 2012;93(4):348-353.
- Wen PY, Cloughesy TF, Olivero AG, Morrissey KM et al. First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma. *Clin Cancer Res.* 2020;26(8):1820-1828.

- Wenger A, Karlsson I, Kling T, Carén H. CRISPR-Cas9 knockout screen identifies novel treatment targets in childhood high-grade glioma. *Clin Epigenetics*. 2023;15(1):80.
- Whitfield BT, Huse JT. Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update. *Brain Pathol*. 2022;32(4):e13062.
- Wickham H, François R, Henry L, Müller K et al. Package ‘dplyr’. A Grammar of Data Manipulation. R package version, 8, 2019.
<https://github.com/tidyverse/dplyr>
- Wirsching HG, Weller M. Does Neuronal Activity Promote Glioma Progression?. *Trends Cancer*. 2020;6(1):1-3.
- Wrensch M, Wiencke J, Molinaro A, Taylor J. Genetic and molecular epidemiology of adult diffuse glioma. *Nature Reviews Neurology*, 2019;15(7).
- Wu C, Zhou F, Ren J, Li X et al. A Selective Review of Multi-Level Omics Data Integration Using Variable Selection. *High Throughput*. 2019;8(1):4.
- Wu W, Klockow JL, Zhang M, Lafortune F et al. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. *Pharmacol Res*. 2021;171:105780.
- Wu YL, Maachani UB, Schweitzer M, Singh R et al. Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells. *Transl Oncol*. 2017;10(2):221-228.
- Xiong L, Wang F, Qi Xie X. Advanced treatment in high-grade gliomas. *J BUON*. 2019;24(2):424-430.
- Xiong Y, Zhang Y, Xiong S, Williams-Villalobo AE. A Glance of p53 Functions in Brain Development, Neural Stem Cells, and Brain Cancer. *Biology (Basel)*. 2020;9(9):285.
- Yan F, Alinari L, Lustberg ME, Martin LK et al. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. *Cancer Res*. 2014;74(6):1752-1765.
- Yang K, Wu Z, Zhang H, Zhang N et al. Glioma targeted therapy: insight into future of molecular approaches. *Mol Cancer*. 2022;21(1):39.
- Yang Q, Wang R, Wei B, Peng C et al. Candidate Biomarkers and Molecular Mechanism Investigation for Glioblastoma Multiforme Utilizing WGCNA. *Biomed Res Int*. 2018;2018:4246703.

- Yang R, Wang M, Zhang G, Bao Y et al. E2F7-EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression. *Br J Cancer*. 2020;123(9):1445-1455.
- Yang X, Gao L, Zhang S. Comparative pan-cancer DNA methylation analysis reveals cancer common and specific patterns. *Brief Bioinform*. 2017;18(5):761-773.
- Yao Y, Dai W. Genomic Instability and Cancer. *J Carcinog Mutagen*. 2014;5:1000165.
- Yi M, Li T, Qin S, Yu S et al. Identifying Tumorigenesis and Prognosis-Related Genes of Lung Adenocarcinoma: Based on Weighted Gene Coexpression Network Analysis. *Biomed Res Int*. 2020;2020:4169691.
- Yu L, Qi ST, Li ZY. Analysis of isocitrate dehydrogenase-1/2 gene mutations in gliomas. *Chin Med J (Engl)*. 2010;123(24):3697-3705.
- Zeng F, Liu X, Wang K, Zhao Z et al. Transcriptomic Profiling Identifies a DNA Repair-Related Signature as a Novel Prognostic Marker in Lower Grade Gliomas. *Cancer Epidemiol Biomarkers Prev*. 2019;28(12):2079-2086
- Zhai K, Mazurakova A, Koklesova L, Kubatka P et al. Flavonoids Synergistically Enhance the Anti-Glioblastoma Effects of Chemotherapeutic Drugs. *Biomolecules*. 2021;11(12):1841.
- Zhang C, Nance EA, Mastorakos P, Chisholm J et al. Convection enhanced delivery of cisplatin-loaded brain penetrating nanoparticles cures malignant glioma in rats. *J Control Release*. 2017;263:112-119.
- Zhang D, Zhao J, Han C, Liu X et al. Identification of hub genes related to prognosis in glioma. *Biosci Rep*. 2020;40(5):BSR20193377.
- Zhang P, Meng X, Liu L, Li S et al. Identification of the Prognostic Signatures of Glioma With Different PTEN Status. *Front Oncol*. 2021;11:633357.
- Zhang Y, Wang K, Zhao Z, Sun S et al. ADAR3 expression is an independent prognostic factor in lower-grade diffuse gliomas and positively correlated with the editing level of GRIA2Q607R. *Cancer Cell Int*. 2018;18:196.
- Zhao M, Li X, Chen Y, Wang S. MD2 Is a Potential Biomarker Associated with Immune Cell Infiltration in Gliomas. *Front Oncol*. 2022;12:854598.
- Zhu J, Kong W, Huang L, Bi S et al. Identification of immunotherapy and chemotherapy-related molecular subtypes in colon cancer by integrated multi-omics data analysis. *Front Immunol*. 2023;14:1142609.

- Zhu M, Bian Y, Jiang J, Lei T et al. Rapid screening for safety of donation from donors with central nervous system malignancies. *Medicine (Baltimore)*. 2020;99(49):e22808.
- Zhuge Y, Ning H, Mathen P, Cheng JY et al. Automated glioma grading on conventional MRI images using deep convolutional neural networks [published correction appears in *Med Phys*. 2023 Sep;50(9):5930-5931]. *Med Phys*. 2020;47(7):3044-3053.
- Zwolak I. Vanadium carcinogenic, immunotoxic and neurotoxic effects: a review of in vitro studies. *Toxicol Mech Methods*. 2014;24(1):1-12.



FAD ME ÖZTOPRAK

Kişisel Bilgiler

İletişim Bilgileri

İletişim Adresi

Izmir Biomedicine and Genome CenterNeuro-Genomics GroupDokuz Eylül(

Telefon

https://ww

E-posta

İnternet Sayfası

29 Eylül 2016 - Şu Anda (7 y 13 ay)

Doktora, Doktora, DOKUZ EYLÜL ÜNİVERSİTESİ, TÜRKİYE

ZMİR ULUSLARARASI BİYOTİP VE GENOM ENSTİTÜSÜ, MOLEKÜLER BİYOLOJİ VE GENETİK (DR) (NG L ZCE)

Diploma Numarası : -

Ağırlıklı Genel Not Ortalaması : 3.35 / 4.0

Öğrenim Bilgileri

07 Ağustos 2009 - 08 Eylül 2015 (6 y 12 ay)

Yüksek Lisans, Tezli Program, ERC YERLİ ÜNİVERSİTESİ, TÜRKİYE

FEN BİLİMLERİ ENSTİTÜSÜ, BİYOLOJİ (YL) (TEZLİ)

Diploma Numarası : 2881

Ağırlıklı Genel Not Ortalaması : 3.06 / 4.0

10 Eylül 2004 - 27 Haziran 2008 (3 y 10 ay)

Lisans, Anadal/Normal Öğretim, ERC YERLİ ÜNİVERSİTESİ, TÜRKİYE

FEN-EDEBİYAT FAKÜLTESİ, BİYOLOJİ PR.

Diploma Numarası : 4151

Ağırlıklı Genel Not Ortalaması : 2.44 / 4.0

NG L ZCE (Okuma: iyi, Yazma: iyi, Konuşma: iyi)

Yabancı Dil Bilgileri

Bilimsel Teknolojik Faaliyet Alanları

Bilimsel Teknolojik Faaliyet Alanı Bilgileri

Temel Bilimler -- Yaşam Bilimleri -- Moleküler Biyoloji ve Genetik -- Genomik

Temel Bilimler -- Yaşam Bilimleri -- Biyoinformatik -- Biyoenformasyon

Anahtar Kelimeler

Glioma

Biyoinformatik

Sistem Biyolojisi

Gen Tedavisi

Ar-Ge Yetkinlik

Makaleler

F. ÖZTOPRAK, Z. IŞIK & Y. OKTAY, Comparative Transcriptome Analysis Identifies Target Genes for Treatment of IDH Wild-type Lower-grade Gliomas , J Tepecik Educ Res Hosp, 2023, 2822-4051, 33, 1, 100 - 119.

F. ÖZTOPRAK & A. JAVED, Case Fatality Rate estimation of COVID-19 for European Countries : Turkey's Current Scenario Amidst a Global Pandemic; Comparison of Outbreaks with European Countries, Eurasian Journal of Medicine and Oncology, 2020, 2587-2400/2587-196X, 4, 2, 149 - 159.

Bildiriler

F. ÖZTOPRAK, Z. IŞIK, E. PETSALAK & Y. OKTAY, Identifying Novel Targets for Therapies in Glioma Using Multi-omics Data, Poster Sunumu, 5th course on Computational Systems Biology of Cancer: Multimodal data integration, 26 Eylül 2022, 30 Eylül 2022.

B. EK NC , T. YARAŞ, F. ÖZTOPRAK & Y. OKTAY, Gliomlara Genetik Yatknlın Moleküler Temellerinin Hücre Modellerinde Genomik ve Transkriptomik Analizi, Sözlü Sunum, Onkolojide z B rakanlar Zirvesi, 14 Kas m 2019, 17 Kas m 2019.

F. ÖZTOPRAK, Z. IŞIK, G. KARAKÜLAH & Y. OKTAY, Moleküler ve Klinik Olarak Farklı Gliom Alt Tipleri Arasndaki Transkriptomik Benzerlikler, Sözlü Sunum, Onkolojide z B rakanlar Zirvesi, 14 Kas m 2019, 17 Kas m 2019.

F. ÖZTOPRAK, Z. IŞIK & Y. OKTAY, Developing Combinatorial Therapies Towards Gliomas by Network-Based Analysis of Whole Transcriptome Data, Sözlü Sunum, 7th International Congress of the Molecular Biology Association of Turkey (MolBiyKon19), 27 Eylül 2019, 29 Eylül 2019.

F. ÖZTOPRAK, K. OKAY, Z. IŞIK & Y. OKTAY, Understanding lower-grade glioma progression by integrative analysis of glioblastoma recurrence, Sözlü Sunum, International Symposium on Health Informatics and Bioinformatics (HIBIT2018), 25 Ekim 2018, 27 Ekim 2018.

B. EK NC , T. YARAŞ, F. ÖZTOPRAK, Z. IŞIK, A. SUNER KARAKÜLAH, M. N. PAM R, K. ÖZDUMAN & Y. OKTAY, An integrated functional genomics approach to understand the earliest stages of glioma development, Poster Sunumu, EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models, 15 Nisan 2018, 17 Nisan 2018.

TÜB TAK Burs ve Destekleri

Proje Bilgileri

20AG006, Hedefe Özgü Pan-Kanser Terapiler (PAN-TER), Burslu, Yürürlükte, KAMAG - Kamu Araşt r malar Destek Grubu, 1004 - Mükemmeliyet Merkezi Destek Program , ARDEB, Projeye Kat lma/Ayr lma Tarihleri: 01.01.2023 - 31.03.2023, Proje Başlang ç/Bitiş Tarihleri: 15.10.2021 - 15.10.2025.
216S771, Türkiye'de Akraba Evliliklerine Bağlı Nörogenetik Hastal k Yükünün Araşt r lmas nda Yeni Genomik Yaklaş mlar, Burslu, Sonuçland , SBAG - Sağ l k Bilimleri Araşt rma Destek Grubu, Uluslararası / RCUK, ARDEB, Projeye Kat lma/Ayr lma Tarihleri: 28.03.2017 - 06.09.2017, Proje Başlang ç/Bitiş Tarihleri: 01.12.2016 - 01.02.2020.

B DEB Destekleri

FAD ME ÖZTOPRAK, Araşt rma Burs ve Destekleri Müdürlüğü, 2214-A Yurt D ş Araşt rma Burs Program (Doktora öğrencileri için), Bursiyer Seçildi, Bursu

Başlamad , 2020 - 2, 01.04.2021 - 30.09.2021.

FAD ME ÖZTOPRAK, Etkinlik Destekleri ve Eğitim Burslar Müdürlüğü, 2211-C
Öncelikli Alanlara Yönelik Yurt içi Doktora Burs Program , Bursu Kesildi, 2020 - 1,
01.03.2020 - 30.09.2022.

Panelistlik/ zleyicilik/Raportörlük Say s

Hakemlik/Panelistlik/D ş Dan şmanl k Say s	ARDEB/B DEB 0	TEYDEB 0	Toplam 0
zleyicilik/Dan şmanl k Say s	ARDEB/B DEB 0	TEYDEB 0	Toplam 0
Raportörlük Say s	ARDEB/B DEB 0	TEYDEB 0	Toplam 0





Comparative Transcriptome Analysis Identifies Target Genes for Treatment of IDH Wild-type Lower-grade Gliomas

Karşılaştırmalı Transkriptom Analizi ile Tanımlanan IDH Yabanıl-tip Düşük-gradeli Gliomların Tedavisine Yönelik Hedef Genler

✉ Fadime Öztoprak¹, ✉ Zerrin Işık², ✉ Yavuz Oktay^{3,4}

¹Dokuz Eylül University, İzmir International Biomedicine and Genome Institute, İzmir, Turkey

²Dokuz Eylül University Faculty of Engineering, Computer Engineering Department, İzmir, Turkey

³İzmir Biomedicine and Genome Center, İzmir, Turkey

⁴Dokuz Eylül University Faculty of Medicine, Department of Medical Biology, İzmir, Turkey

Cite as: Öztoprak F, Işık Z, Oktay Y. Comparative Transcriptome Analysis Identifies Target Genes for Treatment of IDH Wild-type Lower-grade Gliomas. J Tepecik Educ Res Hosp 2023;33(1):100-19

Abstract

Objective: *Isocitrate dehydrogenase 1/2 (IDH 1/2)* mutations define a group of low-grade gliomas (LGGs) that display more favorable prognosis compared with LGGs without them. Although IDH wild-type (IDHwt) LGGs are classified as low-grade, they almost invariably progress to higher grades and rarely respond to aggressive treatment regimes. Here, we employed a comparative transcriptomic approach to identify key genes that could significantly contribute to the aggressive progression of IDHwt LGGs.

Methods: Using The Cancer Genome Atlas LGG cohort data and weighted gene coexpression network analysis methodology, we identified modules that correlated significantly with clinical features. We focused on modules that correlated with *telomerase reverse transcriptase (TERT)* promoter mutation status, as *TERT* promoter mutations are shared between glioblastomas and oligodendrogliomas, however, with two opposite prognostic outcomes. We selected module pathways shared between IDH mutant (IDHmt) and IDHwt LGGs and identified genes that were differentially expressed between the two groups.

Results: Several synaptic proteins are down-regulated in IDHwt compared with IDHmt, while *GNG12* and *VIPR2* are up-regulated. Finally, we identified known drugs that could target many of those genes and therefore could be tested against IDHwt LGGs.

Conclusion: Targeting of multiple candidate genes identified in this study could provide novel approaches toward the treatment of IDHwt LGGs.

Keywords: Low-grade gliomas, IDH 1, differential gene expression analysis, weighted gene co-expression network analysis, therapeutic target

Öz

Amaç: *İzositrat dehidrogenaz 1/2 (IDH 1/2)* mutasyonları, düşük-gradeli gliomların (LGG) daha iyi prognoza sahip bir alt grubunu tanımlar. IDH yabanıl-tip (IDHwt) LGG'ler düşük dereceli olarak sınıflandırılmalarına rağmen, neredeyse her zaman daha yüksek derecelere doğru ilerler ve agresif tedavi rejimlerine nadiren yanıt verirler. Burada, IDHwt LGG'lerin agresif ilerlemesine önemli ölçüde katkıda bulunan anahtar genleri belirlemek için karşılaştırmalı bir transkriptomik yaklaşım kullandık.



Address for Correspondence/Yazışma Adresi: Yavuz Oktay MD, İzmir Biomedicine and Genome Center, İzmir, Turkey. Dokuz Eylül University Faculty of Medicine, Department of Medical Biology, İzmir, Turkey
Phone: +90 232 299 41 00 E-mail: yavuz.oktay@deu.edu.tr
ORCID ID: orcid.org/0000-0002-0158-2693

Received/Geliş tarihi: 08.12.2022
Accepted/Kabul tarihi: 22.01.2023

Öz

Yöntem: Kanser Genom Atlası LGG kohort verilerini ve ağırlıklı gen ortak ifade ağı analizi metodolojisini kullanarak, klinik özelliklerle önemli ölçüde ilişkili olan modüller belirledik. *Telomeraz ters transkriptaz (TERT)* promotör mutasyon durumu ile ilişkili modüllere odaklandık, çünkü *TERT* promotör mutasyonları glioblastomlar ve oligodendrogliomlar arasında paylaşılsa da, bu iki gliom alttipi zıt prognostik özelliklere sahiptir. IDH mutan (IDHmt) ve IDHwt LGG'ler arasında paylaşılan modül yollarını seçtik ve iki grup arasında diferansiyel olarak eksprese edilen genleri belirledik.

Bulgular: Çok sayıda sinaptik protein, IDHwt'de IDHmt'ye kıyasla aşağı regüle edilirken, *GNG12* ve *VIPR2* yukarı regüle edilmektedir. Son aşamada ise, bu genlerin birçoğunu hedef alabilecek ve dolayısıyla IDHwt LGG'lere karşı test edilebilecek bilinen ilaçları belirledik.

Sonuç: Bu çalışmada tanımlanan çoklu aday genlerin hedeflenmesi, IDHwt LGG'lerin tedavisine yönelik yeni yaklaşımlar sağlayabilir.

Anahtar Kelimeler: Düşük-dereceli gliomlar, IDH 1, diferansiyel gen ekspresyon analizi, ağırlıklı gen ortak ekspresyon ağı analizi, terapötik hedef

Introduction

Gliomas represent almost 80% of the primary brain tumors in adults. It constitutes a very heterogeneous group of neoplasms that differs in the context of age at diagnosis, location of the tumor, histological subtype, tumor invasiveness and malignancy, aptness to progression, and response to therapies. Gliomas have traditionally been divided into four grades and two groups: Grade I-II as low-grade gliomas, and grade III-IV as high-grade gliomas⁽¹⁾. Grade IV gliomas glioblastomas (GBM) in particular, are the most common and aggressive form of glioma.

The advances in molecular biology and next-generation sequencing (NGS) lead to the identification of key molecular alteration gliomas. Co-deletion of chromosome arms 1p and 19q (1p/19q codeletion) was the first alteration that was identified in the 1990s⁽²⁾. It leads to oligodendroglial gliomas, is a prognostic factor, and a strong determinant of sensitivity to chemotherapy⁽³⁻⁵⁾. Mutations in isocitrate dehydrogenase (*IDH1/IDH2*) genes are diagnostic and prognostic markers that were identified for the first time in GBM^(6,7), and later observed in myeloid malignancies⁽⁸⁾, cholangiocarcinoma⁽⁹⁾, and melanoma⁽¹⁰⁾ among others^(11,12). They are observed in >70% of grade II-III gliomas [from now on referred to as lower-grade gliomas (LGGs)] and associated with alterations in epigenetic marks genome-wide and with altered cellular metabolism. The third one was two activating mutations in the *telomerase reverse transcriptase (TERT)* promoter (pTERT)⁽¹³⁾. pTERT mutations are observed in primary GBM, as well as in oligodendrogliomas, and they play an important role in tumorigenesis by helping tumor cells evade replicative crisis⁽¹⁴⁾. Until 2016, central nervous system (CNS) tumors were traditionally classified based mostly on the histological features. With better characterization of the molecular alterations thanks to advances in NGS, a new classification system was adopted, which takes into account both histological and molecular features such as IDH mutation

status and 1p/19q codeletion status⁽¹⁵⁾. These alterations are not only important by using a tumor classification but are also important markers of patient survival and response to therapy. Eckel-Passow et al.⁽¹⁶⁾ showed that in LGGs, the patients with only a TERT promoter mutation (considering 1p/19q-codeletion, IDH mutation, pTERT mutation) showed the poorest survival. Patients with IDH and pTERT mutations, indicating oligodendroglial histology, have the best survival. The Cancer Genome Atlas (TCGA) Research Network⁽¹⁷⁾ has created a comprehensive catalog of cancer data at multi-omics level. TCGA has helped researchers study different tumor types at a deeper level, supporting the discovery of new biomarkers and helping further understanding of the mechanisms related to tumor formation, metastasis, subclassification of cancer types, therapy resistance or sensitivity, thus contributing to the diagnosis and treatment of cancer. Verhaak et al.⁽¹⁸⁾ described a gene-expression-based system toward the molecular classification of GBMs and integrated multi-dimensional genomic data to establish patterns of somatic mutations and DNA copy number. Yang et al.⁽¹⁹⁾ used a weighted gene coexpression network analysis (WGCNA) approach on glioblastoma data to explain the underlying molecular mechanisms and identify candidate biomarkers. The researchers proposed *CPNE6*, *HAPLN2*, *CMTM3*, *NMI*, *CAPG*, and *PSMB8* as liquid biopsy markers, and *NUSAP1* and *GPR65* as potential prognostic targets for gene therapy. Xu⁽²⁰⁾ identified differentially expressed genes (DEGs) between LGG and glioblastoma and proposed potential biomarkers and therapeutic targets for gliomas. Despite intense efforts over the past few decades, only minor improvements for treating diffuse gliomas have been made, and no complete cure of patients is still possible. However, it became clear that IDH mutant (IDHmt) gliomas, particularly those with 1p19q codeletion, have much better survival rates and responses to therapy. On the contrast, GBM are highly resistant to therapeutic approaches. The extensive heterogeneous (intra- and inter-tumoral) nature of GBM and

their highly invasive and infiltrative characteristics are the main challenges standing in the way of progress in treating GBM. While IDH wild-type (IDHwt) LGGs are not high grade, their survival is dismal, more similar to GBM than they are to IDHmt LGGs. Here, we performed a comparative analysis of transcriptomic data from LGG IDHmt and LGG IDHwt cohorts of TCGA to identify similarities and differences from a co-expression perspective. We detected gene modules that are likely to express simultaneously under different IDH mutation status. We observed correlations between these modules and the selected clinical features. Next, we determined which biological features are involved in clinically important modules by performing enrichment analysis of module genes using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Comparison of pathway -enriched genes with differentially expressed ones led to a list of candidate genes that were mapped to pathways shared between IDHmt and IDHwt, albeit differently between the two groups. Finally, we screened gene-drug interaction databases to identify drugs and/or small molecules that could alter the expression levels of these candidate genes and hence could be particularly effective against IDHwt LGGs.

Materials and Methods

Data Collection and Preprocessing

Collection and preprocessing of transcriptomic data is performed using the TCGA Biolinks⁽²¹⁾ package, which is created for integrative analysis with the GDC data. The relevant samples were searched and downloaded by

“GDCquery” and “GDCdownload” functions respectively. The samples were prepared by “GDCprepare” function, and relevant clinical data were extracted from the Large Ranged Summarized Experiment Object. Gene expression data (RNA-sequencing) of lower-grade glioma patients were divided into sub-groups according to IDH mutation status (mt: mutated; wt: wild type) (Figure 1). The outlier samples were detected using the average method and manually excluded (Supplementary Figure 1). Finally, we have created two different expression matrices and two different data frames of clinical and molecular characteristics of patients. RNA-sequencing read counts do not show a normal distribution, so count data can be modeled with a poisson or negative binomial distribution⁽²²⁾. Here, we followed the negative binomial distribution and normalized RNA-sequence data with the voom methodology⁽²³⁾. The genes were filtered with the quantile method by setting the threshold value to 0.25. Before starting the analysis, the gene quality was checked.

Construction of the Weighted Gene Co-expression Network

We have constructed scale-free undirected co-expression networks using the WGCNA package in R⁽²⁴⁾. We have used the “pickSoftThreshold” function to determine the soft threshold power beta based on the scale-free topology criterion. For WGCNA, the suggested β value is lowest showing $R^2 > 0.80$ ⁽²⁵⁾. According to the suggested selection criteria, we have picked beta values as “6” for the TCGA IDHmt cohort and “12” for the TCGA IDHwt cohort (Supplementary Figure 2). Gene modules were constructed with a correlation network methodology (module size: 30, merge cut height: 0.25).




Figure 1. Module construction and clinically significant module detection by WGCNA.

WGCNA: Weighted gene co-expression network analysis, TCGA: The Cancer Genome Atlas, LGG: Lower-grade glioma, IDH: Isocitrate dehydrogenase

Identification of Clinically Significant Modules

After the module construction the relationship between module genes and external clinical traits has been observed using eigengene network methodology. Eigengene is the summary profile of the module. Basically, eigengenes were correlated with external traits (features) for the most significant associations. Originally, there were 110 features in the TCGA clinical data frame, but we have created a sub-data frame of 8 features according to the aim of this study. The features selected for this study are: Chr7gain, Chr10Loss, Chr19_20.co.gain, TERT.promoter.status, TERTexpression.log2, TERTexpression.status, ATRX.status, Telomere.Maintenance, BRAF.V600E.status. For further analysis, we have detected the modules that show strong positive and strong negative correlation with the TERT.promoter.status.

Statistical Analysis

We have listed the genes from modules of interest and converted gene names and synonyms to Entrez identifiers. We used the Database for Annotation, Visualization, and Integrated Discovery platform to perform enrichment analysis⁽²⁶⁾. Functional annotation charts were downloaded. A summary of the KEGG pathways was curated in table format for comparison. Due to being enriched in similar pathways and correlated with the pTERT status inversely, we have further analyzed IDHwt blue and IDHmt greenyellow modules by mapping them on KEGG pathway schemes with a KEGG mapper⁽²⁷⁾. We colored the KEGG objects according to their involvement status. The components enriched only in the IDHwt blue module were colored blue; the components enriched only in the IDHmt greenyellow module were colored green; the components enriched in both modules were colored red and the rest of the objects were kept in their default color.

Differential Gene Expression Analysis

We have performed differential gene expression analysis between normal tissue and LGG IDHmt samples; normal tissue and LGG IDHwt samples; LGG IDHmt and LGG IDHwt samples. Normal samples (solid tissue normal) were selected from the TCGA GBM cohort since the TCGA LGG cohort does not include normal samples. We used the “TCGAanalyze_DEA” function in the TCGABiolinks package using the “exactTest” method. The FDR threshold was set to 0.01 and the absolute logarithmic fold change (logFC) was set to 1 to identify DEGs. We have screened DEGs for the blue module on the normal tissue vs LGG IDHwt, and the

greenyellow module on the normal tissue vs LGG IDHmt. Additionally, we have listed the genes that were enriched in common pathways between greenyellow and blue modules. We focused on genes enriched only in the blue module for the next step as they were observed in different components of the same pathways.

Drug-gene Interactions

Using the Drug Gene Budger (DGB) tool⁽²⁸⁾, we have screened drugs that were changing the expression of selected genes accordingly. We have selected drugs that have inhibitory or activatory effects on up-regulated or down-regulated genes, respectively, using the CRowd Extracted Expression of Differential Signatures dataset⁽²⁹⁾.

Results

Pre-processing of TCGA LGG RNASeq Dataset and Construction of Weighted Gene Co-expression Networks

TCGA LGG RNASeq data subgroups based on their IDH mutation status were preprocessed separately. The TCGA LGG IDHmt subgroup consisted of 419 patients, and the TCGA LGG IDHwt subgroup consisted of 94 patients. Both the expression matrices contained 21,022 genes. After filtering and normalization steps, 14,893 genes were left. We have performed a sample-wise hierarchical clustering and detected one outlier sample and five outlier samples in the LGG IDHwt and LGG IDHmt subgroups, respectively. These outliers were excluded from the expression matrices. According to the clinical information, there were 92 pTERT-mutated samples and 143 pTERT wt samples in the IDHmt subgroup; 36 pTERT-mutated samples and 16 pTERT wt samples in the IDHwt subgroup that were recorded. pTERT mutation status was not available for the rest of the samples. We have constructed weighted gene expression networks using selected soft-thresholding powers (IDHmt subgroup: 6; IDHwt subgroup: 12). The modules were generated in the hierarchical clustering tree (dendrogram), and each module was labeled by different colors (Supplementary Figure 3). There were 28 modules constructed in the LGG IDHmt cohort, and 14 modules were constructed in the LGG IDHwt cohort. Genes that have not been clustered in any module were collected in “Grey” modules in both cohorts (LGG IDHmt: 1055 genes, LGG IDHwt: 6314 genes).

Identification of Clinically Significant Modules

After the module construction, we performed a significance analysis to discover gene modules associated with the

clinical traits by observing module-trait relationship plots (Figure 2). We set correlation threshold values above 0.5 and below -0.5 to detect meaningful associations. We did not observe any correlations with Chr19_20.co.gain or BRAF.V600E.status features for the LGG IDHmt subgroup. Hence, these columns are not shown in Figure 2, for simplicity. For the LGG IDHwt subgroup, blue module (# of genes: 1622, cor: 0.61, p-val: 2e-10), green module (# of genes: 655, cor: 0.60, p-val: 5e-10), and tan module (# of genes: 102, cor: 0.59, p-val: 9e-10) showed a positive correlation with TERT promoter mutation status. Yellow module (# of genes: 830, cor: -0.53, p-val: 7e-08) and salmon module (# of genes: 100, cor: -0.51, p-val: 4e-07) had negative correlation values that were below the threshold (Figure 2A). For the LGG IDHmt subgroup, green module (# of genes: 1032, cor: 0.86, p-val: 8e-124), salmon module (# of genes: 391, cor: 0.68, p-val: 2e-58), blue module (# of genes: 1354, cor: 0.54, p-val: 3e-33), darkgreen module (# of genes: 64, cor: 0.52, p-val: 8e-31), and lightgreen module (# of genes: 106, cor: 0.52, p-val: 2e-30) showed positive correlation with TERT promoter mutation status. White module (# of genes: 36, cor: -0.64, p-val: 4e-50) and greenyellow module (# of genes: 538, cor: -0.57, p-val: 1e-37) showed negative correlation values that were below the threshold (Figure 2B).

Enrichment Analysis for Modules of Interest

Table 1 gives a summary of the KEGG pathway enrichment results. These results indicate that, in the IDHwt cohort, modules that are negatively correlated with the pTERT status (pTERT-) are enriched in immune-related pathways and those positively correlated (pTERT+) with the pTERT status are enriched in synaptic and glutamatergic pathways. In the IDHmt cohort, modules that are negatively correlated with the pTERT (pTERT-) status are enriched in cellular differentiation and proliferation, and synaptic pathways. Modules that are positively correlated with the pTERT status (pTERT+) are enriched in metabolomic and immune-related pathways. Interestingly blue module from the IDHwt cohort and greenyellow module from the IDHmt cohort are enriched in similar pathways, but their correlations with pTERT status are in opposite directions. We have investigated common pathways in KEGG to better understand the similarities and differences. We have identified 13 common pathways between the IDHmt greenyellow module and the IDHwt blue module related to synaptic pathways (Table 2). In the "Glutamatergic




Figure 2A. Module-Trait relationships plot for LGG IDHmt samples

LGG: Lower-grade glioma, IDHmt: Isocitrate dehydrogenase mutated, Chr: Chromosome, g: Gain, L: loss, exp: Expression, TERTp: Telomerase Reverse Transcriptase promoter, ATRX: Alpha-thalassemia/mental retardation, X-linked, BRAF.V600E: mutation of the *BRAF* gene in which valine (V) is substituted by glutamic acid (E) at amino acid 600, upper numbers show Pearson correlation, and lower numbers show p-values

Synapse” pathway, glutamate ionotropic receptor NMDA type subunits were annotated in both modules, but in the IDHwt blue module, glutamate ionotropic receptor AMPA type subunit 1 (*GRIA1*) was also annotated. Glutamate

metabotropic receptors were annotated in both the blue and greenyellow modules, but *GRM2* was annotated only in the IDHwt blue module. Other than *GRM2*, G protein alpha subunits (i1, i3 and o1) and adenylate cyclases (*ADCY1*, *ADCY5*) were also enriched in the IDHwt blue module. Cell migration and proliferation are promoted by glutamate receptors by allowing Ca^{2+} entrance into the cells (Supplementary Figure 4A).

When adenylate cyclase is activated by G-protein-coupled receptors, it turns on PKA. This interaction also happens within the mitochondria in the “Retrograde endocannabinoid signaling” pathway (Supplementary Figure 4B). We observed potassium channel proteins in the retrograde endocannabinoid signaling pathway, GABAergic synapse, and cholinergic synapse pathways in the IDHwt blue module (Supplementary Figure 4C).

Differentially Expressed Genes

We have identified 3025 and 2804 genes that were differentially expressed in the LGG IDHmt subtype and in the LGG IDHwt subtype compared to normal samples, respectively. In addition we have identified 1958 genes that were differentially expressed in the LGG IDHwt subtype compared to the LGG IDHmt subtype. Screening the selected modules for the DEGs returned 206 and 984 genes for the IDHmt pTERT- greenyellow module and IDHwt pTERT+ blue module, respectively. We further identified 146 genes that were common between normal vs. IDHwt and IDHmt vs IDHwt DEGs. Fifty-three of these 146 DEGs were upregulated and 93 of them were downregulated.

The lowest logFC value was observed for the *GRIN3A* gene (IDHmt vs IDHwt -1.96; normal vs IDHwt -2.95) and the highest logFC value was observed for the *HPD* gene (IDHmt vs IDHwt 2.01; normal vs IDHwt 6.53). Interestingly, the logFC values for the IDHmt vs IDHwt and normal vs IDHwt groups were not very different for downregulated genes, but there were significant differences for upregulated genes. We have listed 182 genes in the IDHwt blue module and 54 genes in the IDHmt greenyellow module, which were enriched in common pathways; 143 and 27 of them were differentially expressed, respectively. 22 of 182 blue module genes were differentially expressed between IDHmt and IDHwt samples. 15 of 22 genes were also differentially expressed between normal vs IDHwt samples (Table 3).

Module-trait relationships LGG IDHwt




Figure 2B. Module-Trait relationships plot for LGG IDHwt samples

LGG: Lower-grade glioma, IDHwt: Isocitrate dehydrogenase wild-type, Chr: Chromosome, g: Gain, L: Loss, exp: Expression, TERTp: Telomerase Reverse Transcriptase promoter, ATRX: Alpha-thalassemia/mental retardation, X-linked, BRAF.V600E: mutation of the BRAF gene in which valine (V) is substituted by glutamic acid (E) at amino acid 600, upper numbers show Pearson correlation, and lower numbers show p-values

Table 1. KEGG pathway enrichment of the selected modules

IDH mutation status	pTERT status (correlation)	Module	Term	p-value	Bonferroni
Wildtype	Negative	Yellow	hsa04060:Cytokine-cytokine receptor interaction	2.37E-10	7.29E-08
			hsa04064:NF-kappa B signaling pathway	8.00E-08	2.46E-05
			hsa04620:Toll-like receptor signaling pathway	1.68E-06	0.0005
			hsa04650:Natural killer cell mediated cytotoxicity	2.28E-06	0.0007
			hsa04062:Chemokine signaling pathway	2.62E-06	0.0008
		Salmon	hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer	0.0106	0.8196
			hsa04660:T-cell receptor signaling pathway	0.0161	0.9265
			hsa04630:JAK-STAT signaling pathway	0.0501	0.9997
			hsa04662:B-cell receptor signaling pathway	0.0663	0.9999
			hsa04625:C-type lectin receptor signaling pathway	0.0997	0.9999
	Positive	Tan	hsa04621:NOD-like receptor signaling pathway	1.61E-10	1.34E-08
			hsa04622:RIG-I-like receptor signaling pathway	6.66E-06	0.0006
			hsa04625:C-type lectin receptor signaling pathway	0.0052	0.3486
			hsa04620:Toll-like receptor signaling pathway	0.0052	0.3486
			hsa04062:Chemokine signaling pathway	0.0399	0.9658
		Green	hsa04724:Glutamatergic synapse	1.07E-06	0.0003
			hsa04921:Oxytocin signaling pathway	3.44E-06	0.0009
			hsa04022:cGMP-PKG signaling pathway	4.03E-05	0.0116
			hsa04010:MAPK signaling pathway	4.49E-05	0.0129
			hsa04725:Cholinergic synapse	0.0004	0.1027
			hsa04728:Dopaminergic synapse	0.0005	0.1226
		Blue	hsa04721:Synaptic vesicle cycle	1.19E-18	3.77E-16
			hsa04727:GABAergic synapse	5.60E-13	1.77E-10
			hsa04724:Glutamatergic synapse	3.30E-11	1.04E-08
			hsa04723:Retrograde endocannabinoid signaling	5.64E-11	1.78E-08
			hsa04728:Dopaminergic synapse	5.40E-10	1.71E-07
			hsa04080:Neuroactive ligand-receptor interaction	8.20E-10	2.59E-07
			hsa04024:cAMP signaling pathway	9.60E-08	3.03E-05

Table 1. Continued

IDH mutation status	pTERT status (correlation)	Module	Term	p-value	Bonferroni
Mutant	Negative	White	hsa05202:Transcriptional misregulation in cancer	0.0537	0.9903
			hsa04024:cAMP signaling pathway	0.0682	0.9974
			hsa04014:Ras signaling pathway	0.0765	0.9988
		Greenyellow	hsa04724:Glutamatergic synapse	2.11E-08	4.87E-06
			hsa04080:Neuroactive ligand-receptor interaction	3.42E-06	0.0008
			hsa04721:Synaptic vesicle cycle	6.58E-06	0.0015
			hsa04727:GABAergic synapse	0.0001	0.0294
			hsa04723:Retrograde endocannabinoid signaling	0.0004	0.0825
			hsa04725:Cholinergic synapse	0.0032	0.5218
	Positive	Green	hsa00100:Steroid biosynthesis	0.0031	0.6146
			hsa01100:Metabolic pathways	0.0220	0.9990
			hsa00280:Valine, leucine and isoleucine degradation	0.0374	0.9999
			hsa00250:Alanine, aspartate, and glutamate metabolism	0.0416	0.9999
			hsa05231:Choline metabolism in cancer	0.0692	0.9999
		Salmon	hsa04146:Peroxisome	0.0001	0.0312
			hsa05022:Pathways of neurodegeneration - multiple diseases	0.0569	0.9999
			hsa04330:Notch signaling pathway	0.0954	1
			hsa04392:Hippo signaling pathway - multiple species	0.0998	1
		Blue	hsa04060:Cytokine-cytokine receptor interaction	1.81E-09	5.83E-07
			hsa04064:NF-kappa B signaling pathway	6.13E-09	1.98E-06
			hsa04662:B -cell receptor signaling pathway	6.13E-08	1.97E-05
			hsa04621:NOD-like receptor signaling pathway	3.70E-07	0.0001
			hsa04620:Toll-like receptor signaling pathway	4.39E-07	0.0001
		Darkgreen	hsa03010:Ribosome	5.58E-11	3.23E-09
		Lightgreen	hsa04015:Rap1 signaling pathway	0.0075	0.7415
			hsa01100:Metabolic pathways	0.0270	0.9927
			hsa04921:Oxytocin signaling pathway	0.0615	0.9999
			hsa04218:Cellular senescence	0.0634	0.9999
			hsa04390:Hippo signaling pathway	0.0644	0.9999

IDH: Isocitrate dehydrogenase, pTERT: Telomerase reverse transcriptase promoter, KEGG: Kyoto Encyclopedia of Genes and Genomes

Table 2. Common pathways between the IDH mutant (IDHmt) greenyellow module and IDH wild-type (IDHwt) blue module

IDHmt_greenyellow_pTERT-				IDHwt_blue_pTERT+			
Term	Count	%	p-value	Term	Count	%	p-value
hsa04724:Glutamatergic synapse	16	3.0246	0.0000	hsa04721:Synaptic vesicle cycle	36	2.2402	0
hsa04080:Neuroactive ligand-receptor interaction	24	4.5369	0.0000	hsa04727:GABAergic synapse	32	1.9913	0
hsa04721:Synaptic vesicle cycle	11	2.0794	0.0000	hsa04724:Glutamatergic synapse	34	2.1157	0
hsa04727:GABAergic synapse	10	1.8904	0.0001	hsa04723:Retrograde endocannabinoid signaling	39	2.4269	0
hsa04723:Retrograde endocannabinoid signaling	12	2.2684	0.0004	hsa04728:Dopaminergic synapse	35	2.1780	0.0000
hsa04725:Cholinergic synapse	9	1.7013	0.0032	hsa04080:Neuroactive ligand-receptor interaction	65	4.0448	0.0000
hsa04726:Serotonergic synapse	9	1.7013	0.0036	hsa04713:Circadian entrainment	29	1.8046	0.0000
hsa04360:Axon guidance	11	2.0793	0.0064	hsa04024:cAMP signaling pathway	43	2.6757	0.0000
hsa04024:cAMP signaling pathway	12	2.2684	0.0089	hsa04725:Cholinergic synapse	27	1.6801	0.0000
hsa04070:Phosphatidylinositol signaling system	6	1.1342	0.0606	hsa04070:Phosphatidylinositol signaling system	22	1.3690	0.0000
hsa04713:Circadian entrainment	6	1.1342	0.0606	hsa04726:Serotonergic synapse	24	1.4935	0.0000
hsa04728:Dopaminergic synapse	7	1.3233	0.0686	hsa04360:Axon guidance	30	1.8668	0.0002
hsa00330:Arginine and proline metabolism	4	0.7561	0.0952	hsa00330:Arginine and proline metabolism	9	0.5600	0.0441

pTERT- : Negatively correlated modules with TERT promoter status; pTERT+ : Positively correlated modules with TERT promoter status

Table 3. IDH wild-type blue module pathway-enriched DEGs

	logFC.Normal.vs.IDHwt.	Normal	IDHwt	logFC.IDHmt.vs.IDHwt.	IDHmt	IDHwt
<i>SLC1A6</i>	-2.2365	989.8	234.4494	-1.1974	514.5239	234.4494
<i>GRIA2</i>	-1.4941	15266	5926.5056	-1.0580	11873.9067	5926.5056
<i>PLCB1</i>	-1.4048	5828.6	2446.4719	-1.0379	4828.8660	2446.4719
<i>GNG12</i>	2.2310	1181.8	6309.8539	1.5414	2087.4952	6309.8539
<i>GRIN3A</i>	-2.9484	1916.6	272.1124	-1.9578	1032.8684	272.1124
<i>SSTR1</i>	-2.4319	2161.4	449.9550	-1.2700	1018.7297	449.9551
<i>SSTR2</i>	-2.5210	2055	399.4607	-1.7434	1284.4665	399.4607
<i>CHRNA4</i>	-1.6524	2051.6	749.1685	-1.0276	1409.4377	749.1685
<i>GABRB3</i>	-2.2102	9864.4	2436.4719	-1.0300	4725.7607	2436.4719
<i>GABRA3</i>	-2.1735	1813.8	444.5843	-1.5058	1251.0909	444.5843
<i>PDYN</i>	-2.1334	5622.8	1506.6517	1.1126	645.9139	1506.6517
<i>VIPR2</i>	2.3059	329.6	1830.6180	-1.5287	4821.8445	1830.6180
<i>CHRM4</i>	-2.3974	334.2	70.5056	-1.022	136.3301	70.5056
<i>ATP6V1G2</i>	-2.0278	13698.6	3727.4045	-1.0769	7554.8421	3727.4045
<i>GNAL</i>	-2.2018	2163.6	530.2809	-1.0779	1077.7105	530.2809

DEGs: Differentially expressed genes, IDHmt: Isocitrate dehydrogenase mutated, IDHwt: Isocitrate dehydrogenase wild-type, logFC: log-fold change. Genes that were enriched in the IDH wild-type blue module, but not in the IDH mutant greenyellow module are shown in bold.

Drug-gene Interactions

Among the 15 genes that were common between normal vs IDHmt and IDHmt vs IDHwt DEGs, 6 of them were enriched only in the blue module: *GRIA2*, *PLCB1*, *GNG12*, *GABRA3*, *PDYN*, and *GNAL*. We excluded *PDYN* as its expression pattern was not suitable for our hypothesis. *GNG12* was upregulated at IDHwt samples compared with IDHmt and normal samples, whereas the others were downregulated. We have listed inhibitory drugs / small molecules for *GNG12* and activatory drugs / small molecules for *GRIA2*, *PLCB1*, *GNG12*, *GABRA3*, and *GNAL*. Since *GNG12* was the most interesting candidate target, we have compared listed drugs for *GNG12* with drugs targeting other candidates (Table 4). As cisplatin, imatinib, vanadium pentoxide, and vemurafenib affect the expression of four out of five listed genes (including *GNG12*), these compounds were identified as potential therapeutics.

Discussion

Despite the efforts toward better understanding and treating gliomas in the last decades, many questions need to be answered and a great need for new treatments. In this study, we aimed to understand co-expressional dissimilarities, as well as shared pathways, between LGG IDHmt and LGG IDHwt subgroups. Although both subgroups are classified under the low-grade glioma category, their progression and survival times are extremely different. Among LGGs, the most favorable survival rate is observed when *IDH1/2* and pTERT mutations are present together with 1p19q codeletion (IDHmt / pTERTwt / 1p19q-codeleted), and the worst survival rate is observed when only pTERT mutation is present (IDHwt / pTERTmutant / 1p19q-intact)^(16,30). Here, we focused on the transcriptomic basis of these discrepancies with a co-expressional perspective to explore related biological

Table 4. Drug-gene interaction table for IDH wild -type blue module pathway-enriched DEGs

Drug Name	<i>GNG12</i>	<i>GRIA2</i>	<i>PLCB1</i>	<i>GABRA3</i>	<i>GNAL</i>
1,25 dihydroxyvitamin d	x				
4-hydroxynonenal	x		x		x
Adenosine triphosphate	x	x		x	
Alfacalcidol	x				
Aminolevulinic acid	x				x
Androstanolone	x				
Aplidin	x				x
Apratoxin a	x				
Bexarotene	x	x			
Bisphenol a	x		x	x	
Cediranib	x			x	
Cetuximab	x				
Chlorpyrifos	x		x		
Cisplatin	x		x	x	x
Clinafloxacin	x				
Cytarabine	x				
Diclofenac	x	x			x
Doxorubicin	x	x			x
Doxycycline	x				
Estradiol	x		x		
Harman	x				
Imatinib	x		x	x	x
Interferon beta-1a	x				
Interferon gamma-1b	x				x
Mesalazine	x		x		
Metformin	x				x

Table 4. Continued

Drug Name	GNG12	GRIA2	PLCB1	GABRA3	GNAL
Nickel	x				
Plx4032	x		x	x	
Puromycin, ec50, 1 d	x			x	
Puromycin, ec50, 5 d	x				
Resveratrol	x				
Sapphyrin pci-2050	x				
Tibolone	x				
Triiodothyronine-(13c6) hydrochloride (t3 thyronine)	x	x			
Trovaflaxacin	x				
Vanadium pentoxide	x	x		x	x
Vemurafenib	x	x	x	x	
Vx	x				
Y15	x				

DEGs: Differentially expressed genes, Drugs that affect the expression of % genes, including GNG12, are shown in bold.

pathways and their components, and to extract information about mechanisms correlated with selected clinical features. Previously, CNS tumors were classified based on histology. The advancements in the NGS technologies allowed the researchers to profile tumor tissues at the molecular level, revealing the importance of such aberrations. In gliomas specifically, *IDH* mutation status was found to be a deterministic aberration (biomarker) and likely the earliest oncogenic change during gliomagenesis. While *IDHmt* gliomas respond well to therapies, *IDHwt* gliomas have dismal prognosis and eventually progress to GBM⁽³¹⁻³³⁾. Understanding the differences between the two groups will not only provide more insights into the disease mechanisms, but also help designing novel and more effective therapies to prevent cancer progression. We applied a weighted gene co-expression analysis approach and identified modules correlated with clinical features of interest. The “Chr7gain. Chr10Loss” and “*BRAF.V600E.status*” clinical features showed correlations only with the *IDHwt* subtype (Figure 2A, B). Chr7p gain and loss of Chr10q are hallmarks of GBM and likely indicate a subgroup within *IDHwt* LGGs that are destined to progress to the classical type of glioblastoma. Ozawa et al.⁽³⁴⁾ computationally identified *PDGFA* (chr7) and *PTEN* (chr10) as driving initial nondisjunction events in non-GCIMP GBM. *PDGFA* mediates signaling pathways in the regulation of growth and survival of the cells, and *PTEN* codes for an enzyme that plays a role in tumor suppression. *BRAF* gene produces B-raf protein, which is involved in direct cell growth⁽³⁵⁾. V600E stands for the amino

acid substitution at position 600 [from valine (V) to glutamic acid (E)]⁽³⁶⁾. *BRAF.V600E* status is identified as a key driver in certain brain tumors and tumor metastasis (pilocytic astrocytomas, pleomorphic xanthoastrocytoma, ganglioma, and glioblastoma)⁽³⁷⁾. As pTERT mutations are present in both oligodendrogliomas and GBM, two tumor types with opposite prognoses, we decided to identify similarities and differences between *IDHwt* and *IDHmt* LGGs with respect to the pTERT mutation status and selected modules of interest accordingly. We applied enrichment analysis for modules whose correlation value was above 0.5 or below -0.5 (Table 1). *IDHwt* yellow and salmon modules, which are negatively correlated with pTERT status, were enriched in immune-related pathways. On the other hand, the *IDHmt* blue module, which is enriched in immune-related pathways, showed a positive correlation with pTERT status. The immune system is a major component of the tumor microenvironment and is central to tumor progression and invasion. This observation reflects differences in the immune response to *IDHwt* and *IDHmt* tumors and could be explained by differences in tumor antigens, effects of 2-hydroxyglutarate on immune cells, or modulation of tumor-associated immune responses by different oncogenic processes in two tumor types, among others. *IDHwt* modules (green and blue) that were positively correlated with pTERT were enriched in synaptic pathways. On the other hand, in the *IDHmt* subgroup, the greenyellow module was enriched in synaptic pathways and negatively correlated with the pTERT status. We identified 13 common pathways between the *IDHwt* pTERT+ blue module and the

IDHmt pTERT- greenyellow module (Table 2). We observed that different sub-components of these pathways were enriched in the blue module compared to the greenyellow module. Glutamatergic synapse, circadian entrainment, and dopaminergic synapse pathways were particularly interesting, as α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) glutamate receptor (AMPA) and PKC/ERK signaling pathways are involved in the blue module, but not in the greenyellow module (Supplementary Figures 4A, E, F). AMPA receptors play a role in the glioma growth⁽³⁸⁾.

Our results showed that *GNG12* (up-regulated), *GNAL*, *GABRA3*, *GRIA2*, and *PLCB1* (down-regulated) genes were enriched in the IDHwt blue module, but not in the IDHmt greenyellow module. Most of the genes were down-regulated (except *GNG12*) in normal vs. LGG IDHmt and normal vs IDHwt comparisons.

GNG12 is a member of the G-protein family and it plays a role in cellular functions such as cell division, differentiation, and metastasis^(39,40). Liu et al.⁽⁴¹⁾ showed that the proliferation and migration of glioma cells were correlated with *GNG12* expression. Our results indicate that *GNG12* expression is lowest in normal samples followed by IDHmt gliomas and it was the highest in IDHwt gliomas. *GNAL* encodes a stimulatory G protein alpha subunit. A study by Zhang et al.⁽⁴²⁾ related *GNAL* expression levels with gliomas. They identified 24 genes, including *GNAL*, that are related to glioma grade and prognosis. The expression of *GNAL* was inversely correlated with the glioma grade. Our results show that *GNAL* expression is the lowest in IDHwt gliomas followed by IDHmt gliomas and normal samples. Another interesting finding in the glutamatergic synapse pathway is the involvement of PKC/ERK pathway through phospholipase C beta 1 (*PLCB1*). *PLCB1* is correlated with glioma grade and plays a role in maintaining a normal or less aggressive glioma phenotype⁽⁴³⁾. We observed that *PLCB1* was downregulated in the IDHwt subgroup. Patil et al.⁽⁴⁴⁾ showed that *GABRA3* expression was down-regulated in LGGs compared to normal samples and it was the lowest in GBMs. They evaluated TCGA and Cancer Cell Line Encyclopedia glioma data from a global RNA-editome perspective and found that exogenously produced and edited *GABRA3* effectively prevented glioma cells from migration and invasion, but the unedited *GABRA3* did not. High-grade gliomas release high concentrations of glutamate and enhance their malignant^(45,46) and invasive behavior^(47,48). Our results showed that *GRIA2* (Glutamate Ionotropic Receptor AMPA Type Subunit 2) was enriched in the blue module but

not in the greenyellow module. Differential gene expression analysis showed that this gene is down-regulated in IDHwt LGGs compared with IDHmt LGGs and normal samples (Table 3). In parallel with our results, van Vuurden et al.⁽⁴⁹⁾ showed that expression of AMPA receptor (*GRIA1-4*) was decreased by glioma grade (normal>LGG>GBM). The subunit encoded by *GRIA2* is contingent on RNA editing and it is thought to make the channel impermeable for Ca^{2+} (50). Ca^{2+} concentration is important in the intracellular space as it excites Ca^{2+} -dependent signal transduction pathways such as AKT⁽⁵¹⁾, ERK/MAP kinase⁽⁵²⁾, and PKA⁽⁵³⁾, which are involved in cell proliferation and migration. Ramaswamy et al.⁽⁵⁴⁾ showed that AMPA-R enhances the invasion in GBM and ERK signaling affects the expression of calcium-permeable AMPA-R. Lu et al.⁽⁵⁵⁾ suggested *PLCB1* as a candidate biomarker for high -grade gliomas. They showed a correlation between *PLCB1* expression and the patient survival; an inverse correlation between *PLCB1* expression and the pathological grade of glioma. Our results indicated a decrease in the expression of the *PLCB1* in normal samples compared with the IDHmt subtype, and the lowest expression was in the IDHwt subtype. To summarize, the expression patterns of these candidate genes seem to promote a more GBM-like phenotype (aggressive behavior). Using the DGB tool, we listed small molecules/drugs that affect the expression levels of these candidate genes. We searched for inhibitory drugs for the expression of *GNG12* and activator drugs for *GNAL*, *GABRA3*, *GRIA2*, and *PLCB1* (Table 4). We noticed that cisplatin, imatinib, vanadium pentoxide and vemurafenib affect the expression of four out of the five listed genes. Wang et al.⁽⁵⁶⁾ showed active performance and acceptable toxicity of the combined treatment of cisplatin and temozolomide in recurrent GBMs. Enríquez Pérez et al.⁽⁵⁷⁾ showed that cisplatin treatment was beneficial in the treatment of GL261 glioma-bearing C57BL/6 mice, but not GL261-bearing NOD-scid IL2 γ null (NSG) mice. However, the combination of cisplatin with immunotherapy did not yield improved survival. Ferrari et al.⁽⁵⁸⁾ proposed a new platinum-based prodrug as an alternative for cisplatin and its analogs and showed its effectiveness in the U251 cell line. Holdhoff et al.⁽⁵⁹⁾ showed that imatinib increases the radiosensitivity in human GBM by disturbing the autocrine PDGF/PDGFR loop. We are not aware of any study of vanadium pentoxide treatment for glioma; however, Das et al.⁽⁶⁰⁾ reported proliferation inhibition of different cancer cell lines (B16F10, A549, and PANC1) which were treated with vanadium pentoxide nanoparticles (V2O5 NPs: 30-60 nm). Additionally, they showed a significant improvement in the survival of melanoma-bearing C57BL6/J

mice after treatment with V2O5 NPs compared to untreated tumor bearing mice. Vemurafenib is a selective inhibitor of BRAFV600; Kaley et al.⁽⁶¹⁾ reported results of the VE-BASKET study, in which patients with BRAFV600-mutant gliomas received vemurafenib daily; they reported that the efficacy of vemurafenib varies qualitatively by histologic subtype. Nicolaides et al.⁽⁶²⁾ showed that vemurafenib has promising anti-tumor activity in recurrent or progressive BRAFV600E-positive pediatric gliomas with manageable toxicity (Phase I results, Phase II ongoing). Del Bufalo et al.⁽⁶³⁾ also suggested vemurafenib as a treatment option for pediatric low-grade gliomas carrying BRAFV600E. We also propose these drugs, alone or in combination, as possible treatments specifically for IDHwt LGGs.

Study Limitations

In this study, we used publicly available RNA-seq data from a well-characterized cohort. While the number of samples was quite high for the IDHmut LGG group, it was much lower for the IDHwt-pTERTwt subgroup, with 16 samples. Another limitation was related to the interrogation of possible drug candidates that could target many genes in our candidate gene list. As drug-gene interaction data were available for cell lines from cancers other than gliomas, we had to rely on such data. With the possible generation of similar data for glioma cell lines, we can be able to overcome this limitation and determine how it compared to our current findings.

Conclusion

In this study, we have determined potential therapeutic target candidates for IDHwt LGGs. Although these targets need to be validated experimentally, with the help of computational analyses, our study prioritizes potential targets for further investigation.

Acknowledgments

Fadime Öztoprak acknowledges TÜBİTAK 2211-C, YÖK 100/2000, and KYK scholarship programs. Computational analyses reported in this paper were partially performed at TUBITAK ULAKBİM, High Performance and Grid Computing Center (TRUBA resources). Yavuz Oktay is supported by the GEBİP young investigator award of the Turkish Academy of Sciences (TÜBA). This study was supported by TUBITAK grant 117Z981.

Ethics

Ethics Committee Approval: This study does not require ethics committee approval.

Informed Consent: N/A

Peer-review: Externally peer-reviewed.

Authorship Contributions

Concept: F.Ö., Z.I., Y.O., Design: F.Ö., Z.I., Y.O., Data Collection or Processing: F.Ö., Z.I., Analysis or Interpretation: F.Ö., Z.I., Y.O., Literature Search: F.Ö., Y.O., Writing: F.Ö., Z.I., Y.O.

Conflict of Interest: No conflict of interest was declared by the authors.


Financial Disclosure: This study was supported by TUBITAK grants 214S097 and 117Z981.

References

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. *Neuropathol* 2007;114:97-109.
2. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. *Am J Pathol* 1994;145:1175-90.
3. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. *Cancer Res* 2006;66:9852-61.
4. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. *J Clin Oncol* 2013;31:337-43.
5. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. *J Clin Oncol* 2013;31:344-50.
6. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. *Science* 2008;321:1807-12.
7. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. *N Engl J Med* 2009;360:765-73.
8. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *J Clin Oncol* 2010;28:2348-55.
9. Amary MF, Bacci K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. *J Pathol* 2011;224:334-43.
10. Shibata T, Kokubu A, Miyamoto M, Sasajima Y, Yamazaki N. Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. *Am J Pathol* 2011;178:1395-402.
11. Amary MF, Damato S, Halai D, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. *Nat Genet* 2011;43:1262-5.
12. Pansuriya TC, van Eijk R, d'Adamo P, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. *Nat Genet* 2011;43:1256-61.


13. Vinagre J, Pinto V, Celestino R, et al. Telomerase promoter mutations in cancer: an emerging molecular biomarker? *Virchows Arch* 2014;465:119-33.
14. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. *Proc Natl Acad Sci* 2013;110:6021-6.
15. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol* 2016;131:803-20.
16. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. *N Engl J Med* 2015;372:2499-508.
17. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* 2008;455:1061-8.
18. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell* 2010;17:98-110.
19. Yang Q, Wang R, Wei B, et al. Candidate Biomarkers and Molecular Mechanism Investigation for Glioblastoma Multiforme Utilizing WGCNA. *Biomed Res Int* 2018;2018:4246703.
20. Xu B. Prediction and analysis of hub genes between glioblastoma and low-grade glioma using bioinformatics analysis. *Medicine (Baltimore)* 2021;100:e23513.
21. Colaprico A, Silva TC, Olsen C, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. *Nucleic Acids Res* 2016;44:e71.
22. de Torrenté L, Zimmerman S, Suzuki M, Christopeit M, Greally JM, Mar JC. The shape of gene expression distributions matter: how incorporating distribution shape improves the interpretation of cancer transcriptomic data. *BMC Bioinformatics* 2020;21:562.
23. Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol* 2014;15:R29.
24. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. *BMC Bioinformatics* 2008;9:559.
25. Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. *Stat Appl Genet Mol Biol* 2005;4:Article17.
26. Sherman BT, Hao M, Qiu J, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). *Nucleic Acids Res* 2022;50:W216-21.
27. Kanehisa M, Sato Y, Kawashima M. KEGG mapping tools for uncovering hidden features in biological data. *Protein Sci* 2022;31:47-53.
28. Wang Z, He E, Sani K, Jagodnik KM, Silverstein MC, Ma'ayan A. Drug Gene Budger (DGB): an application for ranking drugs to modulate a specific gene based on transcriptomic signatures. *Bioinformatics* 2019;35:1247-8.
29. Wang Z, Monteiro CD, Jagodnik KM, et al. Extraction and analysis of signatures from the Gene Expression Omnibus by the crowd. *Nat Commun* 2016;7:12846.
30. Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. *Neuro Oncol* 2019;21:v1-v100.
31. Gelman SJ, Naser F, Mahieu NG, et al. Consumption of NADPH for 2-HG Synthesis Increases Pentose Phosphate Pathway Flux and Sensitizes Cells to Oxidative Stress. *Cell Rep* 2018;22:512-22.
32. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. *Clin Cancer Res* 2009;15:6002-7.
33. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. *Cancer Res* 2004;64:6892-9.
34. Ozawa T, Riester M, Cheng YK, et al. Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. *Cancer Cell* 2014;26:288-300.
35. Sthanandam G, Kolch W, Duh FM, Rapp UR. Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. *Oncogene* 1990;5:1775-80.
36. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. *Nature* 2002;417:949-54.
37. Kaley T, Touat M, Subbiah V, et al. BRAF Inhibition in *BRAF*^{V600}-Mutant Gliomas: Results From the VE-BASKET Study. *J Clin Oncol* 2018;36:3477-84.
38. Venkataramani V, Tanev DI, Strahle C, et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. *Nature* 2019;573:532-8.
39. Morishita R, Nakayama H, Isobe T, et al. Primary structure of a gamma subunit of G protein, gamma 12, and its phosphorylation by protein kinase C. *J Biol Chem* 1995;270:29469-75.
40. Asano T, Morishita R, Ueda H, Kato K. Selective association of G protein beta(4) with gamma(5) and gamma(12) subunits in bovine tissues. *J Biol Chem* 1999;274:21425-9.
41. Liu R, Liu Z, Zhao Y, et al. GNG12 as A Novel Molecular Marker for the Diagnosis and Treatment of Glioma. *Front Oncol* 2022;12:726556.
42. Zhang D, Zhao J, Han C, Liu X, Liu J, Yang H. Identification of hub genes related to prognosis in glioma. *Biosci Rep* 2020;40:BSR20193377.
43. Ratti S, Marvi MV, Mongiorgi S, et al. Impact of phospholipase C β 1 in glioblastoma: a study on the main mechanisms of tumor aggressiveness. *Cell Mol Life Sci* 2022;79:195.
44. Patil V, Pal J, Mahalingam K, Somasundaram K. Global RNA editome landscape discovers reduced RNA editing in glioma: loss of editing of gamma-amino butyric acid receptor alpha subunit 3 (GABRA3) favors glioma migration and invasion. *PeerJ* 2020;8:e9755.
45. Rzeski W, Turski L, Ikonomidou C. Glutamate antagonists limit tumor growth. *Proc Natl Acad Sci* 2001;98:6372-7.
46. Yoshida Y, Tsuzuki K, Ishiuchi S, Ozawa S. Serum-dependence of AMPA receptor-mediated proliferation in glioma cells. *Pathol Int* 2006;56:262-71.
47. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M. Glutamate release promotes growth of malignant gliomas. *Nat Med* 2001;7:1010-5.
48. Ishiuchi S, Tsuzuki K, Yoshida Y, et al. Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. *Nat Med* 2002;8:971-8.
49. van Vuurden DG, Yazdani M, Bosma I, et al. Attenuated AMPA receptor expression allows glioblastoma cell survival in glutamate-rich environment. *PLoS One* 2009;4:e5953.
50. Barbon A, Barlati S. Glutamate receptor RNA editing in health and disease. *Biochemistry (Mosc)* 2011;76:882-9.
51. Ishiuchi S, Yoshida Y, Sugawara K, et al. Ca2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. *J Neurosci* 2007;27:7987-8001.
52. Wiegert JS, Bading H. Activity-dependent calcium signaling and ERK-MAP kinases in neurons: a link to structural plasticity of the nucleus and gene transcription regulation. *Cell Calcium* 2011;49:296-305.
53. Danbolt NC. Glutamate uptake. *Prog Neurobiol* 2001;65:1-105.
54. Ramaswamy P, Dalavaikodihalli Nanjaiah N, Prasad C, Goswami K. Transcriptional modulation of calcium-permeable AMPA receptor subunits in glioblastoma by MEK-ERK1/2 inhibitors and their role in invasion. *Cell Biol Int* 2020;44:830-7.

55. Lu G, Chang JT, Liu Z, Chen Y, Li M, Zhu JJ. Phospholipase C Beta 1: a Candidate Signature Gene for Proneural Subtype High-Grade Glioma. *Mol Neurobiol* 2016;53:6511-25.
56. Wang Y, Kong X, Guo Y, Wang R, Ma W. Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients. *Medicine (Baltimore)* 2017;96:e6261.
57. Enríquez Pérez J, Fritzell S, Kopecky J, Visse E, Darabi A, Siesjö P. The effect of locally delivered cisplatin is dependent on an intact immune function in an experimental glioma model. *Sci Rep* 2019;9:5632.
58. Ferrari B, Roda E, Priori EC, et al. A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma. *Front Neurosci* 2021;15:589906.
59. Holdhoff M, Kreuzer KA, Appelt C, et al. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. *Blood Cells Mol Dis* 2005;34:181-5.
60. Das S, Roy A, Barui AK, et al. Anti-angiogenic vanadium pentoxide nanoparticles for the treatment of melanoma and their in vivo toxicity study. *Nanoscale* 2020;12:7604-21.
61. Kaley T, Touat M, Subbiah V, et al. BRAF Inhibition in *BRAF*^{V600}-Mutant Gliomas: Results From the VE-BASKET Study. *J Clin Oncol* 2018;36:3477-84.
62. Nicolaides T, Nazemi KJ, Crawford J, et al. Phase I study of vemurafenib in children with recurrent or progressive *BRAF*^{V600E} mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). *Oncotarget* 2020;11:1942-52.
63. Del Bufalo F, Ceglie G, Cacchione A, et al. *BRAF* V600E Inhibitor (Vemurafenib) for *BRAF* V600E Mutated Low Grade Gliomas. *Front Oncol* 2018;8:526.




Supplementary Figure 1. Sample clustering of TCGA LGG IDHmt samples by average methodology A) IDHmt samples, B) IDHwt samples



TCGA: The Cancer Genome Atlas, LGG: Lower-grade glioma, IDHmt: Isocitrate dehydrogenase mutated, IDHwt: Isocitrate dehydrogenase wild-type, e: 10[^], branches reflect the patient barcodes




Supplementary Figure 2. Network topology analysis for soft-thresholding powers. **A)** IDHmt samples, **B)** IDHwt samples
 IDHmt: Isocitrate dehydrogenase mutated, IDHwt: Isocitrate dehydrogenase wild-type




Supplementary Figure 3. Hierarchical clustering of genes with module colors **A)** IDHmt samples, **B)** IDHwt samples
 IDHmt: Isocitrate dehydrogenase mutated, IDHwt: Isocitrate dehydrogenase wild-type




C)



D)





Supplementary Figure 4. Selected common KEGG pathway schemes of the IDHwt pTERT- blue module and IDHmt pTERT+ greenyellow module. **A)** Glutamatergic synapse, **B)** Retrograde endocannabinoid signaling, **C)** GABAergic synapse, **D)** Cholinergic synapses, **E)** Circadian entrainment, **F)** Dopaminergic synapse

IDHmt: Isocitrate dehydrogenase mutated, IDHwt: Isocitrate dehydrogenase wild-type, pTERT: Telomerase Reverse Transcriptase promoter. Pathway sub-components colored in blue are enriched in the blue module but not in the greenyellow module; pathway sub-components colored in green are enriched in the greenyellow module but not in blue module; pathway sub-components colored in red are enriched in both modules